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STEROID NOMENCLATURE*) 
The basic steroid nucleus consists of three fused cyclohexane rings and one 
cyclopentane ring as shown in Fig. la for pregnane, which illustrates the 
atomic numbering and ring nomenclature. The name of the steroid skeletone 
having no carbon side chain at Cn is androstane (Fig. lb). When additionally 
also the carbon atoms numbered 19 and 18 are lacking, the skeletone is named 
estrane and gonane respectively. 
In Figs. 1c and Id pictures are shown indicating the three-dimensional 
structure of androstane. Of the two possible substituents on any given carbon 
atom in the steroid nucleus the one emanating from the nucleus on the same 
side as the Cie and C19 angular methyl groups is called ß-oriented, whereas 
the one on the opposite side is called α-oriented. A ß-oriented bond is 
pictorially represented by a solid line and an α-oriented bond by a broken line. 
A bond whose orientation is unknown is represented by a wavy line (^—~) and 
denoted by the letter | . Substituents lying in the plane of the steroid nucleus 
are equatorial substituents, whereas those extending away from the central 
plane are axial substituents. The configuration of hydrogen at position 5 should 
always be designated by adding α, β, or ξ after the numeral 5, with the numeral 
and letter being placed immediately before the stem name. The configuration 
of a substituent attached at any other center of asymmetry in the nucleus is 
stated by adding α, β or ξ after the numeral denoting the position. Most of the 
naturally occurring steroids including the sex hormones are derivatives of 
5a-androstane. 
Derivatives formed by modification of, or introduction of substituents into, 
a parent compound (e.g. androstane, estrane, gonane, pregnane) are named 
by the usual methods of organic chemistry. Unsaturation is indicated by changing 
terminal "-ane" to "-ene", "-adiene", "-yne", etc. or "-an" to "-en", "-adien", 
"-yn", etc. and a positional numeral placed immediately before the stem name. 
Most substituents can be designated either as prefixes or suffixes, a few only 
as prefixes, e.g. halogens and alkyl groups. When possible one type of sub­
stituent must be designated as suffix. When more types are present, the other 
type(s) must be designated as prefix(es). The choice for suffix is made according 
to an order of preference, that is laid down in the Rules referred to below. 
*) Nomenclature according to IUPAC conventions as far as pertinent to this thesis. For 
the complete guidelines see IUPAC-IUB 1967 Revised Tentative Rules for Steroid 
Nomenclature, Biochim. Biophys. Acta 164, 453 (1968). 
2 
1 — a. Pregnane skeletone, showing atomic numbering and ring nomenclature. 
b. Formula of 5a-androstane according to the conventional projection on the plane 
of the paper, showing the α and β orientation of hydrogen atoms and Cie and 
Ci9 carbon atoms. 
c, d. Three-dimensional structure of Sa-androstane (c) and 5ß-androslane (d), in-
dicating equatorial (e) and axial (a) bonds. 
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SURVEY OF THE TRIVIAL NAMES USED IN THE TEXT AND THE 
CHEMICAL NAMES OF THE STEROIDS 
Chlormadinone 
Chlormadinone acetate 
Corticosterone 
Estradiol 
Estradiol-17a 
Estrenol 
Estrenone 
Estriol 
Estrone 
Ethinylestradiol 
Ethisterone 
Ethynodiol 
Ethynodiol diacetate 
Hydroxyprogesterone 
Lynestrenol 
Lynestrenol acetate 
Medroxyprogesterone 
Medroxyprogesterone acetate 
Megestrol 
Megestrol acetate 
Methyllynestrenol 
Norethindrone 
Norethindrone acetate 
Norethynodrel 
Norgestrel 
Nortestosterone 
Progesterone 
Testosterone 
6-chloro-17a-hydroxy-4,6-pregnadiene-3,20-dione 
6-chloro-3,20-dioxo-4,6-pregnadien-17a-yl acetate 
11 ß,21-dihydroxy-4-pregnene-3,20-dione 
l,3,5(10)-estratriene-3,17ß-diol 
l,3,5(10)-estratriene-3,17a-diol 
4-estren-17ß-ol 
4-estren-17-one 
l,3,5(10)-estratriene-3,16a,17ß-triol 
3-hydroxy-l,3,5(10)-estratrien-17-onc 
17a-ethynyl-l,3,5(10)-estratriene-3,17ß-diol 
17a-ethynyl-17ß-hydroxy-4-androsten-3-one 
17a-ethynyl-4-estrene-3ß,17ß-diol 
17a-ethynyl-4-estrene-3ß, 17ß-diol diacetate 
17a-hydroxy-4-pregnene-3,20-dione 
17a-ethynyl-4-estren-l 7ß-ol 
17a-ethynyl-4-estren-17ß-yl acetate 
6a-methyl-17a-hydroxy-4-pregnene-3,20-dione 
6a-methyl-3,20-dioxo-4-pregnen-17a-yl acetate 
6-methyl-17a-hydroxy-4,6-pregnadiene-3,20-dione 
6-methyl-3,20-dioxo-4,6-pregnadien-17a-yl acetate 
6a-methyl-17a-ethy ny 1-4-estren-17 ß-ol 
17a-ethynyl-17ß-hydroxy-4-estren-3-one 
17a-ethynyl-3-oxo-4-estren-17ß-yl acetate 
17a-ethynyl-17ß-hydroxy-5(10)-estren-3-one 
13ß-ethyl-17a-ethynyl-17ß-hydroxy-4-gonen-3-one 
17ß-hydroxy-4-estren-3-one 
4-pregnene-3,20-dione 
17ß-hydroxy-4-androsten-3-one 
4 
он 
с=сн 
testosterone R, - H norteetosterone P. - H noiethynodr*el 
ethi«terone R»-C=CH norethindrone R--C=CH 
n o i ^ c a t t e l 
HO' 
C = C H 
ethynodiol 
H O ^ / ^ ^ 
C = C H 
сиз 
c=o 
OH 
OH C = 
lyneetrenoi methyl lyneetrenol eetrenol 
^k^v cZ-^^f 
СНз 
c=o 
O H 
eatradiol R . - H hydroxyprogestcrorw R . - H Chlormadinone P . - C l 
elhmyleetradiol R--C=CH medroxyprogesterone R . - C H , megeetrol R . - C H j 
Fig. 2 — Formulae of steroids used in the present investigations. 
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SECTION I 
S C O P E A N D I N T E N T 
7 

CHAPTER 1 
GENERAL INTRODUCTION 
PRINCIPLES OF DRUG ACTION 
The effect of most drugs in biological systems must be regarded as the 
ultimate consequence of a physicochemical interaction between that drug and 
certain functionally important molecules in the living organism (Ariens et al., 
1964). These sites of action are localized in what is called the target tissue of 
the drug. The tissue elements with which the drug combines in a more or less 
specific way and which convert chemical information into a biological response 
are called receptors. 
The strenght of the biological response elicited by a bioactive agent is for 
most drugs dose dependent and may, therefore, be thought to be related with 
the drug concentration in the direct environment of the receptors, viz. the target 
tissue or receptor compartment. The concentration of the drug in the target 
tissue is governed by the time course of the free drug concentration in the blood, 
i.e. the fraction of the drug not bound to plasma proteins. 
The drug may enter the blood circulation system directly by intravascular 
administration or by absorption from a depot like occurs in case of oral, rectal 
and intramuscular administration. Immediately after drug administration and 
during the absorption process the drug is distributed with the blood over the 
organism according to a pattern, that initially will be highly dependent on the 
relative blood supply to the various organs and tissues. This first stage distribu-
tion pattern may considerably differ from the pattern under steady-state con-
ditions, when a constant blood level of the drug is maintained, e.g. by means 
of zero-order infusion. Under these circumstances the distribution pattern will 
depend on the mutual affinity of tissue and drug for each other. Generally, 
however, there will be no equilibrium between drug supply and elimination of 
the drug from the circulation. Then progressive elimination of the drug from 
the circulation and from the biosystem will occur as a result of continuing bio-
transformation and/or excretion processes. The rate of each of these processes 
of distribution, biotransformation and excretion, that thus will contribute 
References p. 20 9 
simultaneously to the termination of drug action, is determined by the physico-
chemical properties of the drug and its interaction with the tissues responsible 
for the elimination (Goldstein et al., 1974). 
So, between the administration of a certain drug product and drug action 
three main phases can be distinguished as depicted in the following scheme 
(Ariens & Simonis, 1974): 
I Pharmaceutical pha^e II Pharmacokinetic phase III Pharmacodynamic рЬаче 
disi η lepra tion of 
dosage form 
dissolution of 
actnc чиіічіапсг 
drup available 
for absorption 
pharmaceutical 
availability 
absorption 
distribution 
metabolism 
excretion 
drug available 
for action 
biological 
availability 
drug-receptor 
interaction 
in target tissue 
It follows that the effective concentration of the drug at the receptor sites and 
therefore the time course of drug action depends in a complex way upon the 
relative rates of the processes comprising the pharmaceutical and pharma­
cokinetic phase. 
The pharmaceutical phase 
The pharmaceutical phase covers the release of the drug from its dosage 
form as a result of the disintegration of the drug product and/or dissolution of 
the active ingredient. The extent and the rate of this process may be influenced 
by various factors such as the particle size and crystal structure of the drug as 
well as the specific properties of the dosage form itself, and determine the 
pharmaceutical availability of that particular drug product. 
The pharmacokinetic phase 
Pharmacokinetics is the quantitative study of the processes of drug absorption, 
distribution, biotransformation and excretion. Mathematical models are used 
to describe these processes with the ultimate aim to provide a tool for a proper 
understanding of the relationship between on the one hand the dose, dosage 
form and route of administration and on the other hand the drug concentration 
in the receptor compartment as a function of time (see e.g. Dost, 1968; Notari, 
1975; Van Rossum, 1971; Wagner, 1971, 1975). 
Various experimental techniques may be used dependent on the kind of in-
10 
formation looked for. Obviously, animal studies offer more possibilities than 
studies in humans, particularly with respect to the investigation of the time 
course of drug distribution and metabolism (this thesis, Chapters 14, 15). Be-
cause repetitive sampling directly in the receptor compartment is generally not 
possible without loss of the integrity of the biosystem, drug concentrations 
in vivo are usually monitored by the analysis of blood and other body fluids 
and excreta. Although this approach is less straightforward, the information 
thus obtained is a quite useful substitute. For most drugs the kinetics of the 
drug-receptor interaction is very fast in comparison with the kinetics of drug 
absorption, distribution and elimination (Van Ginneken, 1977) and in these 
cases the time course of drug action will be reflected in the time course of the 
drug in the blood. This relationship has enabled in a number of selected cases 
even the use of drug levels as therapeutic guides in the individualization of drug 
dosage (Koch-Weser, 1975). 
Complications, however, arise when drugs are retained in the target tissue 
for a relatively long period of time and when the evoked response results from 
a time-consuming multi-step biochemical process. Then the response may ap-
pear and persist after the elimination of the drug. For example, a long-term 
retention in the target cell nuclei has been shown to be a prerequisite fof 
obtaining a full biological response in case of the estrogenic hormones as will 
be outlined in the second part of this chapter. For these compounds the 
relationship between dose and effect is largely obscured owing to pharmaco-
kinetic as well as pharmacodynamic aspects of drug action. 
The pharmacodynamic phase 
Pharmacodynamics deals with the interaction of the drug with the molecular 
sites of action in the target tissue and the consequences thereof. This interaction 
is generally a reversible process. As a result of the interaction conformational 
changes occur in the receptor molecule, which constitute the stimulus finally 
leading via a sequence of biochemical events to the pharmacological response 
within the target tissue or elsewhere in the organism (Ariens et al., 1964; Ariens 
& Simonis, 1974; Ariens & Beid, 1977). The relationship between the stimulus 
and the response is believed to be independent of the properties of the drug 
molecule. It is not quite clear, whether this concept is valid for the mechanism 
of action of steroid hormones. It was demonstrated by Anderson et al. (1975) 
that in contrast with the early estrogenic response the initiation of late estrogenic 
responses require prolonged nuclear retention of the estradiol-receptor complex 
(see second part of this chapter). So, in this model of action later events induced 
References p. 20 11 
by the estrogen-receptor complex are depending not only upon earlier events, 
but upon the continued binding and action of the hormone itself. 
On the other hand it is the goodness of the fit of the drug molecule to the 
receptor site and, therefore, the chemical structure of the drug molecule, that 
will determine the affinity of the binding and that is essential for drug action. 
Depending on the particular structure of a drug molecule and the specificity 
of the binding sites of the numerous receptors in the organism one and the same 
drug may bind to more than one kind of receptors and may so display a mixture 
of activities. Dissociation of activities may be obtained by modification of the 
chemical structure using the results of receptor-binding studies as a guide-line 
(Ariens, 1971; Baulieu, 1975; Raynaud, 1977; Van Kordelaar, 1973; this thesis, 
Chapter 11). 
Besides the affinity to the receptor a drug needs what is called intrinsic 
activity to induce a stimulus. This characteristic indicates the efficacy of the 
drug-receptor interaction. This concept was introduced as it appeared necessary 
to discriminate between on the one hand agonists and on the other hand com-
petitive antagonists. The latter compounds share with the agonists a certain 
affinity to the receptor site, but they lack, once bound, the capacity to induce 
in the receptor those conformational changes indispensable for the induction 
of the stimulus. 
MECHANISM OF ACTION OF SEX STEROID HORMONES 
The regulation of protein synthesis in the target tissues is undoubtedly 
the principal action of steroid hormones. After entering the target cell the 
hormone is bound to a specific hormone receptor. This hormone-receptor 
complex is then transferred to the nucleus in an "activated" form, where it 
is bound to the target cell genome. Subsequently, by a yet undefined process, 
the target cell responds by increased RNA synthesis followed by increased 
protein synthesis. Several excellent and extensive reviews have appeared 
recently, covering the properties of the steroid hormone receptors as well 
as the effects of the steroid-receptor interaction on target cell metabolism 
(Baulieu et al., 1975; Buller & O'Malley, 1976; Gorski & Gannon, 1976; 
Jensen & DeSombrc, 1973; King & Mainwaring, 1974). In this chapter we will 
confine us to the estrogen receptor. Attention is mainly focused on the local-
ization and properties of this receptor and general pharmacological implications 
thereof as far as pertinent to the investigations described in Section HI of this 
thesis. Most of the studies reported thus far have made use of rats. Results 
obtained with other species including man are essentially similar. 
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Estradiol binding to target tissues 
Estrogen responsive tissues have been shown to contain proteins with a high 
affinity and a limited capacity for the binding of estrogenic compounds. Their 
presence was first indicated by the striking affinity of these tissues for the 
endogenous hormone, estradiol, in vivo. Following the administration of physio-
logical amounts of tritiated estradiol to immature rats (Jensen & Jacobson, 
1960) or tritiated hexestrol, a synthetic non-steroidal estrogen, to goats and 
sheep (Glascock & Hoekstra, 1959) a selective accumulation and retention of 
radioactivity trom the blood against a marked concentration gradient was found 
to occur in the uterus, vagina and anterior pituitary, but not in non-target 
tissues like e.g. skeletal muscle and diaphragm. It was subsequently demon-
strated that in spite of its rapid biotransformation only unchanged estradiol was 
retained (Jensen & Jacobson, 1962; Stone, 1964). This selective process was 
found to be estrogen specific and stereospecific, since simultaneous administra-
tion of non-labelled estradiol or other estrogenic compounds like diethylstil-
bestrol markedly decreased estradiol binding, whereas the biologically inactive 
stereoisomer estradiol-17a as well as other non-estrogenic steroid hormones like 
testosterone and corticosterone were inactive in this respect (Noteboom & 
Gorski, 1965). Estrogen-specific accumulation and retention was afterwards also 
demonstrated in the anterior pituitary and various brain regions involved in 
estrogen action such as the preoptic area and hypothalamus (Eisenfeld & 
Axelrod, 1965,1966; Kato & Villee, 1967; King et al., 1965; McEwen & Pfaff, 
1970; Stumpf, 1970). A variety of steroids with estrogenic activity (for review 
see Jensen & DeSombre, 1972) as well as non-steroidal estrogenic and anti-
estrogenic compounds like ethamoxytriphetol (Jensen, 1962), clomiphene 
(Eisenfeld & Axelrod, 1967; Kato et al., 1968; Roy et al., 1964), Parke Davis 
CI-628 (Callantine et al., 1968) and nafoxidine (Eisenfeld & Axelrod, 1967; 
Jensen et al., 1966; Terenius, 1970) prevented the characteristic preferential 
retention of estradiol in the uterus and vagina as well as in the anterior pituitary 
and hypothalamus. 
The intracellular binding sites for estradiol 
1. The cytosol receptor 
The radioactive estradiol taken up by the rat uterus appeared to be associated 
with a different form of the receptor substance in the high speed (105,000xg) 
supernatant (cytosol) of the tissue homogenate than in the heavy, nuclear, 
sediment (Noteboom & Gorski, 1965; Talwar et al., 1964). The cytosol was 
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found to contain a macromolecule with a high affinity (dissociation constant 
10"9-1010 M for estradiol) and specificity for the binding of estrogens (Gorski et 
al., 1968; Toft & Gorski, 1966). The remarkably tight binding of estradiol 
appeared to result from an extremely low rate of dissociation of the complex 
(Korach & Muldoon, 1974a; Sanborn et al., 1971; Truong & Baulieu, 1971). 
The destructive effect of proteinases (Noteboom & Gorski, 1965; Toft & Gorski, 
1966) and the inhibition of estradiol binding by SH group blocking agents 
(Jensen et al., 1967; Kahwanago et al., 1970; Shyamala & Gorski, 1969) as 
well as the protective effect of the reducing agent mercaptoethanol (Mester et 
al., 1970) suggested that the receptor molecule contains an essential protein 
portion and that SH groups are important for its binding activity. The binding 
itself is of non-covalent character as the hormone could be easily extracted by 
organic solvents (Jensen et al., 1966; Maurer & Chalkley, 1967). 
On ultracentrifugation in a sucrose density gradient the cytoplasmic estradiol-
receptor complex could be localized in the 8-9S region (Erdos, 1968; Gorski 
et al., 1968; Rochefort & Baulieu, 1968). In the presence of 0.2-0.4 M KCl 
or NaCl the 8S complex is reversibly transformed into a more slowly sediment-
ing 4S entity (Erdos, 1968; Jensen et al., 1969b; Korenman & Rao, 1968; 
Rochefort & Baulieu, 1968). Forms with intermediate sedimentation charac-
teristics can be obtained depending on the experimental conditions (Chamness 
& McGuire, 1972; Sica et al., 1976; Stancel et al., 1973). The native form of the 
free as well as of the estradiol-bound receptor in the cytoplasm is still unknown. 
In agreement with previous in vivo findings estrogen binding macromolecules 
with properties similar to the estrogen binding sites of the uterus appeared also 
to be present in the cytosol of the anterior pituitary (Korach & Muldoon, 1974a; 
Mowles et al., 1971; Notides, 1970), hypothalamus (Eisenfeld, 1970; Korach & 
Muldoon, 1974b; Mowles et al., 1971), the lactating mammary gland (Gardner 
& Wittliff, 1973; Hsueh et al., 1973), liver (Chamness et al., 1975; Eisenfeld 
et al., 1977), adrenal (Müller & Wotiz, 1978) and some other tissues of the rat 
as well as of other species (for review see Baulieu et al., 1975). 
2. The nuclear receptor 
The major part of the uterine estradiol, which is found in the nuclear fraction 
of the rat uterus up to 6 hours after estradiol administration, appeared to be 
associated with chromatin (King et al., 1966; Maurer & Chalkley, 1967; Teng 
& Hamilton, 1968). Solubilization and extraction of the hormone, unaccom-
panied by DNA, can be accomplished with 0.4 M KCl at pH 8.5 (Риса & 
Bresciani, 1968), yielding an estradiol-receptor complex sedimenting at about 
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5S on sucrose density gradient centrifugation (Giannopoulus & Gorski, 1971b; 
Jensen et al., 1968; Steggles & King, 1970). 
5. Relationship between the nuclear and cytosol receptor 
Incubation of rat uteri with tritiated estradiol at 370C revealed an intra-
cellular distribution of radioactivity as well as the formation of 8S and 5S 
complexes in agreement with the observations after hormone administration 
in vivo. When, however, the incubation was carried out at 20C, the major 
portion of the radioactivity appeared to be present in the extranuclear region 
and appears as 8-9S complex in the cytosol on gradient centrifugation (Gorski 
et al., 1968; Jensen et al., 1968, 1969a, 1969b; Rochefort & Baulieu, 1969; 
Shyamala & Gorski, 1969). Following brief warming to 370C redistribution of 
the steroid within the cell takes place yielding predominantly nuclear bound 
estradiol extractable as the 5S complex. Similarly, when estradiol was ad-
ministered to immature rats in vivo, there was a progressive loss of uterine 
cytoplasmic receptor accompanied by a gradual increase in the amount of 
estrogen-receptor complex found in the nucleus (Anderson et al., 1973; Gorski 
et al., 1971; Sarff & Gorski, 1971). Exposure to high levels of estradiol caused 
almost complete disappearance of the cytosol receptor in vivo as well as in vitro 
(Giannopoulos & Gorski, 1971a). 
Further support for the direct transport of cytosol receptor to the nucleus 
can be derived from the demonstration that formation of the nuclear receptor 
was dependent on the presence of both estradiol and uterine cytosol (Jensen 
et al., 1968, 1972a; Musliner et al., 1970). Transformation of the 4S cytosol 
receptor to the 5S form without loss of its nuclear binding affinity could be 
accomplished by incubation of the cytosol with estradiol in the absence of 
nuclei at 25-37° but not at 0oC (Jensen et al., 1972a). No evidence for the 
presence of the 5S binding protein in the uterine nuclei before estradiol adminis-
tration could be obtained. 
At present, it is not yet clear whether the change of sedimentation coefficient 
of 4S to 5S is related to a purely conformational change or to the addition of 
a subunit (Notides & Nielsen, 1974). Also the relevance of the temperature 
dependence of the receptor "activation" as observed in vitro for hormone 
action in vivo is still questionable. 
Significance of estradiol receptor binding for estradiol action 
Receptor binding and transformation and subsequent translocation of the 
estradiol-receptor complex to the nucleus of the target cell appears to be an 
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indispensable step for estradiol action (Buller & O'Malley, 1976). It has been 
shown to occur in vivo in the rat during physiological fluctuations of estradiol 
levels during the estrous cycle (Clark et al., 1972). Estrogen receptor binding to 
nuclear acceptor sites was also found to be positively related to early and 
late uterotrophic responses (Anderson et al., 1972a, 1973, 1974). Growth 
responses were proportional to the quantity of estrogen-receptor complex, 
which remained bound to the nucleus for 6 hours (Anderson et al., 1975). 
Recently, the different response of the uterus to the "impeded" estrogen estriol 
(Huggins & Jensen, 1955) as compared with estradiol could be correlated with 
the short time of half-life of the estriol-nuclear receptor complex (Clark et al., 
1977). Thus nuclear retention rather than just nuclear binding may determine 
the cellular response. 
The precise nature of the nuclear binding is still unclear and the presence 
and nature of specific acceptor sites for the steroid hormone-receptor complex 
is still controversial (Chamness et al., 1974; Müller et al., 1977) and will not be 
discussed. 
Some pharmacological considerations 
Assuming the general importance of estrogen and other steroid hormone 
receptors, the processes described above, although not quite understood, 
provide a rational and useful basis to explain the actions of estrogenic drugs 
and anti-estrogens on a molecular level. Conversely, exploring the nature of 
the drug-receptor interaction and of the corresponding target cell response will 
contribute to a better understanding of the relationship between the chemical 
structure and drug action, badly needed for the design of highly active and, 
perhaps equally important in the development of drugs with steroid hormone 
action, "pure" drugs with a small spectrum of activities (Raynaud, 1977). 
The binding and the binding parameters of a variety of estrogenic and anti-
estrogenic compounds to the estrogen receptor have been studied in vivo and in 
vitro (Black & Kraay, 1973; Chemayaev et al., 1975; Geynet et al., 1972; 
Hähnel et al., 1973a,b; Jensen & DeSombre, 1972; Jensen et al., 1972b; Makler 
& Eisenfeld, 1974; Raynaud et al., 1973; Rochefort et al., 1972; Shutt & 
Cox, 1972; Skidmore et al., 1972; Van Kordelaar et al., 1975a,b). Estrogenic 
compounds or their metabolites all display binding to a varying extent depend-
ing on their chemical structure. In view of the model of estrogen action in-
troduced by Jensen et al. (1968, 1972a) and Gorski et al. (1968) as outlined 
above, the nature, the magnitude, and the duration of the response evoked will 
be dependent on various factors, including, besides physiological factors like 
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the presence and the intracellular concentration of receptor and the endogenous 
hormone concentration, pharmacological factors like the drug concentration 
in the target tissue, the binding affinity of the drug to the receptor and the 
efficacy thereof. 
1. Receptor availability 
After the entrance of the drug molecule into the target cell the responsiveness 
of the cell to an estrogenic or anti-estrogenic drug is determined in the first 
place by the availability of the cytosol receptor for binding. If the intracellular 
concentration of receptor molecules is depleted one way or another, the cell 
will not show a response normal to the hormone or to the drug. 
The concentrations of unoccupied specific binding sites in the uterus and 
anterior pituitary are of similar order of magnitude in the castrated and cycling 
rat (Ginsburg et al., 1975; Korach & Muldoon, 1974a; Morris, 1976; Notides, 
1970). The concentration in the hypothalamus is at least ten times lower (Gins-
burg et al., 1975; Korach & Muldoon, 1974a; Morris, 1976). Uterine concen-
trations decrease with age, highest levels being found in the prepuberal rat at 
the age of 20-30 days (Feherty et al., 1970; Lee & Jacobson, 1971), although 
there seems to be not a great difference in the binding capacity of the uterus 
between the groups of varying hormonal state. The total number of specific 
binding sites for estradiol is in the uterus about 1012, in the anterior pituitary 
about 1011 and about 1010 in the hypothalamus. Literature data in this respect, 
however, are not unequivocal and do not always allow a valid comparison 
to be made, because the binding capacities are generally expressed on basis of 
DNA, tissue or cytosol protein contents instead of a quantity per whole organ. 
Physiological fluctuations in the available or free cytoplasmic binding sites 
of the uterus, pituitary and hypothalamus occur during the estrous cycle 
(Feherty et al., 1970; Sen & Menon, 1978; Ginsburg et al., 1975; Kielhom & 
Hughes, 1977; Lee & Jacobson, 1971). The fall in cytosol receptor levels 
closely approximates the phase of the cycle when the highest plasma levels of 
estradiol are found, namely at pro-estrus (Brown-Grant et al., 1970; Butcher et 
al., 1974), and coincides with the period of maximal accumulation of estradiol 
receptor in the uterine and hypophyseal nuclei (Clark et al., 1972; Jacobelli, 
1973; Sen & Menon, 1978). 
Apart from a reduction of available binding sites as a consequence of 
estradiol binding, the re-synthesis or replenishment of the cytoplasmic receptor 
is an important factor in receptor availability. Replenishment has been shown 
to be stimulated by estradiol (Clark et al., 1973; Morris, 1976; Sarff & Gorski, 
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1971) and is most markedly at estrus (Sen & Menon, 1978), whereas evidence 
is accumulating that progesterone can antagonize or suppress this process 
(Coulson & Pavlik, 1977; Hsueh et al., 1975, 1976). 
In the light of this physiological variability of the available specific binding 
sites it seems probable that in addition to the dose, the timing of drug ad-
ministration, particularly for those drugs, which are rapidly eliminated, may be 
of critical significance for the intensity of the effect. 
2. Receptor binding 
Binding of estrogens to the cytosol receptor proteins is considered to be a pre-
requisite for action. According to the occupation theory for drug action there 
is a direct relationship between the number of drug-receptor complexes 
formed and the pharmacological response. In the absence of estradiol and 
under conditions of equilibrium the relative number of occupied binding sites is 
dependent on the affinity of the drug to the receptor. An estrogenic response 
may then be observed when the drug under consideration is an agonist or a 
partial agonist. The anti-estrogenic activity of an antagonist without intrinsic 
activity will become apparent only in the presence of the agonist. 
In the presence of estradiol, binding of a drug to the receptor will interfere 
to some extent with estradiol receptor binding. As a consequence of this inter-
action and depending on the total number of bindings sites occupied, the ratio 
between the sites occupied by estradiol on the one hand and the drug on the 
other hand and the nature of the stimulus-effect relationship an estrogenic 
response may be observed, when the drug involved is an agonist, an estrogenic 
or an anti-estrogenic response when the drug is a partial agonist and an anti-
estrogenic response when the drug is an antagonist without intrinsic activity. 
Recently, it has been shown by Bouton & Raynaud (1978) that besides the 
affinity of an estrogen to the estradiol receptor also the single rate constants 
of association and dissociation should be taken into account. The dissociation 
and association constant of the drug-receptor interaction reflect the binding 
affinity of the drug under equilibrium conditions, which may be quite different 
from the actual situation within the cell in vivo. Depending, therefore, on the 
kinetics of the receptor transformation and the nuclear translocation of the 
drug-receptor complex and on the other hand on the rate of elimination of the 
unbound drug from the target tissue, the kinetic rate constants of the drug-
receptor complex may become relevant parameters for the initiation of drug 
action and the evaluation of drag activity. 
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3. Intrinsic activity 
The intrinsic activity of a drug or the efficacy of the drag-receptor inter-
action is generally thought to be materialized in the conformational change and 
concurrent "activation" of the receptor molecule induced by the binding of the 
drug. Although a direct analysis and quantification of this efficacy at the level 
of the drug-receptor complex is not yet possible, the efficacy may be assumed 
to be reflected somehow in one of the consecutive steps subsequent to the for-
mation of the drug-receptor complex. Investigations with respect to the 
mechanism of action of estrogenic and anti-estrogenic compounds have provid-
ed some interesting examples, which are recorded below. 
a. Nuclear translocation 
Depending on the nature of the drug-receptor complex nuclear translocation 
may be inhibited. This kind of inefficacy of the drug-receptor interaction has 
been demonstrated to be the mechanism of action for the anti-mineralocorticoid 
spirolactone SC-26304 (Marver et al., 1974). This spirolactone and aldosterone, 
antagonist and agonist respectively, appeared to compete for the same binding 
sites in renal cells. In contrast, however, with the rapid translocation of the 
aldosterone-receptor complex to the nucleus under appropriate conditions, no 
such nuclear translocation was observed for the spirolactone-receptor complex. 
b. Time of half-life of the chromatin-bound complex 
It has been demonstrated by Anderson et al. (1975) that estrogenicity as 
reflected by stimulation of uterine growth, is directly related to the length of 
time, which the estradiol-receptor complex is retained in the nucleus of uterine 
cells and that there is a requirement of at least 4-6 hours for the induction of 
true growth. Certain estrogens such als estriol are incapable to induce long-
term uterine growth responses in the bioassay and are therefore called "im-
peded" estrogens (Huggins & Jensen, 1955). Recently, Clark et al. (1977) could 
show that the limited uterotrophic response when estriol is administered 
acutely by injection, was due to the short half-life of the estriol-nuclear receptor 
complex. When estriol was administered continuously the substance produced 
an uterotrophic response quantitatively and qualitatively indistinghuishable 
from that induced by estradiol itself. 
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с. Replenishment of the estrogen receptor 
The synthesis of the estrogen receptor, which is regulated by estradiol among 
others, has been shown to be also sensitive to drug action. After an injection 
of estrogen in the rat, the uterine cytoplasmic receptor is depleted owing to the 
translocation of the hormone-receptor complex to the nucleus. Maximal de­
pletion of cytoplasmic receptor has been found to occur at one to four hours 
(Cidlowski & Muldoon, 1974; Gorski et al., 1971). During the period when 
cytoplasmic receptor is reduced the uterus is insensitive to additional exogenous 
estrogen (Anderson et al., 1974). This state is followed by replenishment and 
eventually overshoot in the number of binding sites 24 h later (Sarff & Gorski, 
1971). It is obvious, that any agent interfering with this replenishment process 
is a potential anti-estrogen. Some of the non-steroidal anti-estrogens, e.g. naf-
oxidine, clomiphene and CI-623, act probably via this mechanism (Clark et al, 
1973, 1974) and also progesterone (Hsueh et al., 1975, 1976). A point of major 
interest is, that the latter compound is devoid of estrogenic activity in contrast 
with the former ones. The simultaneous administration of progesterone and 
estradiol results in inhibition or modification of estrogen-induced growth and 
differentiation of target organs. Progesterone, however, does not compete for 
the estrogen receptor binding sites (Toft & Gorski, 1966) nor does it interfere 
with the translocation of the estrogen-receptor complex to the nucleus (Anderson 
et al., 1972b). So it may be inferred that interference with estradiol binding to 
cytoplasmic receptor sites is not essential for the inhibition of an estrogenic 
response. 
On the other hand nafoxidine, given alone or together with estradiol, ap­
peared to be at least as effective as estradiol alone in stimulating uterine growth. 
The antagonistic properties of nafoxidine were observed only when a second 
injection of estradiol was administered 24 hours after nafoxidine treatment. 
Clark et al. (1974) concluded that nafoxidine was an estrogen-antagonist not 
because it competed with estradiol for the receptor binding sites, as it actually 
does (Jensen et al., 1966; Rochefort et al., 1972; Terenius, 1970), to produce a 
complex that is a poor stimulator of growth in the target cell nucleus, but 
because it failed to stimulate the replenishment of the receptor. 
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CHAPTER 2 
THE CONTRACEPTIVE STEROIDS 
HISTORY AND MEDICAL USE 
The synthetic progestins which are the subject of the present investigations, 
have been the product of extensive research efforts in the pursue of orally active 
steroid hormones. Although these compounds are also used in the treatment of 
various gynaecological disorders with notable therapeutic success (Murad & 
Gilman, 1975) and although, actually, the treatment of infertility by the tem-
porarily inhibition of ovulation under the influence of progestational agents 
was an important aspect of the initial studies of Rock et al. (1957), their prin-
cipal application is in the field of oral contraception. 
The physiological parallel of their activity is encountered in the anti-
ovulatory action of progesterone, which becomes manifest in pregnancy, when 
huge quantities of this hormone are produced in the corpus luteum and later 
on in the placenta and as a result ovulation is abolished. The same effect can 
be obtained in normally menstruating women by the oral administration of 
progesterone (Pincus, 1956, 1959; Tyler, 1961). Very high doses, however, 
of 300 mg and more were needed to achieve this purpose, since progesterone 
undergoes rapid biotransformation in the organism. Large-scale oral contra-
ception became thus a reality first, when highly potent orally active steroids 
were synthetized. 
A very potent orally active estrogen became available as early as 1938, when 
ethinylestradiol was synthetized by Inhoffen & Hohlweg (1938). During the 
same year in the search for an orally active androgen they succeeded in the 
synthesis of 17a-ethynyltestosterone or ethisterone, the first orally active pro-
gestin (Inhoffen et al., 1938). Derivatives of this compound, lacking the angular 
methyl group at d o , the so-called 19-nortestosterone derivatives, appeared to be 
much more active. The synthesis of 17a-ethynyl-19-nortestosterone, norethiste-
rone or norethindrone, was achieved by Djerassi et al. (1954) in 1952. Almost at 
the same timeColton (1953,1954) reported the synthesis of norethynodrel. Both 
compounds proved to be very potent progestins and retained their activity when 
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given by mouth. Inhibition of ovulation by these compounds was demonstrated 
in rabbits by Pincus et al. (1956). Extension of these studies (Pincus et al., 
1958; Rock et al., 1956, 1957) revealed their effectiveness also in humans. Oral 
administration in doses of 10 mg a day from the 5th to 25th day of the 
cycle suppressed ovulation. Fertility returned on cessation of treatment. 
In addition to preventing ovulation any practical therapy should also provide 
for withdrawal bleeding with properties approaching the promptness, amount 
and duration of normal menstruation. Continued research revealed (Pincus, 
1959, 1965) that regular menstrual-like bleedings were obtained most frequently 
when progestins were administered together with a synthetic orally active 
estrogen, ethinylestradiol or mestranol (combination-type contraceptive). It is 
to accomplish this goal that both estrogen and progestin are still included in 
most contraceptive regimens. In 1957 Enovid®, containing 10 mg norethynodrel 
and 0.15 mg mestranol, was released by the US government first for the treat-
ment of menstrual disorders, and subsequently in 1960 as an oral contraceptive. 
The other compounds belonging to the same class of 19-nortestosterone 
derived progestins and currently still in use represent later developments. 
Ethynodiol diacetate was also synthetized by Colton (1958), being followed by 
lynestrenol in 1959 (De Winter et al., 1959). In contrast with the former steroids 
norgestrel, which appeared to be the most potent progestin of this group (Edgren 
et al., 1966, 1967), was obtained by total synthesis (Smith et al., 1963) accord-
ing to a novel procedure developed by Hughes & Smith (1960). Comparison 
of the biological activity of the so obtained racemic dZ-norgestrel with the 
resolved enantiomers showed, that the activity resides in the "natural" d-form 
and that the /-form is devoid of activity (Edgren et al., 1963). These obser-
vations are consistent with the high binding affinity of rf-norgestrel to the 
progesterone receptor and the absence of binding in the Z-form (Terenius, 1974). 
The second class of synthetic progestins in use for contraception is the group 
derived from 17a-hydroxyprogesterone, comprising medroxyprogesterone acet-
ate, megestrol acetate and Chlormadinone acetate (Babcock et al., 1958; Ellis 
et al., 1960; Ringold et al., 1959). The latter compounds have been recently 
withdrawn from medical use after the reported appearance of mammary nodules 
in beagles during chronic treatment with these drugs. The relevance, however, 
of these findings for the human situation has been questioned (Briggs, 1977). 
The former compound, medroxyprogesterone acetate, is principally in use for 
parenteral administration as a long acting depot contraceptive. 
When through the years experience was gained it appeared possible to reduce 
the dose of the progestin and later on also the estrogen content considerably 
without loss of the contraceptive effectiveness (Bye & Elstein, 1973; Elstein et 
al., 1974, 1976; Preston, 1972; Schneider et al., 1974; Virtavuo et al., 1977). 
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A still further decrease of the progestin content may be feasible by choosing a 
route of administration which avoids the first passage through the liver (this 
thesis. Chapter 16). 
A successful modification of the combined preparations with fixed doses of 
the active constituents over the entire cycle are the step-up pill and the se-
quentials. With the former type the progestin content is reduced during the 
first 11 days of the contraceptive regimen and in the sequentials the progestin 
is even completely omitted during the first 7 days of treatment. This method 
has the appeal of a more close mimicry of the normal cycle. Both treatments, 
the combination method and the sequential method act by suppressing the 
secretion of the gonadotrophin releasing hormone, which in turn decreases the 
circulating FSH and LH levels. As a result follicular growth in the ovary is 
largely suppressed and the mid-cycle surge of LH, assumed to be of paramount 
significance for the occurrence of ovulation, is prevented (Becker et al., 1973; 
Dufau et al., 1970; Elstein et al., 1974; Schally et al., 1970; Thomas & Ferin, 
1972; Thomas et al., 1972). 
The rationale behind the introduction of another variant, the minipill, which 
contains only a progestin in a low dose, was the elimination of the estrogen. 
The estrogenic component is thought to be responsible for a large deal of the 
side effects of the former preparations. Although, taking the minipill, slight to 
profound changes in the pattern of gonadotrophin secretion have been observed 
(Collins et al., 1974; Friedrich et al., 1975; Moghissi & Marks, 1971 ; Taymor & 
Levesque, 1971) and inhibition of ovulation also at this low dose level, e.g. 
0.5 mg lynestrenol daily, may occur, its principal mode of action is supposed to 
be the induction of a change in the consistency of the cervical mucus, rendering it 
hostile to sperm penetration. This and other actions may contribute also to the 
anti-fertility activity of the combined-type contraceptives, as the incidence of 
escape ovulations with these products is too high to explain their more than 
99.9% effectiveness. 
PHARMACOLOGY 
Progesterone may evoke a variety of biological effects, each of which may 
be used to evaluate and characterize the synthetic progestins, too. Although 
progestational agents share by definition with progesterone the potency to induce 
the secretory transformation of the estrogen-primed endometrium, which is the 
yardstick for the evaluation of activity in the Clauberg test (Clauberg, 1930), 
other progesterone-like activity such as the maintenance of pregnancy, deci-
duomagenic activity, inhibition of ovulation, may be absent or less pronounced, 
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whereas some actions of progesterone may be antagonized. In addition to 
progestational properties some of the synthetic compounds display also markedly 
estrogenic, androgenic and anabolic activity. For this reason a range of bioassays 
is necessary to characterize adequately the biological profile of each newly 
synthetized steroidal compound. It is beyond the scope of this thesis to present 
here a survey of the scala of biological actions exhibited by the contraceptive 
progestins in the various bioassays and observed in clinical trials. Compre­
hensive reviews covering this subject have been edited by Junkmann (1968/ 
1969) and Tausk (1972). The interpretation and the extrapolation of the out­
come of the animal tests to the human have appeared to be complicated very 
much by inter-species differences, probably in part due to species differences 
in the pharmacokinetics of the compounds, and are hampered by a still in­
complete understanding of the physiology of the endocrine systems involved 
(Neumann et al., 1977). 
Confining us in this chapter to the progestational and estrogenic activity of 
the contraceptive steroids in animals and humans, then two classes can be 
discerned, viz. the hydroxyprogesterone derivatives and rf-norgestrel on the one 
hand and the other 19-nortestosterone derivatives on the other hand. The com­
pounds belonging to the former class have shown to be more potent in the 
Clauberg test (Edgren et al., 1967; Kontula et al., 1975; Neumann et al., 1968) 
and to exhibit a more progesterone-like character, effective as they are also 
in maintaining pregnancy. Furthermore, the estrogenic component present in 
the spectrum of activities of the nortestosterone derivatives is absent in 
d-norgestrel and Chlormadinone acetate, medroxyprogesterone acetate and 
megestrol acetate (Edgren et al., 1967; Overbeek et al., 1962). 
Estrogenic activity 
The estrogenic activity of the 19-nortestosterone derivatives has been generally 
attributed to their in vivo conversion into phenolic metabolites, among others 
ethinylestradiol, which is as active as estradiol itself (Fotherby & James, 1972; 
Paulsen, 1965; Petrow, 1966). Ethinylestradiol and other phenolic metabolites 
were reported to be present in the urine of subjects treated with norethindrone 
or norethindrone acetate (Braselton et al., 1977; Breuer et al., 1960; Brown & 
Blair, 1960; Fotherby, 1970; Kamyab et al., 1968a; Langecker, 1961; Okada et 
al., 1964). Similarly, partial conversion of Л-norgestrel (Littleton et al., 1968) 
and lynestrenol (Kamyab et al., 1968b) to phenolic compounds has been report­
ed. The in vivo aromatization of the contraceptive progestins to potentially 
estrogenic compounds has been a matter of concern because of the possible 
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correlation between estrogen content and side effects of the contraceptive pill, 
particularly the increased risk of thrombo-embolic disease (Inman et al., 1970). 
The formation, however, of estrogenic metabolites has been questioned by 
Breuer (1970), who considered the formation of ethinylestradiol from nor-
ethindrone as an artefact arising during the fractionation of the urinary 
metabolites. His assumption was based on the observation by Townsley & 
Brodie (1966) that treatment of lß-hydroxy-19-norandrostenedione with either 
acid or base results in the formation of estrone. Recently, Sisenwine et al. 
(1973, 1974) have isolated lß-hydroxynorgestrel from the urine of women 
treated with dZ-norgestrel and could confirm the aromatization of this steroid 
under acidic and mildly alkaline conditions. After reduction of the lß-hydroxy-
4-en-3-one grouping in the A ring of this metabolite with NaBH4 the fraction 
of the phenolic excretion products appeared to be decreased to only 0.2-0.3% 
of the dose administered. Less than 0.01% of the dose could be identified as 
18-homo-ethynylestradiol and 16ß-hydroxy-18-homo-ethynylestradiol. Although 
the formation of phenolic compounds cannot be totally ruled out and has still 
to be studied for the other contraceptive progestins, a significant contribution 
to the estrogenic activity of the nortestosterone derivatives can hardly be 
expected on account of these findings. 
Investigation of the interaction of the contraceptive progestins with the 
estrogen receptor is a useful and direct approach from the opposite direction, 
which may shed light on the question, whether the estrogenic activity observed 
in vivo is the result of bioactivation of these compounds or may be an intrinsic 
property inherent to their chemical structure (this thesis, Section III). 
That bioactivation, on the other hand, may be an important condition for 
progestational activity is indicated for lynestrenol by the experiments of Kon-
tula et al. (1975). The relative binding affinity of lynestrenol to the progesterone 
receptor of the rabbit uterus was found to be ten times lower than the affinity 
of norethindrone, whereas both compounds appeared to be equipotent in the 
Clauberg assay. The high disappearance rate of lynestrenol from the blood, its 
extensive biotransformation and poor bioavailability after oral administration 
as observed in the present investigations (this thesis, Section IV) is consistent 
with this assumption. 
THE PRESENT INVESTIGATIONS AND THE STRUCTURE OF THIS THESIS 
As outlined in Chapter 1 the relationship between chemical structure and 
drug action and on the other hand dose and effect is dependent upon the affinity 
of a drug to the receptor binding site and its pharmacokinetic behaviour. In the 
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present investigations attention has been paid to both of these aspects with the 
aim to gather more information about the properties of the contraceptive 
steroids. The interaction of these and other, structurally related, compounds 
with the estrogen receptor of the rat and calf has been studied in vivo and in 
vitro and the binding parameters of the binding steroids to this receptor have 
been determined (Section III). On the other hand the pharmacokinetics of one 
of these widely-used drugs, lynestrenol, has been thoroughly explored in the rat 
and mouse (Section IV). For this latter part of the investigations the synthesis 
of tritiated lynestrenol had to be accomplished, because no analytical procedure 
was available, which permitted the determination of the low blood concentrations 
of this compound in the experiments envisaged. The synthesis of lynestrenol-3H 
and the determination of the lipophilicity and protein binding of this compound 
are described in Section II. This section comprises furthermore a description 
and account of those materials and methods, which have been employed in more 
than one chapter of Sections III and IV. In order to preserve the integrity of 
these chapters as much as possible a description of technical and analytical 
procedures pertinent to only one of these chapters has been incorporated in the 
chapter concerned. 
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CHAPTER 3 
SPECIFICATION OF CHEMICALS, SOLVENTS AND STEROIDS 
CHEMICALS 
The chemicals and solvents were of analytical reagent grade (Merck, 
Darmstadt, GFR or Baker, Deventer, The Netherlands) and used without 
further purification, unless otherwise indicated. 
STEROIDS 
Radioactive steroids 
Estradiol-6,7-3H — . Tritiated estradiol with a specific activity of 40 Ci/mmol, 
prepared by the reduction of estrone-6,7-3H with sodium borohydride, was 
obtained from the Radiochemical Centre, Amersham, U.K. The compound was 
stored as a solution in benzene/ethanol 90/10 in tightly closed silanized 
counting vials at a temperature of 1-40C. The identity and radiochemical purity 
of the hormone were authenticated by thin-layer chromatography over 
silicagel pre-coated glass plates (Kieselgel F254, Merck) after the addition of 
25 μg estradiol to serve as carrier for the labelled compound in order to avoid 
adsorption phenomena. The solvent systems used were chloroform/acetone 
70/30 (Rf value estradiol 0.41) and chloroform/ethylacetate 80/20 (Rf value 
estradiol 0.25). An estradiol marker was run on the same plate. Radioactive 
spots were localized by scanning (Berthold Zählratenmesser LB 2722), scraped 
off the plate and assayed for radioactivity by liquid scintillation counting. 
The radiochemical purity was always more than 98%. In experiments, where 
a lower specific activity sufficed, the specific activity was reduced by the addition 
of an aliquot of the non-labelled hormone. 
Lynestrenol-3!! —. Tritiated lynestrenol with a specific activity of 800 
mCi/mmol, was prepared from estrenone-16-3H by reaction with acetylene and 
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potassium t-butoxide in tetrahydrofurane. The tritiation of estrenone and the 
synthesis of lynestrenol-3H are described in Chapter 4. The compound was 
stored as a solution in benzene/ethanol 90/10 in tightly closed silanized counting 
vials at a temperature of 1-40C. The radiochemical purity was checked regularly 
by means of thin-layer chromatography over silicagel as described above. A co-
chromatographed lynestrenol marker was localized by exposing the plate to 
iodine vapour. The solvent systems used were toluene/ethanol 90/10 (Rf value 
lynestrenol 0.7) and cyclohexane/ethylacetate 90/10 (Rf value lynestrenol 0.3). 
Whenever the purity decreased below 97% the material was purified by thin-
layer chromatography in the solvent system n-heptane/acetone 80/20 (Rf value 
lynestrenol 0.5) and subsequent extraction of the lynestrenol from the scraped 
silicagel with dichloromethane/methanol 70/30. Following this procedure more 
than 95% of the tritiated lynestrenol could be recovered. During the in-
vestigations the specific activity of the compound was corrected for the radio-
active decay of the tritium. In experiments, where a lower specific activity of 
the compound sufficed, the specific activity was reduced by the addition of an 
aliquot of the non-labelled steroid. 
Lynestrenol-4-uC —. Lynestrenol-4-14C with a specific activity of 32.5 
mCi/mmol was generously supplied by Organon International, Oss, The 
Netherlands. It was stored as a solution in benzene/ethanol 90/10 at 1-40€. 
The authentication of the identity and radiochemical purity and the, rarely 
necessary, purification of the compound were accomplished as described above 
for the tritiated steroid. The radiochemical purity of the material used in the 
experiments was always more than 98%. In experiments, where a lower specific 
activity sufficed, the specific activity was reduced as described above. 
Non-labelled steroids 
The non-labelled steroids have been obtained from the following sources. 
We gratefully acknowledge a gift of lynestrenol, lynestrenol acetate, estrenol, 
estrenone, methyllynestrenol and 17a-ethynyl-5a-estran-17ß-ol from Organon 
International (The Netherlands), Chlormadinone and Chlormadinone acetate 
from Syntex Corp. (USA), megestrol and megestrol acetate from Novo Industri 
(Denmark), medroxyprogesterone and medroxyprogesterone acetate from 
Upjohn Comp. (USA), ethynodiol and ethynodiol diacetate from G. D. Searle 
& Co. (USA) and ¿-norgestrel and d/-norgestrel from Schering (The Nether-
lands). The other steroids were purchased from Sigma Chem. Corp. (USA) 
with the exception of hydroxyprogesterone (Merck, GFR). 
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The purity of these compounds was checked by thin-layer chromatography 
over silicagel (pre-coated plates Kieselgel F254, Merck) and/or gas-liquid 
chromatography (Hewlett & Packard, Model 402). Additional purification, if 
necessary, was carried out by preparative thin-layer chromatography over 
silicagel (pre-coated plates Kieselgel F254, layer thickness 2 mm, Merck). 
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CHAPTER 4 
SYNTHESIS OF LYNESTRENOL-3H*) 
INTRODUCTION 
In view of unsolved problems encountered in the development of an analysis 
of sufficient sensitivity and specificity for the assay of lynestrenol in biological 
samples the availability of tritiated lynestrenol with high specific activity was 
considered to be an indispensable tool. 
Although lynestrenol is chemically closely related to norethindrone, nor-
ethynodrel and ethynodiol, tritium labelling as described for these compounds 
by Kepler & Taylor (1971) or Chaudhuri & Gut (1969) is not possible because 
of the lack of the oxygen atom at Cs. This also holds for tritium labelling of 
norethindrone as described by Rao (1971). For the same reason various other 
methods, based on partial reduction of unsaturated precursors, are not feasible. 
The only other way to obtain a high specific labelled product, apart from a 
multistep synthesis, would be a halogen-tritium replacement (Chaudhuri & Gut, 
1969; Evans, 1966), but this again would result in complete saturation of the 
C4,5 double bond. 
The pharmacological studies envisaged required a compound with high 
specific activity, even at the expense of non-specificity of labelling. We con-
sidered that this may be best achieved by tritium labelling of estrenone 
(estr-4-en-17-one) via exchange with tritiated water (THO) in dimethyl-
formamide followed by an ethynylation reaction at Ci? to yield lynestrenol. 
The Cie hydrogen atoms of estrenone are susceptible to exchange for tritium 
under conditions causing enolization of the C17 oxo group. After subsequent 
incorporation of the 17a-ethynyl group these labile tritium atoms will be 
stabilized, provided they are not lost in the procedure. The introduction of the 
ethynyl group can be achieved in essentially the same way as described by 
*) In co-operation with Mr. J. S. Favier ( R & D Laboratories, Organon Scientific Develop-
ment Group, Oss, The Netherlands) and Mr. J. P. Kitcher (Organic Department, The 
Radiochemical Centre, Amersham, U.K.). 
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Djerassi et al. (1954), but with some adaptations for radio-isotope work on a 
micro-scale. The sequence of the reactions that was followed is depicted above. 
The specific activity attained depends very much on the temperature and 
duration of the exchange reaction (Evans, 1966). For estrenone this appeared 
to be no problem: heating the non-labelled compound for a period of 16 hours 
at 160oC in an evacuated ampoule with dimethylformamide and water did not 
result in the formation of other products. 
The contamination of estrenone-3H with estranone-3H after the exchange 
reaction, although not very probable, required special attention. Even small 
amounts of estranone-3H, present in е8Ігепопе-яН, would, if not removed, cause 
a serious radiochemical contamination of lynestrenol-3H. The two C17 oxo 
compounds can be separated by thin-layer chromatography (TLC) on silicagel 
silver nitrate plates (Lisboa & Palmer, 1967), but this method cannot be used 
after the introduction of the 17a-ethynyl group. 
The radioactive work described below was carried out under contract at the 
Radiochemical Centre (Amersham, U.K.) by Mr. J. P. Kitcher. 
MATERIALS 
All reagents were of analytical reagent grade. 
Estrenone was obtained from Steraloids Ltd., Croydon, U.K. Lynestrenol, 
used as a carrier during the identification of lynestrenol-3H, was obtained from 
Organon, Oss, The Netherlands. Identity and purity of these compounds was 
authenticated by IR spectroscopy, melting point, mass spectrometry, and gas-
liquid chromatography. 
The following solvents were specially purified. Dimethylformamide (DMF) 
was stored over molecular sieve 4A (BDH Ltd., Poole, Dorset, U.K.) for 
2 days, decanted and then distilled. Tetrahydrofuran (THF) was distilled under 
nitrogen from lithium aluminium hydride, after standing over this compound 
for 24 hours. The distillate was stored under nitrogen, in the dark, in a 
phosphorous pentoxide desiccator and used within five days. Potassium 
t-butoxide was prepared by reacting cleaned potassium (Pearson, 1967) with 
t-butanol under nitrogen. The solution was pumped to dryness on a manifold 
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and the white residue purified by sublimation under reduced pressure. 
Benzene and ethanol used for storage of tritiated materials in solution were 
redistilled prior to use. 
Acetylene was purified by passing it through a cold trap (-80oC), a mercury 
safety valve, an empty bottle, concentrated sulphuric acid, and a soda-lime 
tower. 
RADIOACTIVITY MEASUREMENTS 
Radioactivity measurements were made with a Nuclear-Chicago Mark I 
counter using the toluene: triton XI00 scintillator of Patterson & Greene (1965). 
THIN-LAYER CHROMATOGRAPHY 
Analytical chromatography was performed on Merck 0.25 mm silicagel 
precoated plates, or with plates spread with 10% silver nitrate impregnated 
silicagel (thickness 0.25 mm). Active regions were located by scanning the 
developed plate with a windowless gas flow proportional counter. Steroid 
markers were visualized by spraying with a 2.5% w/v solution of eerie sulphate 
in 1 M sulphuric acid and heating at 110oC for about 10 minutes. 
Preparative chromatography was performed on 1 mm silicagel PF254 coated 
plates. Active regions were located on developed plates by autoradiography. 
Labelled steroids were recovered by scraping off the silicagel and extracting 
with benzene/ethanol 90/10. 
Table 4.1 shows the solvent systems, which were used, together with typical 
Rf values of steroids likely to occur in the crude reaction product. 
RESULTS 
Estrenone-16-3H 
Estrenone (144 mg) was dissolved in a mixture of purified dimethylformamide 
(1 ml) and tritiated water (0.3 ml, 200 Ci). This mixture was sealed in an 
ampoule under vacuum and heated at 140oC for 48 hours. After cooling the 
solvent was removed under vacuum, followed by removal of labile tritium from 
the product by repeated distillation under vacuum with benzene/ethanol 80/20. 
The residue was taken up in chloroform (1 ml) and purified by TLC on two 
1 mm silicagel plates, developed in system C. 
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Table 4.1 — TLC data steroids 
System 
A 
В 
С 
D 
Solvents 
benzene/ethanol 
99/1 
cyclohexane/ethyl acetate 
90/10 
cyclohexane/acetone 
95/5 
cyclohexane/acetone 
95/5 
Adsorbent 
silicagel 
silicagel 
silicagel 
silicagel/AgNOs 
I 
0.38 
0.32 
0.29 
0.00 
II 
0.23 
0.20 
0.23 
0.32 
values steroids1) 
III IV 
0.60 — 
0.54 — 
0.60 — 
0.66 0.85 
V 
— 
0.452) 
— 
— 
') I lynestrenol, II estrenol, III estrenone, IV estranone, V 17ß-ethynyl-estr-4-en-17a-ol. 
г) Broess et al., 1975. 
-&· 
The purified estréneme-16-3H was extracted from the silicagel with 
benzene/ethanol 90/10 and weighed after lyophilisation of the solution. The 
sample was redissolved in benzene/ethanol 90/10, the radioactivity measured 
and its specific activity calculated. The solution of estrenone-16-3H was 
analysed by TLC in systems А, В, С and D. 
Yield: estrenone-3H 1.8 Ci 40.5 mg 
specific activity 12 Ci/mmol 
radiochemical purity 98% in systems А, В, С and D 
Lynestrenol-3H 
The reagents required for the conversion of estrenone-3H to lynestrenol-3H 
were manipulated in an enclosure filled with dry nitrogen. A solution of 
potassium t-butoxide in purified tetrahydrofuran (THF) (20 ml) was prepared. 
Aliquots (2 ml) of this were removed from the enclosure, diluted with water 
(1 ml) and then evaporated under a nitrogen stream to remove excess THF. 
These samples were then titrated against 0.1 M hydrochloric acid to determine 
the base concentration. 
The solution of estrenone-3H in benzene/ethanol was evaporated to dryness 
and 0.12 mmol (31.5 mg) of the residue was dissolved in purified THF (3 ml). 
This together with a rinsing of THF (2 ml) was transferred to a small 
separating funnel. The acetylene flask was evacuated and filled with acetylene 
(volume about 20 ml = 1 mmol). Potassium t-butoxide (0.2 mmol of base) 
in THF (5 ml) was placed in the reaction flask (Fig. 4.1) which was 
temporarily frozen with liquid nitrogen. The space above the solution in the 
separating funnel was partially evacuated and the main system was evacuated 
to a final pressure of about 10 Pa. The acetylene was condensed into the 
reaction flask and the stopcocks were closed. The system was warmed to 0 o C 
and with vigorous stirring the estrenone-3H solution was added from the 
separating funnel. This mixture was stirred for 3 hours. Nitrogen was admitted 
to the system and THF/water 20/1 (0.1 ml) was added to the reaction flask, 
cooled to 0 o C. About 1 minute later Amberlite AG50 № resin (0.5 g) was 
added and the mixture was stirred for a further 20 minutes, whereupon it was 
filtered and the filter washed with THF and benzene. The combined filtrate 
was rotary evaporated under reduced pressure to dryness. The residue was 
taken up in chloroform, a sample was taken for analysis, and the bulk of this 
solution applied to two 1 mm silicagel plates. These and also the analytical 
plate were developed with system B. 
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Fig. 4.1 — Schematic drawing of the apparatus used in the ethynylation of estrenone-16-3H. 
Lynestrenol-3H and estrenone-3H were removed separately from the plate 
and eluted from the silica with benzene/ethanol 90/10. The lynestrenol-3H 
solution obtained was rotary evaporated to small bulk and transferred to a 
tared flask. The residual solvent was removed in vacuo at room temperature 
and pumped to constant weight. The crystalline residue was weighed, redis-
solved in benzene and the radioactivity was measured and the specific activity 
of the product calculated. Subsequently, the solution was analysed in systems 
А , В and С 
Yield: lynestrenol-3H 
specific activity 
recovered estrenone-3H 
29 mCi 10.4 mg 
800 mCi/mmol 
52mCi 
Radiochemical purity 
After determination of the specific activity the lynestrenol-3H, cochromato-
graphed with carrier, was 98% pure in systems A and B, 97% pure in system С 
The impurities were minor decomposition products which had arisen during 
the manipulation of the sample. 
The recovered estrenone-3H was 95% pure in system С The principle im­
purity was Iynestrenol-3H. 
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DISCUSSION 
The dimethylformamide/tritiated water exchange reaction was carried out 
three times in all, the quality (age and previous use) of the solvent mixture 
being varied. The best result was obtained with a freshly prepared solution. 
These results together with the yields in the subsequent ethynylation reactions 
are shown in Table 4.2. The conditions of tritiation in all cases resulted in loss 
of the starting material estrenone, but this was acceptable for the resultant 
decomposition products exhibited low Rf values in system С and were easily 
separated from estrenone-3H. 
In all cases the ethynylation reaction was accompanied by considerable loss 
of tritium from the Cie position. This is demonstrated by the activity yields of 
both lynestrenol-aH and estrenone-3H shown in Table 4.2. In the case where 
the specific activity of the recovered estrenone-3H was measured, it was found 
to be similar to the product, lynestrenol-3H. This result indicates that the 
activity found in the products after the ethynylation reaction could be in 
positions other than Cie. This non-specific introduction of tritium is perhaps 
to be expected, considering the vigorous conditions (140oC, 2 days) of the 
initial tritiation. 
Loss of tritium from the Ci« position during the ethynylation of estrenone is 
not quite unexpected. It is known, that in the ethynylation of carbonyl com­
pounds which have a proton in the α-position, enolization competes with the 
desired reaction (Ziegenbein, 1969) and thus in the present synthesis of 
lynestrenol may lead to loss of label from Cie. 
The present results were confirmed by Broess et al. (1975) in model ex­
periments using deuterium instead of tritium. No significant change in deuterium 
content appeared to occur, when the ethynylation was carried out with an 
excess of ethynyl magnesium bromide in THF. Following this procedure also 
in the synthesis of tritiated lynestrenol from estrenone-16-3H as described in 
the present study, Broess et al. (1975) obtained lynestrenol-16-3H with a specific 
activity of 13.3 Ci/mmol in comparison with 14.0 Ci/mmol for the estren-
one-16-3H. 
SUMMARY 
Estrenone-16-3H with a specific activity of 12.0 Ci/mmol was prepared from 
estrenone by an exchange procedure with tritiated water in dimethylformamide. 
Lynestrenol-3H (specific activity 800 mCi/mmol) was obtained from estren-
one-
3H by reaction with acetylene and potassium t-butoxide in tetrahydrofuran. 
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Table 4.2 — Yields of estrenone-sH and lynestrenol-3H 
't-* 
§ 
α> i-
1 
2 
λ 
Quantity 
estrenone 
mg 
220 
230 
144 
by 
Yield 
weight 
% 
61 
60 
30 
of estrenone-3H 
activity 
mCi 
440 
1020 
1700 
specific 
activity 
mCi/mmol 
880 
2000 
12000 
by 
Yield of lynestrenol-3H 
weight 
% 
23 
60 
32 
activity 
mCi 
23.5 
77 
28 
specific 
activity 
mCi/mmol 
230 
270 
800 
Recovered 
estrenone-3H 
activity 
mCi 
34 
28 
52 
specific 
activity 
mCi/mmol 
240 
— 
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CHAPTER 5 
ASSAY OF RADIOACTIVITY 
INTRODUCTION 
Radioactivity was measured throughout the investigations by means of liquid 
scintillation counting (Horrocks, 1974). This technique is based upon the con-
version of part of the kinetic energy of an ionizing particle (usually originating 
from the decay of a radionuclide) into photons as a result of its interaction 
with scintillator molecules present in the scintillation solution. These photons 
are collected and measured by multiplier phototubes and subsequently the 
pulses from these tubes are summed up, sorted and counted. Although the 
energies of the radiation of a certain radioisotope are always the same, the 
response, which they produce in a particular liquid scintillation sample and, 
therefore, the counting rate measured will differ to a variable extent from the 
actually occurring number of nuclear désintégrations per unit of time. The term 
commonly used to denote the various processes causing a decrease in the photon 
yield of a liquid scintillator solution is "quenching". As a consequence of this 
ever present quenching phenomenon the number of counts per minute (cpm), 
that is measured with the liquid scintillation spectrometer, has to be corrected 
with the help of a calibration curve or otherwise in order to obtain the actual 
number of nuclear désintégrations per minute (dpm). 
MATERIALS AND METHODS 
Apparatus 
The liquid scintillation spectrometer used was a Packard Tri-Carb Model 
3380 (Packard Instruments S.A., Bruxelles, Belgium) equipped with an 
automatic external standardization system. 
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Sample preparation 
The samples were prepared for liquid scintillation counting after digestion, 
if necessary, with Soluene® (Packard) and using Instagel® (Packard) as 
scintillation liquid. Glass counting vials were used (Packard). 
Aliquots of aqueous protein-free solutions and dried aliquots of organic 
solvent extracts were counted after the addition of 10 ml Instagel. In case of 
volumes larger than 0.2 ml the volume was made up to 5 ml with water and 
then thoroughly mixed with 10 ml Instagel. 
The silicagel samples obtained from thin-layer chromatograms were prepared 
for liquid scintillation counting by addition of 5 ml water and 10 ml Instagel 
followed by vigorous shaking. 
Blood plasma, perfusate plasma and protein-containing dialysis samples were 
treated with 1 ml Soluene and warmed for 30 minutes in a water bath at 40 0C. 
Tissue samples were digested similarly with Soluene at a temperature of 550C 
until a clear solution was obtained. After dissolution 15 ml of a mixture of 
Instagel/1.0 M HCl 90/10 was added. 
For the assay of radioactivity in blood and perfusate an aliquot of not more 
than 0.2 ml was mixed with 1.5 ml Soluene/isopropanol 50/50. After digestion 
at room temperature for 10 minutes with occasional swirling 0.5 ml hydrogen 
peroxide 35% (OPG, Utrecht, The Netherlands) was added. After another 
10 minutes at room temperature and gently swirling the loosely capped vial 
was placed in a water bath at 40oC for about 15 minutes. Finally, 15 ml 
Instagel/1.0 M HCl 90/10 was added and mixed with the sample under vigorous 
shaking. 
The radioactivity of faecal samples was determined after the preparation of 
a suspension in water. An aliquot of the suspension (0.05-0.15 ml) was digested 
in triplicate with 1.0 ml Soluene in a water bath at 50oC for 2 hours. Sub-
sequently, 0.5 ml isopropanol was added and the solution was decolorized by 
the addition of 0.2 ml hydrogen peroxide 35%. After standing for 15 minutes 
at room temperature and 2 hours in the water bath at 50oC, 15 ml Instagel/1.0 
M HCl 90/10 was added and radioactivity was determined. 
Liquid scintillation counting 
Radioactivity was measured at preselected optimum spectrometer settings for 
the determination of 3H and "C . Quenching of the samples was corrected 
according to the external standard channels-ratio method using a calibration 
curve. This curve was obtained and checked at least once a week by the 
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assay of blank samples containing hexadecane-3H or hexadecane-14C (The 
Radiochemical Centre, Amersham, U.K.) as an internal standard. Generally, a 
similar curve was obtained with standards quenched with increasing amounts of 
nitromethane. 
Blank samples were used to correct for background activity. 
RESULTS AND DISCUSSION 
Following the procedures outlined above no particular problems were en­
countered in the course of the investigations. An example of a calibration curve 
for quench correction of tritium samples is shown in Fig. 5.1. The points in' 
the curve represent the mean of 5 successive measurements of the counting 
efficiency and the external standard channels-ratio of a series of hexadecane-3H 
standards. The relative error did not exceed ± 0.5% and demonstrates the 
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Fig. 5.1 — Quench correction curve for tritium counting efficiency versus external standard 
channels-ratio. Points in the curve represent the mean efficiency and channels-ratio of 5 
successive measurements of a series of nitromethane quenched standards. The relative error 
for each point is smaller than ± 0.5%. 
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reliability of this technique. The counting efficiency of tritium samples varied 
between 15 and 47%, for carbon-14 samples between 80 and 92%. Incidental 
counting efficiencies for tritium samples below 15% were corrected by means 
of the internal standard method. 
Apart from the applied quench correction the precision of the radioactivity 
value measured for any sample is determined by the total number of counts 
(gross counts) measured during the counting period of the sample and is ex-
pressed in the relative standard deviation of counting. This relative standard 
deviation is represented by the quotient of 100 and the square root of the gross 
count value. Generally, this figure was less than ± 1.0%. Counting of some 
samples, however, with a very low level of radioactivity, like blank samples, 
silicagel samples scraped outside the zones of high radioactivity and certain 
tissue samples, resulted in standard deviations of 2.5% and more, because the 
maximal counting period applied was 20 minutes. 
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CHAPTER 6 
THE RADIOLIGAND BINDING ASSAY USED 
IN THE RECEPTOR BINDING STUDIES 
INTRODUCTION 
The availability of radiolabelled estradiol of high specific activity enables a 
direct measurement of its binding to the estrogen receptor. After preliminary 
experiments it appeared also possible to study the interaction of the other 
compounds under investigation with the receptor using the principle of com-
petition between a radioligand (tritiated estradiol) and a radioinert substance 
for the receptor binding sites (Korenman, 1968). The bound fraction of the 
radioligand is measured by means of liquid scintillation counting after adsorp-
tion and precipitation of the unbound ligand with dextran-coated charcoal 
(Herbert et al., 1965; Korenman, 1968). This technique is widely used in studies 
dealing with the binding of steroid hormones to their receptors as well as to 
antibodies. Several points pertinent to the applicability and a correct use of 
the competitive binding assay deserve further consideration. In this chapter 
special attention is given to the incubation time needed for the radioligand to 
reach binding equilibrium under the experimental conditions applied, the reversi-
bility of binding and the equilibration time for the binding of the competing 
steroids. The binding capacity of the dextran-coated charcoal suspension, the 
effectiveness of this separation procedure and the stability of the radioligand 
binding in the presence of the adsorbant have also been studied. 
EXPERIMENTAL PROCEDURE 
Steroids, dissolved in ethanol, were transferred to silanized conical glass 
tubes. The solvent was evaporated with a weak stream of air. When the initial 
volume did exceed 0.2 ml, the wall of the tube was consecutively rinsed with 
0.2, 0.2 and 0.1 ml ethanol to concentrate the steroids at the bottom. The 
indicated amount of estradiol-3H alone or together with a certain excess of 
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another steroid was incubated with 0.2 ml cytosol (see Chapters 10, 11) under 
continuous and gentle shaking at a temperature of 1-40C. After a period of 
20 hours, unless otherwise indicated, 0.2 ml charcoal-dextran suspension 
(0.1% Aktivkohle, Merck, and 0.05% Dextran Τ 70, Pharmacia, in 0.01 M 
Tris-HCl buffer, pH 7.4, containing 0.0015 M EDTA) was added and the 
incubation was continued for another 15 minutes. Subsequently, the charcoal 
was spun down by centrifugation for 10 minutes at 600xg and 0.2 ml of the 
clear supernatant was put into a counting vial for the assay of radioactivity. 
RESULTS AND DISCUSSION 
Unbound ligand adsorption to dextran-coated charcoal 
1. Binding capacity of the charcoal suspension 
Calf uterine cytosol was incubated overnight with 1.5 nM estradiol-3H and 
15 μΜ estradiol. The effectiveness of the charcoal adsorption of the radioligand 
was measured by comparing the radioactivity of samples not treated with 
charcoal and the radioactivity of samples incubated for 15 minutes with either 
0.1% or 0.5% dextran-coated charcoal suspension. The same results were 
obtained irrespective of the charcoal concentration. Only 1-2% of the radio­
activity measured in the control samples (5300 cpm), probably estradiol bound 
to non-specific binding sites, appeared to be not precipitated. 
2. Influence of time on radioligand adsorption 
Incubation of only the cytosol buffer, containing 1.5 nM estradiol-3H, with 
an equal volume of the 0.1% dextran-coated charcoal suspension revealed 
that adsorption of the radioligand was complete within 15 minutes after the 
addition of the adsorbant. Only 2% of the radioactivity present in the control 
sample (5400 cpm) could be detected after 5 minutes charcoal treatment. After 
15, 30 and 60 minutes the amount left in the solution was less than 0.5% of 
the control level. 
3. Stability of the estradiol-receptor complex 
1.5 nM estradiol-3H was incubated overnight with calf uterine cytosol and 
subsequently for 10, 15 and 30 minutes with an equal volume of 0.1% dextran-
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coated charcoal suspension. No decrease of bound radioactivity could be ob-
served over the time period studied, so it can be concluded that the estradiol 
binding measured in the assay is stabile and resists the charcoal treatment 
under the experimental conditions. 
Equilibration time and reversibility of binding 
Calf uterine cytosol was incubated for increasing periods of time with 11 nM 
estradioI-3H alone or in the presence of 200 nM ethynodiol. After charcoal 
treatment as described above bound estradiol-3H was measured by liquid 
scintillation counting. The results presented in Fig. 6.1 (upper curve) demonstrate 
the high association rate of estradiol to the receptor binding sites. After one 
hour incubation more than 85% of the binding observed ultimately is attained. 
The initial steep incline of the estradiol binding curve is followed by a more 
gradual increase, until a plateau is reached after about 17 hours incubation. 
That the curve observed actually reflects the interaction of estradiol with its 
estradiol3H 
ethmylestradiol 
5 10 15 20 25 30 
time(h) 
Fig. 6.1 — Time course of estradiol binding to calf uterine cytosol. In the presence of an 
excess of ethynodiol the binding of estradiol is reduced, but the shape of the binding curve 
does not change. The points in the curves are the mean of 3 incubations. The residual, non-
specific, binding of estradiol-3H in the presence of a 200-fold excess of ethmylestradiol is 
also shown. 
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specific binding sites is evident from the small fraction of the ligand, that is 
non-specifically bound. This non-specific binding is the estradiol binding 
measured in the presence of an excess (2 μΜ) of the strong binding synthetic 
estrogen ethinylestradiol. 
The other, lower, curve in Fig. 6.1 shows on the one hand, that ethynodiol 
is reversibly bound to the binding sites of the receptor, since inhibition of 
estradiol binding does not increase with time, and on the other hand, that 
equilibrium of the binding is reached after an incubation period of about 
20 hours. 
Under equilibrium conditions the relative error, from which the reproduci­
bility and the precision of the assay may be deduced, appeared to be smaller 
than ± 5% in binding experiments with only the radioligand. In experiments, 
however, concerning the study of the influence of other steroids on estradiol-3H 
receptor binding, the relative error appeared to increase and varied usually 
between ± 5-10%. 
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CHAPTER 7 
THE ASSAY OF LYNESTRENOL IN BLOOD 
AND PERFUSION MEDIUM 
INTRODUCTION 
In general the use of radiolabelled drugs in pharmacokinetic investigations 
has to be considered as second choice for several reasons. Apart from economic 
and practical reasons like the availability of the radiolabelled drugs of interest 
and the more practical drawback inherent to the daily and safe handling of 
radioactive materials and samples, which, additionally, will make the overall 
analysis often more time-consuming than the analysis of radioinert substances, 
the most serious disadvantage is that pharmacokinetic investigations in humans 
using radiolabelled drugs are generally not permitted for ethical reasons. There-
fore, at the initiation of the present investigations extensive efforts have been 
undertaken to develop a gas chromatographic assay for the determination of 
therapeutic blood levels of lynestrenol. 
Because the blood concentration of lynestrenol in humans, when a contra-
ceptive dosage regimen is followed, consisting of a daily intake of 2.5 mg 
of the compound, can be expected to be in the order of nanograms per ml and 
less, the choice of the analytical technique is limited by the required sensitivity. 
The sensitivity of gas chromatography with electron-capture detection has been 
shown previously to meet this requirement in the analysis of compounds with a 
high electron-absorption coefficient as it is the case for many pesticides (Krejci & 
Dressier, 1970). Because the electron-absorption coefficient of lynestrenol is too 
low to permit a sensitive analysis by means of this technique, some derivatives 
were synthetized with better properties in this respect, viz. lynestrenol hepta-
fluorobutyrate and the chloro-, bromo- and iodomethyldimethylsilylether of 
lynestrenol. The gas chromatographic properties of the latter compound were 
superior and the detector response allowed the quantitation of minute amounts 
of only 25 picogram. The necessary two-step derivatization procedure appeared 
to result in a quantitative conversion. Problems, however, were encountered with 
the specificity of the assay and could not be overcome (Van Kordelaar, 1972). 
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For this reason the pharmacokinetics of lynestrenol has been studied using the 
radiolabelled compound. The lynestrenol concentrations may then be deter­
mined by measuring the isotope content of the sample with the help of liquid 
scintillation counting (this thesis, Chapter 5). 
EXPERIMENTAL PROCEDURE 
Extraction 
Immediately after collection the samples were cooled in ice and processed 
during the same day. A volume of 0.1 ml perfusate, blood or plasma was 
transferred to a conical glass tube and diluted with an equal volume of water. 
After the addition of 4 volumes ethanol, containing 100 μg lynestrenol/ml, the 
mixture was extracted with consecutively 2, 1 and 1 ml n-hexane by vigorous 
stirring for 1 minute using a whirl-mixer. The combined extracts were evapor­
ated in a counting vial with a weak stream of air and radioactivity was measured 
by means of liquid scintillation counting. 
Thin-layer chromatography 
Duplicate hexane extracts obtained from a sample volume of 0.2 ml instead 
of 0.1 ml were used for the fractionation of radioactivity by means of thin-layer 
chromatography. Because of the decreasing level of radioactivity during the 
experiment the sample volume was increased to 1.0 ml and 0.4 ml for the last 
and the last but one sample respectively. After intraduodenal administration of 
lynestrenol TLC was performed with only one sample of 0.5 ml volume. The 
other volumes used in the extraction procedure were accordingly adapted. 
Chromatography was carried out over silicagel pre-coated glass plates 
(Kieselgel F254, Merck) in the solvent system toluene/ethylacetate 80/20 or 
toluene/ethanol 90/10. Lynestrenol was localized by exposing the developed 
chromatogram to iodine vapour. The developed area was divided into 10 bands, 
one corresponding to the marker steroid added initially to the sample, 4 zones 
of 0.5 cm width adjacent to the lynestrenol region, and another 5 zones of about 
equal size. The bands were scraped off with a razor blade and the silicagel was 
transferred to a counting vial for the assay of radioactivity. The fraction of the 
total plate radioactivity measured in the lynestrenol region and in the narrow 
zone just above was used for the calculation of the lynestrenol content of the 
hexane extract. 
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Recovery 
Four blank samples to which a known amount of IynestrenoI-3H had been 
added, were extracted with hexane as described. The mean value of the effi-
ciency of these extractions was used to correct the experimental data. 
RESULTS AND DISCUSSION 
Specificity 
Because the measurement of radioactivity is essentially non-specific, as the 
result will represent the total isotope content of the sample including lynestrenol 
itself as well as its conversion or degradation products, the separation of the 
parent compound from these products prior to the measurement of radio-
activity is necessary. In the present analysis a two-step separation was applied, 
namely extraction of the lynestrenol from the aqueous sample with an organic 
solvent and thin-layer chromatography of the extract. 
1. Extraction procedure 
For the extraction procedure the choice of a non-polar solvent was considered 
to be most promising in view of the lipophilic nature of lynestrenol itself 
(Chapter 8) and the increased polarity of its conversion products (Chapter 12). 
On the other hand the use of a rather volatile solvent would facilitate the 
necessary volume reduction of the extract to a high extent. A very effective 
extraction of lynestrenol could be attained by using n-hexane, which appeared 
to yield a recovery of about 90% and more, whereas at the same time the 
majority of the metabolites remained in the aqueous phase. Lysis of the 
erythrocytes by dilution of the sample with water and the precipitation of the 
plasma proteins by the subsequent addition of 4 volumes ethanol prior to the 
extraction improved the precision of the procedure. 
In order to prevent the loss of significant amounts of lynestrenol by adsorp-
tion to the glass-ware and to avoid similarly the occurrence of artefacts during 
chromatography of nanogram and subnanogram amounts, the ethanol added to 
the sample contained an excess of non-labelled lynestrenol. This latter com-
pound could, moreover, serve as a marker to localize the radiolabelled com-
pound after development of the chromatogram. 
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2. Thin-layer chromatography 
The present knowledge of those biotransformation products of lynestrenol, 
which may be assumed to be extractable to some extent with n-hexane, is limited 
to the observation of a metabolite excreted in the bile with the tentative structure 
17a-ethynyl-5i-estrane-3|,17ß-diol (Coert et al., 1975; Mazaheri et al., 1970; 
this thesis, Chapter 12) and the conversion of lynestrenol to norethindrone, 
reported by Mazaheri et al. (1970), Murata (1967) and Yamamoto (1968). 
So in any case an effective separation of lynestrenol from these and other 
hydroxylated and oxygenated derivatives was required. Because the conversion 
of lynestrenol to less polar compounds was considered to be not very likely in 
view of reports concerning the biotransformation of ethynodiol (Cook et al., 
1973; Kishimoto et al., 1972), norethindrone (Braselton et al., 1977; Cook 
et al., 1974; Gerhards et al., 1971), norethynodrel (Cook et al., 1972; Kishimoto 
et al., 1972) and norgestrel (Gerhards et al., 1971; Hendeles et al., 1972), the 
choice of a solvent system for chromatography allowing a great mobility to 
lynestrenol but restricting the mobility of the compounds mentioned above was 
supposed to give optimal results. The solvent systems toluene/ethylacetate 80/20 
and toluene/ethanol 90/10 meet these requirements as is illustrated by a Rf value 
of lynestrenol in both systems of about 0.7 and on the other hand Rf values for 
norethindrone, ethynodiol and the metabolite of about 0.25 in the former sol-
vent system and 0.48, 0.40 and 0.34 respectively in the latter solvent system. 
In the course of the investigations three out of four of the narrow silicagel 
zones adjacent to the lynestrenol marker were always devoid of radioactivity. 
Sometimes, however, and only in extracts of rat blood but never in extracts of 
perfusion medium, a variable amount of radioactivity, up to 25% of the 
radioactivity measured in the lynestrenol region on the chromatographic plate, 
appeared to be present in the zone just above the lynestrenol marker. No regular 
pattern could be observed in the appearance of this phenomenon in a qualitative 
and quantitative sense, so the presence of a conversion product is not very 
probable. Moreover, a similar phenomenon was sometimes observed in thin-
layer chromatography of comparable amounts of lynestrenol-3H added to 
hexane extracts of blank rat blood and subjected to the same experimental 
procedure. Because, however, 17a-ethynyl-5a-estran-17ß-ol appeared to display 
an analogous mobility in the chromatographic systems applied, the specificity 
of the assay was further substantiated by means of gas chromatography. To 
obtain sufficiently high blood levels of lynestrenol and the hypothetical 
metabolite a rat was injected 3 times at 30 minutes intervals with 0.5 mg 
lynestrenol and sacrificed 90 minutes after the first injection by decapitation. 
The blood was collected in a heparinized tube and processed as usual without, 
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however, the addition of lynestrenol as a marker for chromatography. After 
extraction and chromatography the silicagel zone corresponding with the 
lynestrenol spot and the zone of interest just above were scraped off the plate. 
The silicagel was extracted with dichloromethane/methanol 70/30. After the 
evaporation of the solvent with a weak stream of air the residue was dissolved 
in hexane and injected in a gas Chromatograph (Hewlett Packard Model 402) 
equiped with a flame ionization detector, a solid injection system and a capil-
lary column (SE-30, 25 m, LKB no. 74). The gas chromatogram of the blood 
extract and a standard solution containing lynestrenol and 17a-ethynyl-5a-
estran-17ß-ol is shown in Fig. 7.1. Obviously, the latter compound is absent in 
the blood extract. The minor peaks in the gas chromatogram of the extract 
eluting before lynestrenol were also present in a blank blood sample of the 
detector response (e/o ) 
100 -, 
5 0 -
column S E - 3 0 length 2 5 m 
oven lemperatûre 230oC 
( lame ionization detector 
range 10 
attenuation θ 
12 16 2 0 
t i m e CmmJ 
Fig. 7.1 — Gas chromatograms of a standard solution (left), containing 17a-ethynyl-5a-
estran-17ß-ol (a) and lynestrenol (b), and of an extract of rat blood (right) obtained from 
the animal after lynestrenol injection. For experimental details see text. For comparison, 
the retention times of norethynodrel (c) and norethindrone (d) are also indicated. 
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same rat, which was subjected to an identical procedure. The same results were 
obtained in a similar experiment with another animal. 
In view of these findings we thought it justified to consider also the radio-
active material present in the narrow zone just above the lynestrenol marker 
as lynestrenol. 
Sensitivity and sample volume 
The sensitivity of the determination of lynestrenol-3H and lynestrenol-14C by 
means of liquid scintillation counting is limited by the specific activity of the 
steroid and, like for any assay, by the volume of the sample. Principally, the 
specific activity of the lynestrenol-3H, about 700 mCi/mmol during the in-
vestigations, enables the accurate quantification of amounts of lynestrenol as 
small as 50 picogram, corresponding with 275 dpm. The comparatively low 
specific activity of the available lynestrenol-4-14C, 32.5 mCi/mmol, restricted 
the use of this compound to experiments, where the analysis of excreta was 
envisaged, and to distribution studies by means of whole-body autoradiography. 
Assuming a somewhat higher threshold level of radioactivity of 500 dpm 
instead of 275 dpm for the experimental samples in the present investigations, 
then it will be possible to measure lynestrenol concentrations of 1 ng/ml in an 
extract obtained from a sample of 0.1 ml volume with a standard error of 
counting of 1.5% at a counting efficiency of 40-45% and using a counting time 
of 20 min. The chromatographic step, however, in the assay of lynestrenol 
requires at least double the sample volume as a consequence of the decreased 
counting efficiency of the silicagel samples (about 25%). Moreover, the fraction 
of lynestrenol in the hexane extract is calculated as the percentage of the sum 
of the radioactivity present in 10 silicagel samples after correcting these samples 
for the background radioactivity (about 200 cpm total). For this reason the 
sample volume has to be increased above 0.2 ml for blood and perfusate samples 
with lynestrenol concentrations below 4 ng/ml. 
Obviously, therefore, the total volume of blood and perfusate available for 
sampling will determine ultimately the lowest concentrations which can be 
measured, as well as the number of samples that can be taken for analysis. 
The available sample volume is restricted by the total blood volume of the 
animal or the total volume of the perfusion medium in the experiments with the 
isolated perfused liver and is determined on the other hand by the number of 
samples to be taken in order to allow a meaningful pharmacokinetic analysis 
of the concentration-time course of the drug. 
In the experiments with the isolated perfused rat liver the volume of perfusate, 
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which is available for sampling without disturbance of the physiological state 
of the liver under the experimental conditions is only determined by the design 
of the perfusion apparatus and the volume of the perfusion medium. Because, 
however, the volume of distribution of the drug in these experiments is in the 
same order of magnitude as the volume of the perfusion medium (Chapter 15), 
the fraction of the total volume used for analysis should not exceed 5% in 
order to avoid errors in the estimation of the elimination time constant from 
the slope of the concentration-time curve (Nagashima et al., 1968). Taking this 
restriction into account a complete analysis of 8-9 perfusate and perfusate 
plasma samples could be accomplished in these experiments. This number was 
sufficient to obtain reliable and significant information about the time course 
of lynestrenol over a wide concentration range. 
With respect, however, to the in vivo experiments a complete analysis of each 
sample, including thin-layer chromatography, appeared to be not feasible for the 
following reasons. In the first place the number of samples had to be increased 
as a consequence of the more complex profile of the concentration-time curve 
of lynestrenol as compared with a mono-exponential decay observed in the 
isolated liver. Secondly, the number of low level samples was considerably 
greater, particularly after intraduodenal administration of lynestrenol. Finally, 
the total blood volume available for analysis was smaller than in the in vitro 
studies: to maintain the physiological state of the animal as much as possible 
the total blood volume taken for analysis in the course of the in vivo experiments 
did not exceed 2 ml. This volume represents 15-20% of the total blood volume 
of the rat (about 6 ml/100 g body weight, Altman, 1961). As a consequence 
of this unfavourable combination of factors a complete analysis including thin-
layer chromatography was carried out on 5 out of 13 samples following in-
tra-arterial injection of lynestrenol and on 1 out of 13 samples in case of in-
traduodenal administration of the compound. The consequences of this 
procedure for the interpretation of the experimental results are discussed in 
Chapter 16. 
Recovery, reproducibility and precision 
The fraction of lynestrenol recovered after the extraction procedure was 
measured in each experiment using blank samples to which a known amount of 
lynestrenol-3H was added. The efficiency observed in the course of the in-
vestigations varied between 88 and 94% for the extraction of perfusate samples, 
between 92 and 95% for the extraction of perfusate plasma and between 91 
and 96% for the extraction of rat blood. Besides the good reproducibility, which 
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may be deduced from these figures, the precision of the extraction was equally 
good as is illustrated by the small relative error, which did not exceed ± 3 %. 
The concentration range of the radiolabelled drug encountered in the ex­
periments was not of significance for the overall performance of the assay as a 
consequence of the large excess of non-labelled lynestrenol added prior to the 
extraction. 
Pharmacokinetic analysis 
Pharmacokinetic analysis of the lynestrenol blood and perfusate levels was 
accomplished by fitting of the experimental data to the mathematical equations 
pertinent to the pharmacokinetic model, which was considered to give the best 
approximation of the concentration-time profile observed. Curve fitting was 
performed with the aid of the non-linear regression computer program 
FARMFIT*). Detailed information on this program has been provided previous­
ly by Breimer (1974). From the best fit of the data the pharmacokinetic para­
meters are calculated. Furthermore, the program provides the goodness of fit 
expressed as the standard error for the ordinate mtercept(s) and the elimination 
time constant(s) of the best-fitting concentration-time curve, assuming a 
relative error in the experimental data of + 5 %. 
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CHAPTER 8 
LIPOPHILICITY AND PROTEIN BINDING OF LYNESTRENOL 
INTRODUCTION 
It is nowadays well established, that the extent of plasma protein binding 
and the physicochemical properties of a drag under physiological conditions 
may have an important bearing on its distribution, biotransformation and 
excretion and, therefore, also on the course of drug activity in a qualitative 
and quantitative sense (Dayton et al., 1973; Goldstein et al., 1974; Jusko & 
Gretch, 1976; Raaflaub, 1970; Wilkinson & Shand, 1975). 
According to common theories in pharmacology only the unbound or free 
drug fraction in the blood diffuses through the capillary walls, reaches the site 
of drug action and is subject to renal elimination from the body. Since 
generally the binding of drugs to plasma proteins is readily reversible and obeys 
the law of mass action, particularly the albumin-drug complex, which is quan­
titatively by far the most important for the great majority of drugs, may serve 
as a circulating drug reservoir, that will release part of the drug when the free 
drug concentration in the blood decreases as a consequence of proceeding bio­
transformation and excretion processes. The possible significance of the carrier 
and reservoir function of the blood proteins will be greater for drugs displaying 
a poor solubility in water and a high degree of protein binding. Moreover, 
protein binding may protect the drug to some extent against biotransformation 
in the liver, like has been demonstrated for warfarin (Yacobi & Levy, 1975; 
Yacobi et al., 1976), dicumarol (Lai & Levy, 1977), bilirubin (0ie & Levy, 
1975) and phenytoin (Gugler & Azamoff, 1976), although for a highly protein 
bound drug like propranolol biotransformation in the liver appeared not to be 
restricted to the unbound fraction (Evans & Shand, 1975). 
The passage of drugs across biological membranes by passive diffusion is 
generally considered to be limited to the uncharged molecule and to be favoured 
by a high degree of lipid solubility (Goldstein et al., 1974; Raaflaub, 1970). 
Drug partitioning between two immiscible liquid phases, one of which water 
and the other one a non-polar organic solvent like η-heptane, may be used as a 
64 
model for the distribution in the organism between the various body fluids and 
the cell membranes. 
In view of the apparent significance of the protein binding and lipophilicity 
also for the pharmacokinetic investigations envisaged, the partitioning of 
lynestrenol over n-heptane/water and its binding to serum albumin have been 
studied and are reported below. 
MATERIALS AND METHODS 
Assay of protein binding 
The binding of lynestrenol to bovine serum albumin (BSA, Povite, 
Amsterdam, The Netherlands) was determined by means of equilibrium dialysis 
in the apparatus described by Rodrigues de Miranda (1975). The apparatus 
consists of six pairs of teflon cells of 3.5 ml volume each, separated by a semi­
permeable membrane (cellulose acetate, AKU, Arnhem, The Netherlands) and 
clamped together. Both cells of a pair contained 3.0 ml 0.1 M phosphate buffer, 
pH 7.4, and 0.02% NaNs as a bacteriostatic. The protein compartment, addition­
ally, contained 2.9% BSA (0.42 mmol/1) and in most experiments also the 
lynestrenol. In spite of its low solubility in water it appeared possible to obtain 
lynestrenol concentrations of more than 1 μg/ml by taking advance of the solubil-
izing properties of the protein. The protein/lynestrenol-3H solution was prepared 
by incubation of the protein solution with an aliquot of pure lynestrenol-3H 
for 1 hour at 37 0 C . Some experiments were carried out starting with 
lynestrenol-3H in the protein-free compartment. The latter solution was prepared 
by adding an aliquot of lynestrenol-'H dissolved in ethanol to the buffer 
solution to a final ethanol concentration of 2%. During the dialysis the cells 
were placed in a water bath at 37 0 C and were rotated at a rate of 1 r.p.m. 
for 24 hours. This equilibration period was chosen from preliminary experiments, 
where lynestrenol was added alternatively to the protein and to the other 
compartment. At equilibrium the lynestrenol-3H concentration was measured 
at both sides of the membrane by liquid scintillation counting of 1.0 ml of 
the respective solutions. The difference between the total concentrations in the 
protein and in the protein-free compartment represents the fraction of lynestren­
ol, that is protein bound. Dividing this fraction by the concentration measured 
in the protein compartment and multiplying by 100 gives the percentage of 
binding. The albumin content at equilibrium was measured spectrophotometri-
cally at 279 nm (Zeiss PMQ-II). 
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Determination of the partition coefficient 
Drag partitioning was studied by shaking 3.0 ml 0.1 M phosphate buffer, 
pH 7.4, saturated with η-heptane, and 1.0 ml η-heptane, saturated with buffer, 
in stoppered silanized glass tubes for a period of 24 hours at room temperature. 
Lynestrenol-4-14C, radiochemical purity 98.8%, was dissolved in the organic 
phase at concentrations of 0.4 and 0.8 μg/ml. The phases were allowed to 
separate by standing for 1 hour and the equilibrium concentrations were deter­
mined by liquid scintillation counting of 0.1 ml η-heptane and 2.5 ml buffer 
as described in Chapter 5. 
RESULTS 
Protein binding 
The protein binding was determined at equilibrium concentrations varying 
from 2 to 1700 ng lynestrenol/ml, which were in the range of the blood con­
centrations encountered in the rat in vivo and in vitro in the perfusion experi­
ments. The results are shown in Fig. 8.1 and demonstrate that more than 97% 
0/o bound 
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Fig. 8.1 — Diagram illustrating the binding of lynestrenol to bovine serum albumin 
measured by means of equilibrium dialysis. The lynestrenol concentrations are the concen­
trations at equilibrium. Each experiment was carried out in duplicate or in triplicate. 
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of the lynestrenol is bound to the protein at all concentrations. The association 
constant of the drug-protein complex was determined with the help of the 
reciprocal plotting method of Klotz (1946), using the equation: 
l/r = 1/n + 1/n . Кл . l/[Ar] 
where r represents the fraction of the macromolecules occupied by drug mol­
ecules, η is the number of independent binding places, Кд is the association 
constant and [Ак] is the unbound drug concentration. When plotting l/r against 
1/[Ак] a straight line was obtained in the present study. From its slope a value 
for K.v could be calculated of 8.9xl04 M 1 , assuming the existence of one binding 
place for each albumin molecule. The number of binding places per molecule 
could not be established from the present experiments, because the low solubility 
of lynestrenol made it impossible to reach high enough drug concentrations. 
Lipophilicity 
The determination of the lipophilicity of lynestrenol as a partition coefficient 
between η-heptane and water is complicated by its low solubility in the aqueous 
phase and a very good solubility in the organic phase. Under these circum­
stances it is conceivable that at concentrations exceeding the solubility of the 
compound in the buffer the partition coefficient measured is influenced by the 
lynestrenol concentration in the organic phase and will correspond ultimately 
with the ratio of the concentrations of the saturated solutions. In order to avoid 
this complication the initial concentrations of lynestrenol in the heptane were 
chosen as low as possible (about 0.4 and 0.8 ц§/т1). Using these concentrations 
the determination of lynestrenol in the buffer appeared to be just feasible. 
The results obtained are shown in Table 8.1 and demonstrate, that lynestrenol 
Table 8.1 — Partition coefficient of lynestrenol 
EQUILIBRIUM CONCENTRATION PARTITION COEFFICIENT 
mean (dpm/ml) ± S.D. (n = 5) n-heptane/buffer 
η-heptane buffer 
99,200 ± 700 19.3 ± 1.5 5140 ± 400 
204,600 ± 1800 43.5 ± 3.2 4700 ± 350 
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is a highly lipophilic compound. The values of the partition coefficient measured 
at both concentrations are an indication, that no saturation of the buffer with 
lynestrenol did occur. 
DISCUSSION 
The results presented show unequivocally that protein binding and lipophili-
city of lynestrenol are high and may have an important influence on its phar­
macokinetic behaviour. 
Regarding on the one hand the extremely high lipophilicity of lynestrenol 
and on the other hand the fairly strong binding of testosterone, progesterone 
and estradiol to BSA with association constants between 104 and 105 M 1 
(Westphal, 1971), the extensive and rather strong binding of the former steroid 
is not an unexpected finding. An inverse relationship between the binding 
affinity of steroids to serum albumin and the number of polar groups has been 
observed previously by Eik-Nes et al. (1954) and Westphal & Ashley (1962). 
The validity of this polarity rule has since been confirmed in many instances 
(Scholtan, 1968; Westphal, 1971). 
The concentration range studied in the dialysis experiments covered the 
perfusate and blood levels of lynestrenol encountered in the isolated perfused 
rat liver preparation as well as in the rat in vivo (this thesis, Section IV). 
Because the binding of lynestrenol to albumin within this concentration range 
appeared to be constant and, moreover, the metabolic clearance of lynestrenol 
appeared to be of the non-restrictive type (Shand et al., 1976; Wilkinson & 
Shand, 1975) as far as albumin is concerned (Van Kordelaar et al., 1978; this 
thesis, Chapter 15), it seems unlikely that this binding could complicate the 
pharmacokinetic behaviour of the drug. However, following intra-arterial ad­
ministration of lynestrenol to rats a decrease of the clearance of the compound 
was observed by us as compared with the isolated rat liver (this thesis, Chapters 
15, 16). The liver preparation was perfused with a semi-synthetic medium con­
taining only BSA and no other serum proteins. This raises the question, whether 
there are additional binding sites for lynestrenol present in rat blood, e.g. 
globulins, with a binding affinity and capacity high enough to reduce the 
metabolic clearance rate of the compound to the extent observed. This aspect 
deserves further investigation and is discussed in Chapter 16. 
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CHAPTER 9 
EFFECT OF CONTRACEPTIVE STEROIDS AND RELATED 
COMPOUNDS ON THE DISTRIBUTION PATTERN OF 
ESTRADIOL-3H IN THE OVARIECTOMIZED RAT 
INTRODUCTION 
Since the investigations of Eisenfeld & Axelrod (1965, 1966), Glascock & 
Hoekstra (1959), Jensen & Jacobson (1962), Kato & Villee (1967), Stone et al. 
(1963) and others concerning the specific uptake and retention of estrogenic 
hormones by their target tissues, much progress has been made in the elucidation 
of the underlying mechanism of their observations. In recent years investigations 
in several laboratories have established that target tissues for estradiol contain 
cytoplasmic proteins with a high affinity, a high degree of specificity and a 
limited capacity for the binding of estrogens. At present, evidence is growing, 
that these proteins are indispensably implicated in estradiol action, and there-
fore may be regarded as the estrogen receptor molecules (Baulieu et al., 1975; 
Buller & O'Malley, 1976; Gorski & Gannon, 1976; Jensen & DeSombre, 1973). 
Consequently, interference with estradiol binding to these proteins by other com-
pounds could modulate or change the course of processes controlled by estradiol 
and other estrogens (see Chapter 1). 
Endogenous as well as exogenous compounds have been demonstrated to 
influence the binding of estradiol in its target tissues and to possess either 
estrogenic or anti-estrogenic properties (see Chapter 1 and references thereof). 
In this connection, contradictory results have been reported for some contra-
ceptive progestins (Eisenfeld & Axelrod, 1965, 1967; Rosner et al., 1972; 
Saucier et al., 1970; Watanabe et al., 1968). Because of the possible 
significance of such an interaction for the mechanism of action and the biologi-
cal profile of these compounds as well as their pharmacokinetic behaviour, 
further investigations in this field seemed worth-while. A study has been made 
of the influence of contraceptive progestins and related compounds on the 
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binding of estradiol to the estrogen receptor of the rat in vivo and in vitro. In 
this chapter the results obtained from in vivo experiments are described. 
Evidence is presented, that the contraceptive progestins of the 19-nortestoste-
rone series (including lynestrenol) are able to interfere with the binding of 
estradiol to the estrogenic target tissues. Experiments in vitro with the 105,000xg 
supernatant of rat uterus homogenates have confirmed these results (Van 
Kordelaar et al., 1975) and are the subject of Chapter 10. 
MATERIALS AND METHODS 
Animal experiments 
In all experiments young adult Wistar rats (Centraal Proefdierenbedrijf TNO, 
Zeist, The Netherlands) were used, 3 weeks after ovariectomy. All compounds 
were administered via the tail vein under light ether anaesthesia. The unlabelled 
compounds were given 5 min before estradiol-3H unless otherwise indicated. 
The control animals received the solvent only. One hour after the injection of 
0.1 μg/100 g estradiol-6,7-3H, specific activity 40 Ci/mmol, the animals were 
killed by decapitation. Blood was collected in a heparinized tube and the heart 
was removed immediately. Then the skull was opened to remove the brain and 
the anterior pituitary. The brain was frozen and thereafter dissected according 
to the scheme given in Fig. 9.1. The cortex sample is not indicated in Fig. 9.1 
and was taken from the parietal lobes of the cerebrum. As for the other brain 
samples, the names mentioned and used throughout the text do not pretend to 
describe the brain areas in a strictly anatomical sense, as adjacent structures 
are included. During the dissection of the body the removed organs and 
tissues were cooled on ice. After rinsing with saline and blotting on filter-paper 
the whole organ, but not more than 50-100 mg, was put in a pre-weighed 
counting vial for radioactivity assay by liquid scintillation counting. In each 
experiment two or three animals served as controls. The control data collected 
over the whole period of the present study have been grouped together for the 
statistical evaluation of the results obtained. 
Test compounds 
Specifications of the steroids and other compounds used have been given in 
Chapter 3. 
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Fig. 9.1 — Dissection scheme of the rat brain illustrated in a mid-sagittal view and an 
external view from the ventral surface. The shadowed areas indicate the position of the 
samples taken according to the stereotaxic atlas of the rat brain (König & Klippel, 1963). 
ί Ψ | ^ | Γ ί : amygdala 
$Ш<Ш$ preoptic area 
ШШШт 
tractus diagonalis with part of the septum (referred to as septum) 
thalamus 
;'·:·;-Χ;'.·>"; septal tissue (referred to as septum) 
ViVííVv1 hypothalamus 
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Tissue analysis of estradiol-3H 
The tissues of 5-7 rats were pooled and analysed according to the method 
used by Jensen & Jacobson (1962) with some modifications. Immediately after 
sacrifice of the animals the collected tissues were frozen in liquid nitrogen and 
stored in a freezer at -250C. After thawing in the cold room the tissues were 
minced, if necessary, and homogenized in 10 volumes of cold water using a 
teflon-glass Potter-Elvehjem type homogenizer or an Ultra-Turrax TP 18/2. 
The homogenate was diluted with 4 volumes of ice-cold ethanol and 25 μg of 
unlabelled estradiol, estrone and estriol were added to serve as a carrier for 
the radioactive hormone and the main metabolites. After stirring for 15 min 
the insoluble material was removed by centrifugation and the supernatant 
concentrated by evaporation of the ethanol under a stream of nitrogen. The 
aqueous solution was consecutively extracted twice with light petroleum 80/100 
and 3 times with freshly distilled diethylether. The joint ether fractions were 
subjected to thin-layer chromatography over silicagel (pre-coated plates 
Kieselgel F254, Merck) in the solvent systems chloroform/ethylacetate 80/20 
or chloroform/methanol 97/3. Reference steroids (estradiol, estrone, estriol) 
were chromatographed on the same plate. The developed area (15 cm) was 
divided into 30 bands, and the silicagel of each band was scraped off and put 
into a vial for liquid scintillation counting. The co-chromatographed reference 
compounds were localized by exposing the plates to iodine vapour. The 
recovery of estradiol-3H for the whole procedure was more than 90%. 
Injection solutions 
Since none of the compounds injected is water soluble, use has been made 
of a mixture of saline/ethanol 90/10 for the radioactive estradiol and saline/etha­
nol 50/50 for most of the other steroids. Norgestrel and Chlormadinone acetate 
were administered dissolved in propyleneglycol/ethanol 50/50, because of their 
poor solubility in the former solvent combination. In all experiments a volume 
of 0.2-0.3 ml was injected. 
In the course of the experiments no differences have been observed between 
the data collected from the control rats, which received saline/ethanol 90/10, 
saline/ethanol 50/50 or propyleneglycol/ethanol 50/50 as the solvent mixture. 
Assay of radioactivity 
Radioactivity was measured by liquid scintillation counting as described in 
Chapter 5. The standard error of counting was 1.0% for the samples of 
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g) Table 9.1 — The distribution pattern of estradioMH in the rat one hour after intravenous injection 
Ì 
S la) lib) Hie) IVd) 
5 TISSUE 
Plasma 
Heart 
Liver 
Kidney 
Adrenal 
Uterus 
Vagina 
Anterior pituitary 
Muscle 
Fat 
Diaphragm 
Brain cortex 
Thalamus 
Hypothalamus 
Preoptic area 
Amygdala 
TD 
Septum 
dpm/mg 
48.6 ± 
46.9 ± 
724 ± 
188 ± 
219 ± 
990 ± 
336 ± 
1.5 (62) 
1.1 (62) 
23 (36) 
6.2 (36) 
4.9 (61) 
31 (61) 
Π (62) 
1458 ± 40 (62) 
28.7 ± 
122 ± 
40.8 ± 
38.4 ± 
50.4 ± 
91.7 ± 
167 ± 
83.6 ± 
59.5 ± 
70.8 ± 
0.7 (62) 
3 5 (58) 
1.1 (62) 
0.9 (62) 
2.7 ( 8) 
1.4 (62) 
2.9 (61) 
1.3 (61) 
1.1 (60) 
1.3 (60) 
E Í 
19 
25 
7.4 
47 
51 
88 
73 
93 
— 
57 
— 
20 
— 
71 
73 
64 
ί « 
Ει 
10 
13 
8.8 
7.3 
21 
1.7 
4.5 
2.1 
— 
20 
— 
10 
15 
8.1 
14 
18 
EJ 
2.4 
10 
5.2 
4.0 
3.6 
0.8 
2.8 
0.6 
— 
1.0 
— 
9.9 
1.0 
1.5 
1.3 
6.8 
dpm/mg 
50.9 ± 
43.6 ± 
722 ± 
172 ± 
165 ± 
49.5 ± 
34.8 ± 
86.8 ± : 
22.6 ± 
118 ± 
29.9 ± 
42.6 ± 
52.1 ± 
43.0 ± 
53.0 ± 
43.6 ± 
46.6 ± 
42.8 ± 
2.1 
2.4 
26 
14 
11** 
2.0*** 
3.9*** 
L0*** 
1.3* 
6.6 
1.5** 
3.1 
1.9 
2.7*** 
3.1*** 
2.5*** 
1.9** 
2.1*** 
dpm/mg 
48.5 ± 4.6 
51.2 ± 2.8 
641 ± 26 
244 ± 37 
248 ± 19 
1194 ± 89 
421 ± 58* 
1405 ± 120 
34.3 ± 2.0 
159 ± 18 
43.2 ± 3.8 
45.4 ± 3.3* 
53.3 ± 4.1 
97.5 ± 5.1 
160 ± 14 
76.2 ± 3.8 
68.1 ± 5.2* 
71.5 ± 3.3 
a) Mean ± SE (total radioactivity) in dpm/mg wet tissue of the control data collected over the period covered by the present study. 
Figures in brackets indicate the number of animals. 
b) The tissues of 6 animals were pooled and analysed as described in the experimental part. The results are expressed in percent of the 
total radioactivity. Abbreviations: Ei = estrone, E¡ = estradiol, Ез = estriol. 
^j c) 5 min before estradiol-'H the rats were injected with 20 μg/100 g estradiol (N = 5). 
d) 5 min before estradioI-1,H the animals were injected with 1 mg/100 g testosterone (Ν = 5). 
Different from control (I) at Ρ < 0.05 *, Ρ < 0.01 **, Ρ < 0.001 *** (Student's Mest). 
Table 9.2 — Comparison between estradiol 
Animals (N) 
Survival (min) 
TISSUE 
Plasma 
Heart 
Cortex 
Pituitary 
Uterus 
Preoptic area 
206 ± 
301 ± 
324 ± 
1462 ± 
403 ± 
546 ± 
5 
5 
13 (47) 
25 (70) 
28 
139 
30 (86) 
22 
5 
15 
dpm/mg wet tissue ± SE 
98 ± 8.1 (45) 
141 ± 12 (61) 
149 ± 12 
1493 ± 132 
599 ± 68 (83) 
335 ± 17 
70 ± 
91 ± 
78 ± 
5 
30 
2.7 (38) 
6.2 (56) 
4.0 
1588 ±127 
812 ± 
248 ± 
103 (82) 
13 
The rats received an intravenous injection of 0.1 μζ estradiol-sH/100 g body-weight. The figures in 
Table 9.3 — Effect of 19-norsteroids 
Number of rats (N) 
Dose (μΒ/100 g) 
TISSUE 
Plasma 
Heart 
Adrenal 
Uterus 
Vagina 
Pituitary 
Brain cortex 
Preoptic area 
Hypothalamus 
Amygdala 
TD 
Septum 
Control 
62 
48.6 ± 1.5 
46.9 ± 1.1 
219 ± 4.9(61) 
990 ± 31 (61) 
336 ± 11 
1458 + 40 
38.4 + 0.9 
167 ± 2.9(61) 
91.7 ± 1.4 
83.6 ± 1.3 (61) 
59.5 ± 1.1 (60) 
70.8 ± 1.3 (60 
Ethynodiol 
37.8 
40.6 
146 
89.2 
40.4 
81.0 
35.4 
50.2 
43.3 
44.4 
46.2 
43.7 
5 
200 
+ 
+ 
+ 
+ 
+ 
± 
± 
± 
± 
+ 
+ 
± 
Norethynodrel 
5 
200 
Mean dpm/mg ± SE 
2.7 
2.0 
12*** 
4.1*** 
2.6*** 
3.1*** 
2.8 
2.7*** 
2.6*** 
2.8*** 
3.1** 
2.5*** 
54.4 ± 6.5 
43.8 ± 4.0 
146 ± 11*** 
157 ± 14*** 
64.1 ± 3.1*** 
130 ± 3.1*** 
33.1 ± 3.0 
50.3 ± 3.2*** 
42.1 ± 3.3*** 
44.3 ± 3.6*** 
44.0 ± 3.8*** 
41.7 ± 4.0*** 
Lynes ¡trenol 
9 
200 
59.2 ± 
52.1 ± 
194 ± 
464 ± 
161 ± 
300 ± 
38.9 ± 
80.1 ± 
58.2 ± 
56.0 ± 
52.9 ± 
53.5 ± 
3.9 (8)* 
2.5 
8.4 
22*** 
8.0*** 
20*** 
19(8) 
3.5*** 
2.8*** 
3.1*** 
2.4* 
2.8*** 
The compounds were injected into the tail vein 5 min before the iv administration of 0.1 μg 
in brackets indicate the number of samples if differing from N. Different from control at Ρ < 0.05 *, 
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distribution with time in target and non-target tissues 
62 
60 
48.6 ± 1.5 (19) 
46.9 ± 1.1 (25) 
38.4 ± 0.9 (20) 
1458 ± 40 (93) 
990 ± 31 (88) 
167 ± 2.9(73) 
— 
34 ± 
25 ± 
19 ± 
1324 ± 
975 ± 
102 ± 
7 
120 
dpm/mg wet 
2.7 (22) 
1.1 (35) 
1.2 
107 
49 (88) 
5.5 
5 
240 
tissue ± SE 
29 ± 1.2 (13) 
20 ± 0.5 
16 ± 0.6 
1030 ± 80 
769 ± 44 (87) 
69 ± 2.7 
5 
480 
25 ± 1.9 (7.3) 
12 ± 0.5 
10 ± 0.6 
401 ± 22 
268 ± 20 (78) 
22 ± 2.2 
brackets give the percentage of the total radioactivity present as estradiol. 
on estradiol-3H distribution in the rat 
Norethindrone 
5 
200 
50.2 ± 
52.7 ± 
215 ± 
457 ± 
170 ± 
412 ± 
43.0 ± 
86.5 ± 
65.0 ± 
65.7 ± 
57.0 ± 
60.4 ± 
3.0 
3.7 
15 
34*** 
18*** 
25*** 
2.9 
6.8*** 
4.8*** 
4.8*** 
4.1 
4.2* 
d-Norgestrel 
8 
400 
48.5 ± 3.3 
50.1 ± 2.5 
207 + 15 
919 ± 50 
275 ± 15 
1112 ± 59** 
42.9 ± 2.0 
140 ± 6.8** 
85.6 ± 3.2 
79.4 ± 4.3 
62.0 ± 3.9 
70.2 ± 4.6 
Nortestosterone 
5 
Mes 
47.6 
44.6 
178 
966 
296 
996 
38.3 
110 
64.5 
57.6 
49.7 
56.9 
400 I 
in dpm/mg ± 
+ 
± 
± 
+ 
+ 
+ 
+ 
± 
± 
+ 
+ 
± 
5.4 
4.1 
17 
187 
35 
48** 
3.3 
6.0*** 
3.2*** 
3.8*** 
3.9* 
3.7** 
Estrenol 
6 
200 
SE 
59.6 ± 4.1* 
63.5 ± 4.1*** 
307 ± 2 0 * * * 
900 ± 34 
326 ± 32 
890 ± 4 4 * * * 
57.5 ± 4.2*** 
153 ± 8.0 
92.4 ± 4.9 
87.5 ± 4.5 
76.4 ± 5.2*** 
81.2 ± 5.0* 
Methyllyn 
6 
20C 
47.3 ± 
47.4 ± 
214 ± 
1105 ± 
364 ± 
1260 ± 
39.5 ± 
152 ± 
85.0 ± 
80.2 ± 
60.4 ± 
70.8 ± 
estrenol 
1 
1.6 
2.5 
11 
193 
37(5) 
111 
3.2 
4.7 
3.5 
2.4 
4-7 (4) 
4.4 (4) 
estradiol-3H/100 g body-weight. The rats were sacrificed one hour after the last injection. The figures 
Ρ < 0.01 **, Ρ < 0.001 *** (Student's /-test). 
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peripheral tissues and not more than 2.5% for the brain samples and the 
silicagel samples. The counting efficiency of the tissue samples varied between 
15 and 36%. The counting efficiency of the silicagel samples was about 32%. 
RESULTS 
Distribution pattern of estradiol-3H 
With regard to the distribution pattern of estradiol-3H in the rat it can be 
seen from the results given in Table 9.1, that the anterior pituitary, uterus, 
vagina, preoptic area, hypothalamus, amygdala and, to a smaller extent, 
adrenals, tractus diagonalis (TD) and also the septum selectively accumulate 
and retain unchanged estradiol. Moreover, if 5 min before the tritiated estradiol 
injection a 200-fold excess of the hormone or another estrogen is administered, 
the radioactivity in these same tissues is reduced to a level corresponding to 
the fraction of the metabolites in the first experiment. The radioactivity level in 
the other tissues, however, remains unchanged. Furthermore, the observed 
distribution pattern appears to be estrogen specific, because administration of a 
10,000-fold excess of testosterone before estradiol-3H has no effect at all. The 
results mentioned so far are thus in agreement with and complementary to 
previous studies (Eisenfeld & Axelrod, 1966; Jensen & Jacobson, 1962; Kato & 
Villee, 1967; McEwen & Pfaff, 1970; Pfaff, 1968; Stumpf & Sar, 1971 ; Zigmond 
& McEwen, 1970). 
The uptake and retention of unchanged estradiol in the pituitary, uterus and 
preoptic area against a concentration gradient, in contrast to the heart and 
brain cortex, is obvious from the data given in Table 9.2. Although the preoptic 
area does not show an accumulation and retention like that observed for the 
uterus and pituitary, the difference is, however, evident in comparison with the 
cortex. In this respect one has to take into consideration, that compared with 
the capacity of the peripheral organs, the total specific binding capacity for 
estradiol in the CNS target tissues seems to be rather low as can be derived 
from the extent to which the estradiol uptake is reduced by a preceding in-
jection of the unlabelled hormone (Table 9.1). Hence the possibility of ob-
serving a differential distribution pattern of the hormone within the brain is 
determined largely by the dissection procedure used: the specific-bound 
activity is superimposed upon the activity present on account of the non-specific 
distribution processes. Thus when the former is small relative to the latter, 
"contamination*' of receptor-rich with receptor-poor material will influence the 
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results to a great extent. For that reason the dissection procedure used has been 
derived from the radioautographic data reported by Stumpf (1970). 
Effect of contraceptive progestins and related compounds 
The distribution pattern of estradiol one hour after injection changed very 
much under the influence of a previous injection of the contraceptive progestins 
ethynodiol, norethynodrel, norethindrone and lynestrenol. These compounds, 
administered in 2000-fold excess, reduced the uptake of estradiol significantly 
in all target tissues (Table 9.3), although with different potency. The other 
members of the series of the 19-norsteroids tested, however, demonstrated less 
or no activity in this respect. Methyllynestrenol appeared to be inactive, and 
nortestosterone was more active than d-norgestrel, but in spite of a double dose 
less active than norethindrone. Estrenol reduced the radioactivity in the pituitary 
only. The increased levels of radioactivity in the heart, adrenal and CNS tissues 
in this experiment are probably the result of the high plasma and cortex levels. 
The same phenomenon was observed after the administration of megestrol, 
megestrol acetate and the acetate esters of medroxyprogesterone and Chlorma-
dinone. These hydroxyprogesterone derivatives did not reduce the radioactivity 
in the target tissues even after administration in a 4000- to 5000-fold excess 
over estradiol-3H (Table 9.4), but seemed at this high dose level to have some 
influence on the clearance of estradiol from the plasma. Similar results have 
been reported by Eisenfeld & Axelrod (1967) for Chlormadinone acetate and 
medroxyprogesterone acetate. 
Because in the case of norethindrone, ethynodiol and lynestrenol the acetate 
esters are clinically of importance, these compounds have also been studied. 
From Table 9.5 it is apparent, that the esters have the same properties as the 
parent alcohols, but in a quantitative way they seem to possess a somewhat 
lower potency. This activity may be explained either by direct binding to the 
receptor or it could result from hydrolysis of the esters after the injection. The 
velocity of the hydrolysis should then be very high, as administration of 
lynestrenol 5 min after estradiol no longer results in a significant decrease of 
radioactivity in the hypothalamus and preoptic area (Table 9.6). 
Influence of the time of administration 
Studying the influence of the time of administration of lynestrenol on the 
estradiol distribution pattern, it was observed, that the applied sequence of 
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Table 9.4 — Effect of hydroxyprogesterone derivatives 
Number of rats (Ν) 
Dose (μ&ΊΟΟ g) 
TISSUE 
Plasma 
Heart 
Muscle 
Adrenal 
Uterus 
Vagina 
Anterior pituitary 
Brain cortex 
Preoptic area 
Hypothalamus 
Amygdala 
TD 
Septum 
Control 
62 
— 
48.6 ± 1.5 
46.9 ± 1.1 
28.7 ± 0.7 
219 ± 4.9(61) 
990 ± 31 (61) 
336 ± 11 
1458 ± 40 
38.4 ± 0.9 
167 ± 2.9(61) 
91.7 ± 1.4 
83.6 + 1.3 (61) 
59.5 ± 1.1 (60) 
70.8 ± 1.3 (60) 
Chlormadinone 
5 
435 
Mean dpm/mg ± SE 
48.2 ± 
51.0 ± 
27.6 ± 
247 ± 
1035 ± 
393 ± 
1407 ± : 
42.6 ± 
175 ± 
89.4 ± 
85.6 ± 
64.5 ± 
74.1 ± 
2.5 
2.4 
1.4 
15 
161 
24 
132 
2.8 
5.9 
4.1 
3.4 
3.4 
2.6 
Medroxy­
progesterone 
5 
435 
44.9 ± 
47.6 ± 
24.6 ± 
245 ± 
885 ± 
354 ± 
1342 ± 
41.9 ± 
163 ± 
90.8 ± 
91.1 ± 
61.6 ± 
69.8 ± 
3.4 
3.1 
1.0 
10 
82 
31 
150 
4.4 
3.5 
5.3 
12 
3.1 
2.7 
The compounds were injected into the tail vein 5 min before the iv administration of 0.1 ЦЕ 
figures in brackets indicate the number of samples if differing from N. Different from control at 
Table 9.5 — Comparison of the effects of steroid alcohols and the corresponding 
Control 
Lynestrenol 
Lynestrenol acetate 
Ethynodiol 
Ethynodiol diacetate 
Norethindrone 
Norethindrone acetate 
N 
62 
9 
5 
5 
6 
5 
6 
Plasma 
Mean dpm/mg 
48.6 ± 1.5 
59.2 ± 3.9 (8)* 
48.0 ± 2.5 
37.8 ± 2.7 
60.5 ± 8.3* 
50.2 ± 3.0 
65.5 ± 6.2** 
Uterus 
± SE 
990 ± 31 (61) 
464 ± 2 2 * * * 
647 ± 65** 
89.2 ± 4.1*** 
179 ± 11*** 
457 ± 34*** 
564 ± 48*** 
The progestins were injected into the tail vein 5 min before the iv administration of 0.1 μg 
progestins were given in a dose of 200 μ%/100 g except norethindrone acetate (250 μg/100 g). Different 
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on estradiol- 3H distribution pattern in the rat 
Megestrol 
5 
500 
54.0 ± 
66.5 ± 
37.8 ± 
262 ± 
1014 ± 
396 ± 
1579 ± 
55.3 ± 
220 ± 
119 ± 
107 ± 
77.7 ± 
94.6 ± 
2.9 
2.8*** 
2.1*** 
9.5* 
137 
43 
182 
3.1*** 
11*** 
5.7*** 
6.5** 
4.6*** 
3.6*** 
Chlormadinone 
acetate 
7 
400 
63.6 ± 
67.4 ± 
39.7 ± 
288 ± 
929 ± 
371 ± 
1484 ± 
51.9 ± 
207 ± 
117 ± 
112 ± 
83.9 ± 
105 + 
Mean dpm/mg 
3.5** 
2.1*** 
1.4 (5)*** 
15 (5)*** 
97 
21 
150 
2.1*** 
14*** 
4.4*** 
2.5 (5)*** 
3.1 (5)*** 
7.9 (5)*** 
Medroxy­
progesterone acetate 
± SE 
75.3 
82.6 
9 
500 
+ 
+ 
46.3 ± 
372 
1191 
420 
1763 
74.3 
245 
135 
127 
98.0 
116 
± 
+ 
± 
± 
+ 
+ 
+ 
+ 
± 
+ 
4.3*** 
2.9*** 
2.4*** 
16*** 
104 
30** 
76** 
2.9*** 
12*** 
3.9*** 
2.8*** 
3.9*** 
3.9*** 
Megestrol acetate 
5 
500 
73.6 ± 
85.7 ± 
46.9 ± 
283 ± 
915 ± 
366 ± 
1256 ± 
69.0 ± 
198 ± 
129 ± 
118 ± 
93.1 ± 
106 ± 
6.8*** 
4.2*** 
2.9*** 
23*** 
66 
27 
84 
6.5*** 
12** 
6.5*** 
7.7*** 
7.2*** 
19*** 
estradiol-'H/lOO g body-weight. The animals were sacrificed one hour after the last injection. The 
Ρ < 0.05 *, Ρ < 0.01 **, Ρ < 0.001 *** (Student's í-test). 
acetates on the uptake of estradiol-3H by the target tissues of the rat 
Ant. pituitary 
1458 ± 40 
300 ± 20*** 
530 ± 67*** 
130 ± 3.1*** 
93.9 ± 20*** 
412 ± 25*** 
577 ± 79*** 
Cortex 
Mean dpm/mg 
38.4 ± 0.9 
38.9 ± 1.9 (8) 
44.6 ± 2.3 
35.4 ± 2.8 
35.5 ± 2.2 
43.0 ± 2.9 
49.0 + 3.8** 
Hypothalamus 
± SE 
91.7 ± 1.4 
58.2 ± 2.8*** 
77.3 ± 2.9** 
43.3 ± 2.6*** 
43.0 ± 2.8*** 
65.0 ± 4.8*** 
79.5 ± 5.1 (4)* 
Preoptic area 
167 ± 2.9 (61) 
80.1 ± 3.5*** 
119 ± 6.8*** 
50.2 ± 2.7*** 
51.1 ± 2.6*** 
86.5 ± 6.8*** 
103 ± 5.9*** 
estradiol-'H/lOO g body-weight. The animals were killed ^one hour after the last injection. The 
from control at Ρ < 0.05 *, Ρ < 0.01 **, Ρ < 0.001 *** (Student's Mest). 
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administration of these compounds is of crucial significance for the occurrence 
and the extent of binding inhibition in the target tissues (Table 9.6). Although 
the maximal effect was obtained, when lynestrenol was administered 5 min 
before the estrogen, the inhibition of estradiol uptake remained considerable, 
when lynestrenol was injected 30 and 60 min prior to estradiol. A rapid 
decrease, however, of the inhibitory effect appeared to occur when lynestrenol 
was administered after estradiol. The difference is most pronounced in the CNS 
tissues. As a consequence of the small binding capacity for estradiol in these 
tissues in comparison with the uterus and the anterior pituitary, which is evident 
from the data presented in Table 9.1 and has been confirmed later on in in-
vestigations using cytosol samples of rat pituitary, hypothalamus and uterus 
(Korach & Muldoon, 1974; Morris, 1976), it is conceivable, that at similar 
ligand concentrations the fraction of occupied receptor molecules in the CNS 
target tissues may exceed the corresponding fraction in the uterus and pituitary. 
If the occupation of the receptor binding sites is followed by the translocation 
of the estradiol-receptor complex to the target cell nucleus (see Chapter 1) 
and, consequently, by a decrease of specific binding sites in the cytosol, this 
could explain the more rapid abolishment of the lynestrenol effect in the CNS 
tissues. Moreover, it is obvious from the data in Tables 9.1 and 9.2, that apart 
from receptor-bound estradiol a relatively large pool of "non-specific" estradiol 
is present in the CNS target tissues, which may be supposed to be available for 
an exchange with the receptor-bound hormone. In this respect just an opposite 
relationship may exist for the ratio between the "non-specific" radioligand and 
the competing lynestrenol in the pituitary and the uterus, because about 90% 
of the estradiol in these organs appeared to be specifically bound (Tables 9.1, 
9.2). For this reason it may be assumed, that, in case of exchange between 
bound and unbound hormone, in these tissues an exchange of estradiol for 
lynestrenol is more likely to occur than in the CNS tissues. 
Similarly, the influence of time on the observed effect, when lynestrenol is 
administered prior to estradiol, may be explained in terms of depletion of cytosol 
receptor, dissociation of the lynestrenol-receptor complex, and elimination of 
lynestrenol. Distribution studies with lynestrenol in mice have indicated, that 
the high lipophilicity of lynestrenol will delay its elimination from the central 
nervous system (see Chapter 14). This delay may contribute to the comparatively 
high degree of inhibition in these tissues, that is observed, when the compound 
is injected 60 min before estradiol. On account of the present findings, however, 
a differentiation between the relative importance of pharmacokinetic and binding 
parameters for the results obtained is difficult. Further investigations using 
other techniques, e.g. chase experiments with radiolabelled and radioinert ligand, 
may shed more light on this aspect. 
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Table 9.6 — Effect of time of administration of lynestrenol on estradiol-3H binding in the target tissues 
Number of rats 
TISSUE 
Plasma 
Heart 
Adrenal 
Uterus 
Vagina 
Anterior pituitary 
Cortex 
Preoptic area 
Hypothalamus 
Amygdala 
TD 
Septum 
60 min before 
41.8 
40.6 
209 
856 
217 
591 
35.4 
82.0 
54.0 
52.8 
46.5 
51.9 
5 
± 2.6 
± 2.5 
± 9.8 
± 58 
± 28** 
± 20*** 
± 2.2 
± 6.1*** 
± 2.3*** 
± 2.6*** 
± 2.4** 
± 2.6*** 
30 min 
4 
58.6 ± 
52.5 ± 
233 ± 
586 ± 
144 ± 
601 ± 
46.5 ± 
102 ± 
69.3 ± 
69.0 + 
62.0 ± 
65.0 ± 
before 
3.9 
2.9 
9.8 
36** 
29*** 
166*** 
2.9* 
9.3*** 
4.6*** 
4.9** 
4.0 
4.5 
5 min 
9 
before 
Mean dpm/mg 
59.2 ± 
52.1 ± 
194 ± 
464 ± 
161 ± 
300 ± 
38.9 ± 
80.1 ± 
58.2 ± 
56.0 ± 
52.9 ± 
53.5 ± 
3.9* 
2.5 
8.4 
22*** 
8.0*** 
20*** 
1.9 
3.5*** 
2.8*** 
3.1*** 
2.4* 
2.8*** 
5 min after 
± SE 
53.3 
50.9 
214 
519 
231 
825 
41.9 
146 
85.3 
83.6 
63.2 
73.7 
5 
± 4.6 
± 2.9 
± 12 
± 28*** 
± 19** 
± 63*** 
± 1.1 
± 10 
± 3.9 
± 3.7 
± 2.3 
± 4.3 
15 min 
4 
48.0 ± 
51.7 ± 
226 ± 
582 ± 
263 ± 
1119 ± 
39.0 ± 
148 ± 
90.7 ± 
80.6 ± 
61.8 ± 
69.1 ± 
after 
6.5 
6.0 
24 
81** 
20 
109* 
3.8 
14 
6.6 
9.0 
6.9 
7.5 
30 min 
4 
53.8 ± 
43.2 ± 
208 ± 
805 ± 
341 ± 
1526 ± 
34.6 ± 
150 ± 
85.9 + 
78.7 ± 
55.8 ± 
71.2 ± 
after 
1.2 
2.1 
13 
150 
45 
63 
2.2 
3.7 
1.6 
2.0 
1.8 
1.9 
The compounds (200 μg/100 g lynestrenol and 0.1 μg/100 g estradiol-ЭН) were administered into the tail vein. Lynestrenol was injected 
either before or after estradiol as indicated. The animals were killed one hour after the estradioMH injection. 
The results have been compared for the statistical evaluation with the control data given in Table 9.3. 
Different from control at Ρ < 0.05 *, Ρ < 0.01 **, Ρ < 0.001 *** (Student's Mest). 
influence of tne aose 
The inhibition of estradiol binding in the target tissues increases 
increase of the lynestrenol dose. In Fig. 9.2 this dose-effect relatio 
illustrated for the preoptic area, the anterior pituitary and the uterus. 
latter organs the fraction of the total radioactivity, that is estrogen 
bound, is 90-95%, for the preoptic area this fraction is about 65% (Ta 
In order to make a correct comparison of the relationship between ι 
and the inhibition of estradiol binding this difference should be tal 
account. Therefore, the reduction of specific binding was calculated 
organ after correcting the total radioactivity measured for the corres 
non-specific fraction. The residual binding in the tissues observed in the 
of an excess of non-labelled estradiol (Table 9.1, column III) was co 
to be a good approximation of this fraction. 
Looking at the curves thus obtained (Fig. 9.2) it is evident, that al 
a dose range of 25-50 μg lynestrenol per 100 g body-weight the inhil 
estradiol binding in the pituitary and preoptic region is considerable г 
be of relevance for the activity of lynestrenol and probably also eth 
norethynodrel and norethindrone. Furthermore, it can be observed 
degree of inhibition obtained with the same dose of lynestrenol is muc 
specific b i n d i n g l " / · c o n t r o l ) 
100 
75 -
5 0 -
25 -
10 2 5 50 100 2 0 0 4 0 0 
lynestrenol(>jg/100g) 
Fig. 9.2 — Relationship between the lynestrenol dose and the reduction ol 
estradiol-3H binding. The experimental procedure and the control animals are th 
mentioned in Table 9.3. Each point in the curves represents the mean of at least 5 ι 
values in per cent of the corresponding control. 
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for the pituitary and preoptic area than for the uterus. This difference could be 
caused by a higher ratio of lynestrenol over estradiol in the environment of the 
receptors or by a difference in the binding affinities of the steroids to the 
receptors in the respective tissues. This latter possibility does not seem to be 
very probable in the light of other investigations (Ginsburg et al., 1974; 
Kahwanago et al., 1970; Korach & Muldoon, 1974; Notides, 1970; Talley et 
al., 1975). Distribution studies, on the other hand, with tritiated lynestrenol in 
the mouse revealed, that after intravenous injection the concentration of this 
compound was much higher in the pituitary than in the uterus (see Chapter 14, 
Table 14.1). This observation and the different concentration-time course of 
estradiol uptake in the uterus and pituitary as shown in Table 9.1 are strong 
indications that distribution factors are involved. 
DISCUSSION 
Previous studies 
The experimental results described above indicate the existence of a com-
petitive interaction between estradioMH and the contraceptive progestins of 
the 19-nortestosterone group with regard to estradiol binding to the estrogen 
receptor. This interaction may contribute to the spectrum of activity of these 
steroids. Estrogenic effects of norethindrone, norethynodrel, ethynodiol and 
lynestrenol are known from bio-assay procedures (Desaulles & Krähenbühl, 
1964; Elton & Nutting, 1961; McGinty & Djerassi, 1958; Overbeek et al., 1962; 
Saunders et al., 1957) as well as from clinical studies (Paulsen et al., 1962; 
Paulsen, 1965), but have been attributed to their highly questionable (Breuer, 
1970; Sisenwine et al., 1974) biotransformation to A-ring aromatized metab-
olites. Although it has been demonstrated by us (Van Kordelaar et al., 1975) 
that the active progestins as such can compete with estradiol for the receptor 
binding sites, in vivo estrogenic conversion products may still be involved. The 
metabolic clearance rate of lynestrenol in the rat seems high enough to account 
for a contribution of metabolites to the observed effect (this thesis, Chapter 
16). A rapid disappearance from the blood of rabbits and humans has also 
been observed by others after the administration of ethynodiol, norethindrone, 
norethynodrel and lynestrenol (Cook et al., 1972, 1973; Gerhards et al., 1971; 
Kamyab et al., 1967, 1968a,b). The elucidation, however, of the chemical 
structure of a number of these metabolites up to the present does not support 
this possibility (Breuer, 1970; Coert et al., 1975; Cook et al., 1972, 1973; 
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Freudenthal et al., 1971; Gerhards et al., 1971; Kishimoto et al., 1972a,b; 
Mazaheri et al., 1970; Okada, 1972; Palmer et al., 1969; this thesis, Chapter 12). 
In norethindrone, reduction of the 4-en-3-one group in ring A to the 5a-estran-
3ß-ol isomer may be expected to give rise to increase of binding affinity. A 
similar effect may result from the reduction of norethynodrel to 17a-ethynyl-
5(10)-estrene-3ß,17ß-diol (see Chapter 10). At present, however, no information 
is available with respect to the significance of these metabolic pathways in the 
overall elimination of the compounds and with respect to the concentration-
time course of these metabolites in the blood and target organs. As far as 
lynestrenol is concerned the data in Table 9.6 also indicate, that the metabolites 
formed in the first hour after the administration of the compound do not 
potentiate the ultimate effect. 
The results obtained in the present study are in accordance with the ob-
servations of Eisenfeld & Axelrod (1965, 1967) for norethynodrel, norethin-
drone, Chlormadinone acetate and medroxyprogesterone acetate, of Saucier et al. 
(1970) for norethynodrel and of Banerjee et al. (1973) for norethindrone. The last 
investigators also reported a reduction in estradiol uptake in the uterus, vagina, 
adrenal, pituitary and hypothalamus by d/-norgestrel in a dose of 100 μg/100 g 
body-weight; in a quantitative sense the effect observed for dZ-norgestrel was 
equal to that of the same dose of norethindrone. In the present study 200 
i^g/lOO g norethindrone in vivo was far more active than 400 μg/100 g d-nor-
gestrel; after d-norgestrel administration a small though significant decrease in 
estradiol uptake was only observed in the pituitary and preoptic area. In vitro 
the reduction of estradiol-3H binding to the rat uterine receptor was marginal 
for both d- and ¿/-norgestrel in contrast to the effect of norethindrone (Van 
Kordelaar et al., 1975). We have no explanation at the moment for this 
discrepancy in results. In this connection, however, it should be pointed out, 
that norgestrel has been claimed to be completely devoid of estrogenic properties 
(Edgren et al., 1966, 1967). 
From the results mentioned in Table 9.3 and in Chapters 10 and 11, it can 
be derived that the competing progestins have different binding affinities, 
which are much smaller than the affinity of estradiol to the receptor. 
These low binding affinities could at least partially explain the negative results 
reported by Watanabe et al. (1968). In view of the study of Eisenfeld & Axelrod 
(1965) these investigators did expect a specific uptake and retention of norethy-
nodrel, norethindrone and ethynodiol into the uterus, pituitary and hypothala-
mus of the rat after the injection of the tritiated progestins in a dose of 0.1 
μg/100 g body weight. Such a distribution pattern, however, is only to be 
expected with the specific activity of 3.5 Ci/mmol used, providing the binding 
affinity of the progestins is of the same order of magnitude as that of estradiol. 
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This condition is not required for observing the competitive interaction in the 
test system used by Eisenfeld & Axelrod (1965, 1967) and in the present study. 
In contrast to the data presented here and by Eisenfeld & Axelrod (1967), 
Rosner et al. (1972) reported a reduction of estradiol uptake in the uterus and 
pituitary of the rat after the administration of Chlormadinone acetate. It was 
also observed that the decrease in uterine radioactivity 1 h after the estradiol 
injection was restricted entirely to the nuclear cell fraction. In view of this 
result these investigators assumed the occurrence of a competition between 
estradiol and Chlormadinone for binding to the estrogen receptor. It is, however, 
not clear from their assumption why the maximal decrease of radioactivity in 
the uterus and pituitary (about 50%) already occurred at submaximal doses of 
Chlormadinone administered, whereas the maximal decrease obtained does not 
correspond with the estradiol fraction that is specifically bound in this organ 
(cf. Fig. 9.2 and Table 9.1). Since they did not observe a reduction of 
hypothalamic estradiol either and since no studies with the receptor protein 
in a cell-free system were performed, the influence of some non-specific process 
in their experiments cannot be excluded. 
Inhibition of ovulation 
Most compounds that have been studied, are frequently prescribed for 
contraceptive purposes because of their anti-ovulatory action. Although the 
mechanism of action of the contraceptive steroids in current use is still not 
quite understood, changes in the synthesis, storage and release of the gonado-
trophic hormones have been demonstrated in animals and humans and seem 
to be responsible for the effect (Becker et al., 1973; Dufau et al., 1970; 
Labhsetwar, 1973; Schally et al., 1968, 1970; Thomas & Ferin, 1972; Thomas 
et al., 1972). Since estradiol binding to pituitary and CNS receptors may trigger 
feed-back effects on gonadotrophin release and ethynodiol, norethynodrel, 
norethindrone and lynestrenol and their acetates interfere with estradiol binding 
in these same tissues after the administration of anti-ovulatory doses, it seems 
not improbable that the pattern of attack for the ovulation inhibition is in-
congruous with that of the non-competing progestins. An additional indication 
for this assumption may also derive from the observation of a difference in the 
mechanism of action between lynestrenol and methyllynestrenol as shown by 
Overbeek & De Visser (1964). Further support for this concept is given by the 
observations of Baker et al. (1973). After implantation of norethynodrel, 
norethindrone and medroxyprogesterone in the pars distalis of the rat pituitary, 
both norethynodrel and norethindrone induced hypertrophy of the prolactin 
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cells and a reduction in size of the luteinizing hormone synthetizing cells, 
whereas medroxyprogesterone caused no changes at all. The extrapolation of 
such a divergent mechanism of action for the competing nortestosterone 
derivatives and the non-competing steroids from rat to man seems permissible 
as far as the properties and nature of the estrogen receptors are concerned. 
Although the receptors have not yet been isolated in a purified form, studies 
with the human and rat uterine receptor (Evans & Hähnel, 1973; Hähnel, 1971; 
Hähnel et al., 1973; Korenman, 1970; Martin, 1972; Notides et al., 1972) 
on the one hand and the receptors of the uterus, hypothalamus and pituitary 
on the other hand (Ginsburg et al., 1974; Jensen et al., 1969; Kahwanago et al., 
1970; Korach & Muldoon, 1974; Kato, 1973; Notides, 1970;Talley et al., 1975) 
have revealed no substantial differences. 
SUMMARY 
The distribution pattern of estradiol in ovariectomized rats as a function of 
time has been studied following intravenous administration of the tritiated 
hormone. Estrogen specific binding with limited capacity was observed in the 
uterus, vagina, anterior pituitary, adrenals, preoptic area, hypothalamus, 
amygdala, septum and tractus diagonalis. Maximal uptake of estradiol in the 
pituitary occurred within 5 min, in the uterus 60 min after injection and remained 
almost unchanged at this level for more than two hours. The binding capacity 
per mg tissue decreased in the order pituitary, uterus, vagina, preoptic area, 
adrenals, hypothalamus, amygdala, septum and tractus diagonalis. 
The hormone concentration in these tissues one hour after estradiol-3H in-
jection was lowered by previous administration of ethynodiol, norethynodrel, 
lynestrenol and norethindrone, whereas medroxyprogesterone, Chlormadinone, 
megestrol and methyllynestrenol had no effect. The same results were obtained, 
when instead of the steroid alcohols the corresponding acetate esters were ad-
ministered. For norgestrel, estrenol and nortestosterone the effect in the dose 
range studied was limited to the pituitary and preoptic area. 
For lynestrenol the inhibition of estradiol binding in the target tissues was 
almost the same when the progestin was given 60 and 5 min before estradiol, 
whereas in the case of administration 30 min after estradiol no inhibition was 
observed. The reduction of estrogen binding appeared to be dose-dependent, 
but the dose required to obtain a certain effect for the uterus was four times as 
high as for the pituitary. 
Discrepancies between previous studies and the implications of the present 
findings for the mechanism of action of ovulation inhibition by these progestins 
are discussed. 
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CHAPTER 10 
EFFECT OF CONTRACEPTIVE STEROIDS AND RELATED 
COMPOUNDS ON ESTRADIOL-^H BINDING TO THE RAT UTERINE 
RECEPTOR IN VITRO 
INTRODUCTION 
In Chapter 9 of this thesis it has been shown that contraceptive progestins of 
the 19-nortestosterone series are able to interfere to a varying degree with 
estradiol binding in the target tissues of the female rat. The extent to which this 
interaction occurs, is determined by the concentration of the inhibitor in the 
receptor compartment and its affinity to the receptor. The former parameter 
depends on the dose, the route of administration and the pharmacokinetics of 
the compound studied, viz. the rate of absorption, distribution, metabolism and 
excretion; the latter depends on its molecular structure. Since on the one hand 
the progestins studied are metabolised extensively and very rapidly (Fotherby, 
1974; Fotherby & James, 1972; Thijssen, 1972) and for this reason metabolites 
could be responsible for the effect, and on the other hand a very short time of 
half-life could mask an interaction in vivo, additional studies have been under-
taken using a less complicated test system. Evidence, that the in vivo decrease 
in the binding of estradiol may be caused by a competition of the unchanged 
progestins with estradiol for the receptor binding sites has been obtained from 
incubation experiments with the 105,000xg supernatant of rat uterus homogenate. 
In order to gain an insight into the structural requirements of significance for 
the occurrence of binding, the behaviour of some related compounds has also 
been studied. 
MATERIALS AND METHODS 
Binding studies with rat uterine cytosol 
The estrogen receptor preparation was obtained from the uteri of 24-28 days 
old Wistar rats. The uteri were trimmed of fat and other tissue, minced, washed 
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with buffer (0.01 M Tris-HCl, pH 7.4, containing 0.0015 M EDTA) and the 
tissue was then homogenized with carborundum in the same buffer solution. 
The homogenate was centrifuged for 1 h at 105,000xg in a Spinco L2-75B ultra-
centrifuge using a Spinco 50ТІ rotor. The supernatant was diluted with buffer 
to a volume of 1.0 ml per uterus in the case of incubation studies and 1.0 ml 
per 3-5 uteri for incubation experiments followed by density gradient cen-
trifugation, and used on the same day. The protein content was determined 
according to Lowry et al. (1951). All manipulations with biological material 
were performed at 1-4° C. 
For the incubations silanized glass tubes were used to prevent adsorption 
phenomena. The indicated amount of estradiol-3H alone or together with a 
certain excess of a non-labelled steroid was incubated under continuous and 
gentle agitation with 0.2 ml cytosol until equilibrium was attained; 20 h appeared 
to be sufficient. Afterwards free and bound hormones were separated by the 
addition of 0.2 ml of a charcoal-dextran suspension (0.1% Aktivkohle, Merck, 
and 0.05% Dextran Τ 70, Pharmacia, in Tris-EDTA buffer) as described by 
Herbert et al. (1965) and discussed in Chapter 6. After stirring for 15 min the 
charcoal was spun down (10 min, 600xg) and 0.2 ml of the clear supernatant 
was put in a counting vial or layered on linear gradients of 5 tot 20% sucrose 
(SIGMA) in Tris-EDTA buffer, pH 7.4. The gradients, 4.0 ml in polyallomer 
tubes, were centrifuged for 7 h at 300,000xg in a Spinco L2-75B ultracentrifuge 
with a Spinco SW 56ТІ rotor. After the run 23-25 fractions were tapped from 
the bottom of the tubes with the aid of a LKB peristaltic pump and collected 
directly in counting vials (LKB fraction collector Ultrorac). Beef liver catalase 
(Boehringer) and bovine serum albumin (BSA, Sigma) were used as standards 
for sedimentation coefficient estimations by the method of Martin & Ames 
(1961). The proteins were localized with the help of a LKB Uvicord II spec­
trometer. 
Test compounds 
Specifications of the steroids and other compounds used have been given in 
Chapter 3. 
Determination of Ru values 
The RM values of the steroids were determined by reversed-phase chromato­
graphy on silicagel-coated glass plates (Kieselgel 60 F254, Merck) impregnated 
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with silicone fluid as a non-polar stationary phase (silicone MS 200, Midland 
Ltd., U.K.). The impregnation was carried out by developing the plates over­
night in a chromatographic chamber containing 200 ml 5 per cent by weight 
of silicone oil in ether. After the application of the compounds (10 μg/spot) 
the plate was developed with silicone saturated acetone/water mixture 50/50 at 
room temperature over a distance of 15 cm. The spots were detected by iodine 
vapour or UV-absorption. 
Assay of radioactivity 
The radioactivity of incubation and gradient samples was measured by liquid 
scintillation counting as described in Chapter 5. The standard error of counting 
was 2.5% or less and the counting efficiency was about 45%. 
RESULTS 
Properties of the receptor preparation; effect of drugs on estradiol binding 
In Table 10.1 the results are shown of experiments, in which different cytosol 
batches have been incubated with estradiol-3H and the progestational drugs 
under discussion. By way of comparison some estrogens have been included. 
Each compound was incubated with at least two cytosol preparations. 
From the results with estradiol-17ß, estradiol-17a, ethinylestradiol and 
diethylstilbestrol on the one hand and progesterone, corticosterone and 
testosterone on the other hand, it is obvious that 90-95% of the total binding 
measured is stereospecific for estradiol, estrogen specific and of limited 
capacity. After incubation of the cytosol with estradiol-3H and centrifugation 
of the mixture on a density gradient the peak of radioactivity was localized in 
the 8-9S region (Fig. 10.1a). These observations are in accordance with the 
characteristics of the estrogen receptor as reported in the literature (Notides, 
1970; Toft & Gorski, 1966; Toft et al., 1967). 
In some experiments a small peak of radioactivity also appeared in the 4S 
region. As the presence of this peak was also inhibited by estrogenic, but not by 
other substances, it is presumably the more slowly sedimenting "high salt" 
receptor species (DeSombre et al., 1969). This phenomenon and also the 
tendency of the 8S receptor to form more rapidly sedimenting aggregates has 
been investigated by Chamness & McGuire (1972), Sica et al. (1976) and 
Stancel et al. (1973), and may be attributed to protein-protein interactions 
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g> Table 10.1 — Binding of estradiol-3H to rat uterine cytosol in the presence of estrogenic and non-estrogenic compounds 
Cytosol preparations 
Number of incubations (N) 
CONTROL 
TEST COMPOUNDS 
Estradiol-17ß 
Ethinylestradiol 
Diethylstilbestrol 
Estrone 
Estradiol-17a 
Progesterone 
Testosterone 
Corticosterone 
Ethynodiol 
Norethynodrel 
Lynestrenol 
Norethindrone 
d-Norgestrel 
<H-Norgestrel 
Estrenol 
Nortestosterone 
-
nmol 
0.10 
0.10 
0.10 
0.10 
1.00 
1.00 
1.00 
1.00 
0.25 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
I 
4 
4280 ± 70 
369 ±21 
4165 ± 28 
4379 ± 34 
885 ± 43 
3304 ± 26 
3941 ± 84 
3448 ± 15 
Π 
5 
4277 ± 
332 ± 
677 ± 
576 ± 
553 ± 
913 ± 
73 
7 
29 
50 
14 
56 
in 
5 
cpm ± 
3859 ± 41 
377 ± 6 
573 ± 27 
2804 ± 38 
3188 ± 79 
IV 
5 
SE 
4569 ± 
401 ± 
402 ± 
587 ± 
459 ± 
4543 ± 
3980 ± 
3573 ± 
1893 ± 
73 
9 
16 
14 
37 
51 
28 
43 
17 
V 
5 
5003 ± 
4616 ± 
419 ± 
817 ± 
2265 ± 
3915 ± 
67 
35 
14 
18 
92 
130 
VI 
5 
4396 ± 141 
267 ± 8 
4056 ± 74 
4007 ± 227 
3929 ± 96 
Methyllynestrenol 1.00 
Ethisterone 1.00 
Ethynodiol diacetate 0.2S 
Lynestrenol acetate 1.00 
3787 ± 44 
2745 ± 50 
3802 ± 131 
2880 ± 105 3810 ± 168 
3301 ± 51 3818 ± 86 
4416 ± 72 
4068 ± 62 
2557 ± 69 
Norethindrone acetate 1.00 
Hydroxyprogesterone 1.00 
Medroxyprogesterone 1.00 
Chlormadinone 1.00 4373 ±84 
3983 ± 67 
4265 ± 105 
4135 ± 132 
3577 ± 39 4047 ± 69 
4520 ± 12 
4124 ± 85 
Megestrol 1.00 
Medroxyprogest. acetate 1.00 
Chlormadinone acetate 1.00 
Megestrol acetate 1.00 
3901 ± 90 
4255 ± 23 
4303 ± 45 
4340 ± 36 
4147 ± 41 
4563 ± 36 4623 ± 78 
3863 ± 12 
4221 ± 88 
4278 ± 68 
0.2 ml of rat uterine cytosol was incubated with 0.5 pmol of estradi ol-'H alone (control) or together with the indicated amount of the 
test compound. The values are means ± SE of N incubations and represent half of the total bound radioactivity. The protein content 
of the 6 cytosol preparations varied between 0.6 and 0.7 mg/ml. 
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resulting from environmental conditions, including among others the protein 
concentration, the ionic strenght and aging of the cytosol. 
Assuming in the present study that a reduction of estradiol binding of more 
than 10 per cent in the uterine cytosol, is the result of an occupation of receptor 
binding sites, ethynodiol, norethynodrel, lynestrenol, estrenol, norethindrone, 
nortestosterone, ethisterone and the acetate esters of ethynodiol and lynestrenol 
are to be considered as inhibitors, but not the hydroxyprogesterone derivatives 
and methyllynestrenol (Table 10.1). As to norgestrel and norethindrone acetate 
the results obtained indicate almost negligible effects. The density gradient 
patterns of Figs. ЮЛЬ and 10.1c confirm these results. All the active compounds 
suppress to some extent the peak of the estradiol-receptor complex. This sup­
pression appeared to be dose dependent as is demonstrated for lynestrenol in 
Fig. 10.Id. In the presence of a sufficiently high excess of inhibitor, as in the 
case of ethynodiol in Fig. 10.1b, a total displacement of estradiol from its 
specific binding sites could be observed. 
Competitive interaction 
In order to decide whether this inhibitory effect reflects a change in the 
affinity or in the number of available estradiol binding sites, three lots of 
cytosol have been incubated with increasing concentrations (0.50-3.75 nM) of 
the radioactive ligand alone and also in the presence of two concentrations 
inhibitor. The double reciprocal plots (Lineweaver & Burk, 1934) obtained as 
the result of experiments with ethynodiol and lynestrenol are shown in Fig. 10.2 
and are typical for a competitive interaction. The apparent dissociation constants 
(KD) for estradiol as calculated from these plots are 2.5xl0"10 M for experiment 
a and 3.8xl0"10 M for experiment b and indicate strong affinity for the receptor 
binding sites. Ethynodiol has a markedly higher affinity than lynestrenol as is 
demonstrated by Kj values of 4.5xl0"9 M and l . l x l O 7 M respectively. The 
binding capacity of cytosol a for estradiol-3!! is 0.75 pmol/mg protein and of 
cytosol b 0.62 pmol/mg protein. 
-<-
Fig. 10.1a-d — Sucrose density gradient patterns of 105,000xg rat uterine cytosol after 20 h 
incubation at 1-30C with estradiol-'H alone or together with one of the unlabelled com­
pounds in the amounts indicated. Before centrifugation (7 h at 300,000xg) the unbound 
estradiol-3H was removed with dextran-coated charcoal. BSA and beef liver catatase 
(sedimentation coefficients 4.6 and 11.3 respectively) were used as standards to estimate 
the sedimentation coefficient. 
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Fig. 10.2 — Competitive inhibition by ethynodiol (a) and lynestrenol (b) of estradiol-'H 
binding to rat uterine receptor. The cytosol was incubated with increasing concentrations 
(0.50-3.75 nM) estradiol-'H alone (i = 0) or together with the indicated concentration of 
inhibitor i. The free estradiol-'H concentration was calculated as the difference between the 
total and bound estradiol-'H. The double reciprocal plots a and b are from two different 
cytosols. Each point represents the mean of two (a) or four (b) incubations. 
While a report of the present investigations was in the press (Van Kordelaar 
et al., 1975) Terenius (1974), in a similar study using rabbit uterine cytosol 
instead of rat uterine cytosol, obtained results in agreement with our obser­
vations. The binding affinity of the synthetic progestins to the estrogen receptor 
decreased in the sequence ethynodiol, norethynodrel, norethindrone. Lynestrenol 
was not studied. Norgestrel and the hydroxyprogesterone derivatives appeared to 
be inactive. The Ki value of ethynodiol (2.4x10β M) compares favourably with 
our value of 4.5x10» M. 
DISCUSSION 
Structural requirements for receptor binding 
From the data in Table 10.1 some conclusions may be drawn with regard 
to the structural requirements of the ligand, which favour receptor binding. 
Other studies have already stressed the significance of the phenolic hydroxyl 
group at Сз and the 17ß-hydroxyl function of estradiol for its attachment to 
the receptor sites (Chemayaev et al., 1975; Hähnel et al., 1973; Katzenellen-
bogen et al., 1973; Korenman, 1969; Raynaud et al., 1973). Changes in the 
structure of the molecule at these positions always resulted in a decrease of 
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binding affinity. Obviously the 17a-ethyny] group has rather unique properties 
in this respect. The introduction of this substituent not only results in a decrease 
of metabolism (Fotherby & James, 1972; Thijssen, 1972), but also greatly 
promotes binding to the estrogen receptor: compare the inhibition of binding 
by lynestrenol and estrenol, by norethindrone and nortestosterone, and by 
ethisterone and testosterone. This is consistent with the observations of 
Korenman (1969), Raynaud et al. (1973) and Shutt & Cox (1972) for ethinyl-
estradiol and estradiol respectively. In the present study estradiol and ethinyl-
estradiol inhibit estradiol-3H binding to the same degree, but this has to be 
attributed to the fact, that in the presence of a 200-fold excess of these com-
pounds, total displacement of estradiol-3H from the specific binding sites has 
already occurred. 
The high binding affinity of ethynodiol compared with lynestrenol and 
norethindrone is an indication, that its equatorially oriented 3ß-hydroxyl 
function contributes considerably to a good fit with the receptor binding site. 
On the other hand, the decrease of binding affinity in comparison with estradiol 
is probably related with its changed stereochemistry after partial saturation of 
the A-ring, which has lost the planar conformation present in estradiol. Also 
the contribution of the alicyclic 3ß-hydroxyl may be less effective in non-binding 
interactions with the receptor site than the phenolic hydroxyl of estradiol. 
After removal of the 3ß-hydroxyl from ethynodiol binding affinity is 
decreased (cf. lynestrenol), but still significantly higher than after its replace-
ment with а Сз oxo group, even in the absence of the 17a-ethynyl group (cf. 
estrenol). The conformation of this oxo group is apparently an important factor: 
the conformation present in norethynodrel with the oxo group above the plane 
of the molecule is opposite to that of the weak binder norethindrone, whereas 
the interatomic distance between the Сз oxo and 17ß-hydroxyl measured by 
X-ray crystallography is probably almost equal, cf. 17ß-hydroxy-4-androsten-
3-one 1.094 nm and 17ß-hydroxy-5(10)-estren-3-one 1.087 nm. In estradiol 
hemihydrate the distance between the Сз and C17 hydroxyl is 1.093 nm (Duax 
& Norton, 1975). The comparatively small difference of binding affinity between 
norethynodrel and lynestrenol on the one hand and the large difference between 
norethynodrel and ethynodiol on the other hand seems to indicate, that the 
contribution of the Сз oxo group to the binding is rather small, although 
steric factors may be involved, too. An explanation for this poor contribution 
could be, that polarization of the oxo group yields a negative center at the 
Сз position in contrast with the charge distribution in ethynodiol and estradiol. 
Acetylation of the 3ß- and 17ß-hydroxyl groups decreases the activity of 
ethynodiol, lynestrenol and norethindrone. Terenius (1974) reported a Kj value 
for ethynodiol diacetate of 9.9xl0"8 M, a 40-fold increase in comparison with 
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ethynodiol. To what extent the residual activity results from some hydrolysis 
during the 20 h incubation procedure or has to be considered as an intrinsic 
property of the acetate ester itself, remains to be studied. Katzenellenbogen et 
al. (1973) observed a rapid hydrolysis of estradiol-3-acetate when incubated 
with rat uterine cytosol for 1 h at 0oC. 
The lack of activity of Chlormadinone, megestrol and medroxyprogesterone 
is quite understandable in the light of the results obtained with progesterone 
and methyllynestrenol. The presence of a 6a-methyl substituent seems to be 
matched with loss of binding ability (compare lynestrenol and methyllynestre-
nol). A decrease of binding ability is also observed after the introduction of 
the 19-methyl group as shown by the difference between testosterone and 
nortestosterone, although in ethisterone the 17a-ethynyl group seems to be able 
to overcome this to some extent. Previously, a slight inhibition of estradiol 
binding to the estrogen receptor has been shown by Korenman (1969) and 
Notides et al. (1972) for 5-androstene-3ß,17ß-diol, 4-androstene-3ß,17ß-dioI 
and 5a-androstane-3ß,17ß-diol. The 3ß-hydroxyl in these compounds is equa-
torially oriented like in ethynodiol. On the other hand, 5ß-androstane-3a,17ß-
diol as well as the 5a-isomer appeared to be inactive (Hähnel et al. 1973). 
For this reason it may be concluded that steroids of the androstane series may 
still bind to the estrogen receptor, provided that favourable conditions are 
preserved at the Сз or C17 position of the molecule. In this connection the 
18-methyl group seems to be of less importance than the 19-methyl group. 
Hähnel et al. (1973) reported equal affinity for estradiol and 18-norestradiol. 
On the other hand, it is evident from the very weak activity of norgestrel, that 
the introduction of an ethyl group in this position almost completely eliminates 
any activity. 
Correlation with results obtained in vivo (Chapter 9) 
In general the results of the incubation experiments correlate very well with 
the data of Tables 9.3 and 9.4 in the preceding chapter. The acetate esters, 
however, of ethynodiol, norethindrone and lynestrenol in vitro displayed a 
much smaller effect than the parent compounds in contrast to an almost equal 
activity in vivo (Chapter 9, Table 9.5). Apparently, the esters in vivo are 
hydrolysed very fast to the respective alcohols. 
On the contrary, lynestrenol and estrenol appear to be more active in vitro 
than in vivo. An explanation for this difference could be a rather high metabolic 
clearance rate of lynestrenol and estrenol in comparison with norethynodrel 
and norethindrone and the generation of inactive or less active biotransformation 
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products: Mazaheri et al. (1970) and Okada (1972) reported biotransformation 
of lynestrenol to norethindrone. Analogously, formation of nortestosterone 
from estrenol could occur via the same mechanism. In the present study, 
however, we could not get proof for the presence of norethindrone in the bile 
and urine of the rat after the administration of lynestrenol. Another metabolite 
could tentatively be identified as 17a-ethynyl-5i-estrane-3'i,17ß-diol (see 
Chapter 12). Binding of the 5a-estran-3ß-ol isomer of this structure with the 
estrogen receptor seems very likely in view of the activity of 5a-androstane-
3ß,17ß-diol mentioned above. So this conversion, if actually of significance, 
provides no explanation for the question under consideration. 
In this connection attention should also be paid to plasma protein binding 
and physicochemical aspects, particularly lipophilicity, which are also important 
factors involved in the kinetics of distribution and elimination and therefore 
in drug action. The determination of the lipophilicity of this group of steroids 
as a partition coefficient between water and organic solvents is complicated 
by their extremely low solubility in water and their high solubility in most 
organic liquids. A good differentiation, however, is also possible with the help 
of reversed-phase thin-layer chromatography (Boyce & Milborrow, 1965). 
Between the partition coefficient a and the Rf value obtained from a liquid-
liquid partition chromatography system the following relationship exists 
(Martin, 1949): 
a = К (Rf1 — 1), where К = constant for the system. 
Bate-Smith & Westall (1950) introduced the term RM ( = log (Rf-i — 1)). The 
change in the value of RM with the introduction of a substituent has been shown 
to be very useful in the characterization of the relative lipophilicity within a 
series of compounds (Bush, 1961; Stahl, 1969). From the data in Table 10.2 
it can be observed that introduction of an oxygen function in the A ring of the 
steroid molecule results in a very large decrease of the RM value for all 
nortestosterone derivatives and so in a marked difference in lipophilicity 
between lynestrenol and estrenol on the one hand and ethynodiol, norethindrone, 
norethynodrel, norgestrel and nortestosterone on the other. The lipophilic nature 
of lynestrenol and estrenol may give rise to a more rapid accumulation in the 
fatty tissues of the rats immediately after injection and consequently in lower 
effective concentrations in the receptor compartments as compared with the 
more polar structures. A rapid and pronounced uptake of lynestrenol in the 
brown adipose tissue of mice has actually been observed in the present study 
(Chapter 14). 
Also plasma protein binding may be an important parameter in the relationship 
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Table 10.2 — The lipophilic character of the 19-norsteroids studied as 
expressed by their Rji values 
Mean RM value Inter-plate SE 
Methyllynestrenol 
Lynestrenol 
Estrenol 
Norethynodrel 
d-Norgestrel 
Norethindrone 
Ethynodiol 
Nortestosterone 
> 1 . 3 
0.755 
0.683 
- 0.128 
- 0.199 
- 0.319 
- 0.329 
- 0.401 
— 
0.023 
0.031 
0.034 
0.023 
0.035 
0.035 
0.025 
between the dose and the drug concentration reached in the target tissue. The 
greater estrogenic activity of the 11-methoxy derivatives of estradiol and ethinyl-
estradiol in spite of a stronger receptor binding of these latter compounds could 
be attributed to the comparatively small fraction of the derivatives bound to 
plasma proteins and concurrently higher uterine concentrations (Raynaud, 1973; 
Raynaud et al., 1973). Although we have no information about the binding of 
the nortestosterone derivatives to rat plasma proteins, a possible role for this 
parameter in the different in vivo/in vitro activities observed should also be 
taken into account. 
Implications of the receptor interaction 
The possible implications of the interaction of the progestins with the 
estrogen receptor for the biological activity of these compounds, viz. in addition 
to progestational activity an inherent estrogenicity or anti-estrogenic action, 
have already been outlined in a more general context in Chapter 1, to which 
we refer. 
SUMMARY 
Incubation of the 105,000xg supernatant of rat uterus homogenate with 
estradiol-3!! resulted in an estrogen specific binding of limited capacity to a 
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macromolecule sedimenting in the 8-9S region after density gradient centrifu-
gation. The contraceptive progestins of the 19-nortestosterone series were able 
to interfere with estradiol binding in contrast to the hydroxyprogesterone 
derivatives Chlormadinone, medroxyprogesterone and megestrol. The interaction 
appeared to be competitive. The strongest inhibition of estradiol binding was 
observed in the presence of ethynodiol, followed by norethynodrel, lynestrenol 
and norethindrone respectively. Norgestrel was almost inactive. Of the related 
structures tested estrenol displayed more, nortestosterone and ethisterone less 
activity than norethindrone, 6a-methyllynestrenol showed only border-line 
activity. 
In comparison with norethynodrel and norethindrone, lynestrenol and 
estrenol appeared in vitro to be stronger competitors for estradiol than in vivo 
(this thesis. Chapter 9). This may be due to the great difference in lipophilic 
character which is reflected in the RM values of these compounds. 
From the results obtained it may be concluded, that the presence of a 
17a-ethynyl substituent promotes receptor binding, whereas the introduction 
of methyl substituents in the positions 6, 10 and 18 causes the opposite effect. 
The relationship between the various ring A structures and the affinity to the 
receptor is discussed. 
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CHAPTER 11 
AFFINITY OF THE CONTRACEPTIVE PROGESTINS TO THE CALF 
UTERINE RECEPTOR: 
BINDING STUDIES AS A TOOL IN DRUG RESEARCH*) 
INTRODUCTION 
In the preceding chapter we have shown, that the estrogenic activity of the 
17a-ethynyl-19-nortestosterone derivatives used in contraception, often attri-
buted to the formation of estrogenic metabolites (Fotherby & James, 1972), 
may be explained by the competitive interaction of these progestins with 
estradiol for its binding sites on the estradiol receptor. Furthermore, an insight 
was obtained in some structural requirements important for the occurrence of 
binding and the binding affinity of the compounds studied. For a more quan-
titative approach and a comparison, however, of this latter property within a 
series of compounds, the use of one and the same receptor preparation is to be 
preferred. The receptor content and the ratio of the specific and the non-
specific binding sites vary with each preparation as is obvious from the binding 
experiments described in Chapter 10. Moreover, the rat uterus appeared us to 
be a rather laborious and expensive source of receptor material, particularly for 
large-scale work. For these reasons, we have directed our attention to the calf 
uterine receptor. The isolation of the estrogen binding protein from calf uteri 
and its characterization have been the subject of investigations in several labora-
tories (Baulieu et al., 1971; DeSombre et al., 1971; Puca et al., 1971; and 
others). We have studied the binding of estradiol to the calf uterine cytosol 
and determined the relative potency of the 19-nortestosterone derived progestins 
to displace estradiol from its specific binding sites. From the data obtained 
the binding parameters of these compounds could be calculated. The possi-
bilities and limitations of this kind of studies as compared with the bio-assay 
methods in use for the evaluation of steroid hormone activity (Astwood, 1970; 
Dorfman, 1969; Emmens, 1969) will be discussed. 
*) Presented at the 33rd Int. Congress Pharmaceut. Sci., Stockholm, September 2-7, 1973. 
References p. 117 JQ7 
MATERIALS AND METHODS 
Preparation of the calf uterine cytosol 
The calf uteri were obtained from the slaughter-house, cooled in ice im­
mediately after excision and processed the same day. The subsequent manipula­
tions with the biological material were carried out at 1-40C. After cutting the 
tissue with scissors the pieces were washed in buffer (0.01 M Tris-HCl with 
0.001 M EDTA, pH 7.4) and homogenized in 0.5 volume of the same buffer 
using a Waring blendor. Homogenization was achieved by 5-10 pulses of 10 
seconds duration with 2 minutes cooling inbetween. The homogenate was cen-
trifuged for 10 minutes at IS^OOxg, the pellet was discarded and the super­
natant centrifuged again for 1 hour at 105,000xg in a Spinco L2-75B ultra-
centrifuge using a Spinco 50ТІ rotor. The 105,000xg supernatant (cytosol) of 
successive runs were pooled, mixed thoroughly, divided into 1.4 ml fractions 
and stored deep-frozen at -80oC to preserve the full binding capacity. The 
protein content of the cytosol stock, determined according to Lowry et al. 
(1951), was 12.7 mg/ml. 
Binding experiments 
The procedures used in studying steroid-receptor binding have been described 
in detail in the preceding chapter and are discussed in Chapter 6. For the 
determination of the dissociation constant of estradiol binding to the receptor 
the cytosol was diluted 10 fold. The use of this dilution allowed measurements 
tobe made between 20 and 80% saturation of the receptor binding sites, where 
the most accurate measurements of the dissociation constant and binding 
capacity can be done (Deranleau, 1969), and simultaneously over a concen­
tration range of estradiol-3H, where the ratios bound/unbound can be most 
accurately determined in the assay procedure applied. 
Test compounds 
Specifications of the steroids have been given in Chapter 3. For the deter­
mination of the binding inhibition curves the specific activity of the tritiated 
estradiol was reduced to 8.0 Ci/mmol by the addition of the non-labelled com­
pound. 
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Assay of radioactivity 
The radioactivity of incubation and gradient samples was measured by liquid 
scintillation counting as described (Chapter 5). The standard error of counting 
was 2.5% or less, the counting efficiency was about 45%. 
RESULTS 
Properties of the calf uterine receptor; effect of progestins on estradiol binding 
The pattern of estradiol binding to the calf uterine cytosol in the presence 
of increasing concentrations (0.5-6 nM) of the tritiated hormone alone or 
together with a 500-fold excess of the synthetic non-steroid estrogen diethyl-
stilbestrol (DES), which has a comparable affinity to the receptor binding sites, 
is shown in Fig. 11.1a. Two classes of binding sites can be discerned, one with 
high affinity and low capacity and the other one with much lower affinity and 
high capacity. The difference becomes manifest in the presence of excess DES, 
resulting in the displacement of estradiol from the saturable high affinity binding 
sites, but without influence on the high capacity binding of the hormone. By 
1 2 3 4 5 6 0 5 1 0 1 5 2 0 
estradiol ЪИ (nM) estradiol 3Hbound (nM) 
Fig. 11.1 — a. Binding curves of estradiol-3H to calf uterine cytosol. Total binding and 
binding in the presence of a 500-fold excess of diethylstilbestrol were measured. High 
affinity binding was calculated as the difference of the total and low affinity binding. The 
points represent the mean of 3 experiments. 
b. Scatchard plot of the high affinity binding curve. 
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subtracting the low affinity binding curve from the total binding curve a curve 
is obtained representing only high affinity binding. The Scatchard plot 
(Scatchard, 1949) corresponding to this latter binding curve is shown in 
Fig. 11.1b. For the high affinity binding sites a dissociation constant of 
3.9xl0"10 M can be calculated with a binding capacity of 1.4 pmol/mg protein. 
The specificity of the high affinity binding sites for estrogenic compounds is 
apparent from the lack of influence of a 2000-fold excess of testosterone, 
progesterone and corticosterone on estradiol binding, whereas a 50-fold excess 
of ethinylestradiol or DES was able to abolish the high affinity binding com-
pletely (Fig. 11.2a,c). The peak of radioactivity in the gradient appeared to be 
localized in the 8S region (Fig. 11.2c). 
Displacement of estradiol from its specific binding sites occurred to a varying 
degree in the presence of ethynodiol, norethynodrel, norethindrone (Fig. 11.2b) 
and lynestrenol (Fig. 11.2c). Norgestrel and the hydroxyprogesterone derivatives 
megestrol acetate, Chlormadinone acetate and medroxyprogesterone acetate 
were devoid of activity in this respect. The increase of the inhibition of estradiol 
binding in the presence of an increasing excess of the inhibitor and the 
reversibility of lynestrenol binding to the estradiol receptor is shown in Fig. 
11.2c and Fig. 11.2d respectively. 
Binding affinity of the progestins 
A quantitative insight in the potency of the competing steroids to displace 
estradiol from its binding sites on the receptor can be obtained by determining 
under defined conditions for each compound the amount necessary to reduce 
the specific binding of tritiated estradiol by 50%. The undiluted cytosol was 
incubated with 30 nM estradiol-3H alone and in the presence of increasing 
amounts of the competing steroids. The total binding of estradiol thus measured 
was corrected for non-specific binding: the residual binding after incubation of 
the control samples with a 500-fold excess DES. It was observed, that the non-
Fig. 11.2a-d — Sucrose density gradient patterns of 105,000xg calf uterine cytosol after in-
cubation of 0.2 ml cytosol with estradiol-'H alone or together with one of the unlabelled 
compounds in the amounts indicated. Incubations were carried out at 1-30C for a period 
of 20 h, unless otherwise indicated (exp. d). Before centrifugation (7 h at 300,000xg) the 
unbound estradiol-aH was removed with dextran-coated charcoal. BSA and beef liver 
catalase were used as standards to estimate the sedimentation coefficient (Martin & Ames, 
1961). 
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specific binding in the control samples (about 10% of the total binding) and 
in the samples with the progestins was the same. By plotting of the residual, 
specific, estradiol binding as a function of the molar ratio of the respective 
progestins and estradiol on a semi-log scale a series of almost parallel sigmoid-
shaped curves was obtained (Fig. 11.3). The relative activity (RA) of the 
steroids is also shown in this figure and was calculated from the quotient of the 
molar ratio for estradiol itself (A) and the molar ratio of the respective progestin 
(B), corresponding to 50% residual binding of the tritiated hormone, according 
to the formula: RA = A/B (Korenman, 1969, 1970). 
It can be observed from the inhibition curve of estradiol in Fig. 11.3, that a 
molar ratio of unity does not correspond with 50% reduction of binding. This 
can be explained by taking into consideration the shape of the binding curve 
in Fig. 11.1. Obviously, the occurrence and the extent of the reduction of 
estradiol binding, that will be observed, is a function not only of the molar 
ratio of the competing steroids, but also of the degree of receptor saturation. 
The concentration of estradiol-3H used in the present experiments corresponded 
to approximately 83% receptor saturation in the control samples. 
From the RA values of the competing steroids the ratio of the association 
estradiol JH bound (% control ) 
Molar raho progeetm/estradtot 
Fig. 11.3 — Binding inhibition curves of estradiol-'H showing the inhibition of estradiol-'H 
receptor binding in the presence of increasing excess of the non-labelled ligand and the 
competing nortestosterone derivatives. The relative activity (%) was calculated from the 
molar ratio progeslin/estradiol-3H corresponding to a residual estradiol binding of 50%. 
Each point in the curves represents the mean of S incubations. 
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Table 11.1 — Survey of RA, RAC and affinity constants of the nortestosterone 
derived progestins*) 
COMPOUND 
Estradiol 
Ethynodiol 
Norethynodrel 
Lynestrenol 
Norethindrone 
d-Norgestrel 
RA 
100 
11 
0.59 
0.33 
0.02 
^ 0 . 0 2 
RAC 
100 
8.7 
0.45 
0.25 
0.01 
<C0.01 
KA 
2.6x10» 
2.2x10» 
1.2x107 
6.5x10« 
3.8x105 
<105 
KD 
3.9x10·»· 
4.5x10-9 
8.7x10-8 
1.5x10-7 
2.6x10« 
>io-« 
*) Calculated from the data of Figs. 11.1 and 11.3. 
Abbreviations and symbols: RA denotes relative activity in inhibiting estradiol receptor 
binding (%), RAC denotes ratio of association constants progestin/estradiol (%), KA and 
KJJ denote association (M1) and dissociation constant (M). 
constants (RAC) can be calculated using the equation derived by Korenman 
(1970): 
RAC = 
R.RA 
R + Ì — RA 
where RAC = KAoomi>et,tor/KAestradio1 and R represents the ratio of free to 
specific-bound estradiol-3H at 50% competition. Under the conditions of the 
present assay the ratio of free to specific-bound estradiol-3H in the absence 
of competitor was 16/14 (see Fig. 11.1a), so R = 3.3. Like the RA value the 
RAC value is usually expressed in per cent (RAC χ 100). Because the dis­
sociation constant of estradiol to the cytosol receptor protein was determined in 
the same cytosol under similar experimental conditions, the affinity constants 
of the progestins could also be calculated. A survey of these values is given in 
Table 11.1. 
DISCUSSION 
The calf uterus as a source of receptor material 
The present experiments have demonstrated, that the calf uterine cytosol 
contains a macromolecule with a high affinity and limited capacity for the 
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binding of estrogens. These properties, particularly specificity of binding, are 
considered to be characteristic for receptor molecules (Baulieu et al., 1971). 
The sedimentation pattern in the sucrose gradient, the dissociation constant 
and the binding capacity of the cytosol are consistent with previous reports 
concerning more extensive studies of the physicochemical properties of the calf 
uterine receptor (Baulieu et al., 1971; Puca et al., 1971). Comparative in-
vestigations of the estrogen receptors isolated from various mammalian species 
including the cow and the rat have shown a strong similarity even in immuno-
chemical respect (Greene et al., 1977). The similarity of the receptors of the 
calf and rat uterus also with respect to their binding of compounds with less 
high affinity is supported by the results described in this and the preceding 
chapter. It seems justified, therefore, to conclude that with the calf uterus we 
have at our disposal an excellent alternative source of estrogen receptor 
material, that is easily to obtain and more economic and less laborious than the 
immature rat uterus and particularly suited for the preparation of larger quan-
tities of cytosol. 
Comparative binding affinity and biological activity 
Because the action of estrogenic hormones in stimulating growth and function 
of female reproductive tissues takes place primarily, though perhaps not ex-
clusively, through their interaction with the receptor protein present in the 
target tissues (Gorski & Gannon, 1976; Jensen & DeSombre, 1973; O'Malley & 
Means, 1974), the study of this interaction can be considered as an important 
instrument for obtaining a proper understanding of the biological activity of a 
particular drug and as a rational approach to the design and screening of poten-
tial drugs. 
From the various assays of biological activity currently in use for the evalu-
ation of sex hormone activity the relationship between structure and activity is 
difficult to assess (Grover & Odell, 1975; Raynaud et al., 1973). The activity 
measured is the final product of a chain of biochemical events in the responsive 
tissue and becomes manifest a relatively long period of time after the hormone-
receptor interaction has occurred. As a consequence the information concerning 
the intrinsic activity of the compounds tested is confused very much by dis-
tribution and elimination processes occurring over the same time interval. No 
discrimination is possible between the effects of the compound administered 
and of its often multiple and unknown metabolites. Moreover, many of the 
synthetic compounds are not „pure", but show several types of activity, the 
particular spectrum displayed being characteristic for the substance. Estrogenic, 
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Table 11.2 — Comparative binding affinity and estrogenic potency 
COMPOUND 
Estradiol 
Ethinylestradiol 
Ethynodiol 
Ethynodiol diacetate 
Norethynodrel 
Lynestrenol 
Norethindrone 
¿-Norgestrel 
Medroxyprogesterone acetate 
Megestrol acetate 
Chlormadinone acetate 
RAC2) 
Estrogenic Activity (E.D. 75%, mg/kg)1) 
in the Allen-Doisy test 
100 
n.d. 
> estradiol 
8.7 
n.d. 
ethynodiol 
0.45 
0.25 
0.01 
« 0.01 
not binding 
not binding 
not binding 
Subcutaneous 
0.003 
0.0025 
active 
0.45 
1 
9 
100 
inactive 
inactive 
Oral 
0.050 
5-10 
inactive 
inactive 
inactive 
inactive 
References 
Desaulles & Krähenbühl, 
Desaulles & Krähenbühl, 
Overbeek et al., 1962 
Elton et al., 1962 
Elton & Nutting, 1961 
Elton et al., 1962 
Desaulles & Krähenbühl, 
Desaulles & Krähenbühl, 
Overbeek et al., 1962 
Desaulles & Krähenbühl, 
Edgrenetal., 1966; 1967 
Edgrcn et al., 1967 
David et al., 1963 
Hecht-Lucari et al., 1965 
1964 
1964 
1964 
1964 
1964 
0 The activities derived from Overbeek et al. (1962) and Elton et al. (1961; 1962) represent our own estimations based on the data as 
presented by these authors and assuming a body-weight of 200 g for the rats used in the assay. 
*) RAC denotes the ratio of association constants progestin/estradiol (%). 
androgenic, anabolic and progestational activities may occur simultaneously and 
interfere with each other. For this reason tests on compounds of mixed activity 
may be difficult to interpret (Astwood, 1970). 
Binding studies offer the advantage of a direct insight in the relationship 
between chemical structure and receptor binding in the target tissue. The iden-
tity of the compound binding to the receptor is known and its binding affinity 
can be measured. Total absence of binding or a very low binding affinity 
preclude intrinsic estrogenic activity. Examples of this in the present in-
vestigations are norgestrel and the hydroxyprogesterone derivatives, which have 
been demonstrated to be devoid of estrogenic activity in the bio-assay (David 
et al., 1963; Edgren et al., 1966; Edgren et al., 1967; Hecht-Lucari et al., 1966). 
Binding affinity alone, however, does not imply estrogenic activity in vivo as it 
does not distinguish between estrogens and competitive inhibitors. This aspect 
has already been discussed in Chapter 1. For this reason the measurement of 
binding affinity can not be used as a substitute for the bio-assay. 
In Table 11.2 the RAC values of the contraceptive steroids have been 
brought together with some data from the literature (David et al., 1963; 
Desaulles & Krähenbuhl, 1964; Edgren et al., 1966; Edgren et al., 1967; 
Elton & Nutting, 1961; Elton et al., 1962; Hecht-Lucari et al., 1966; Overbeek 
et al., 1962) concerning their activity in the vagina cornification assay (Allen-
Doisy test). Vagina cornification in the spayed rat is the most specific biological 
test available for the determination of the estrogenicity of a compound 
(Astwood, 1970). It can be observed from the results shown, that the ranking 
order of activity in the bio-assay and in the binding studies is the same. 
Furthermore, it is obvious that the relative binding affinity of the nortestosterone 
derivatives is higher than their relative potency in vivo. This may be explained 
by their rapid biotransformation (see Chapters 12, 15, 16), but other factors 
may be involved as has been discussed above and in Chapter 1. There is another 
reason, however, to be very cautious in drawing conclusions from relative 
activity values in vivo: the biological activity of the test compound as well as 
the activity of the reference compound may vary considerably and independently 
as illustrated in Table 11.2 by lynestrenol and ethinylestradiol. Quantitative 
structure-activity relationship studies of synthetic steroids should, therefore, 
not rely on the bio-assay alone, unless the pharmacokinetics of the compounds 
studied has been thoroughly explored in the species employed for testing 
activity. 
The results presented in Section III illustrate, that the study of the inter-
action and affinity of the contraceptive steroids to the estrogen receptor may 
contribute to a better understanding of their biological activity and mode of 
action. Although it has to be realized, that apart from the binding affinity the 
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intrinsic activity of a compound is pertinent to the extent of its in vivo activity 
(Ariens et al., 1964), the interaction with the receptor still has to be considered 
as a prerequisite for any action at all. In this connection, therefore, it can be 
concluded that drug-receptor interaction studies are a promising and multivalent 
tool in the design, screening and evaluation of compounds with sex hormone 
activity. 
SUMMARY 
Incubation of the 105,000xg supernatant of calf uterine homogenate with 
estradiol-3!! resulted in an estrogen-specific binding to a macromolecule with 
a sedimentation coefficient of 8-9S. The binding was furthermore characterized 
by a high affinity (KD = 3.9x1010 M) and a limited capacity (1.4 pmol/mg 
protein). In contrast with Chlormadinone, medroxyprogesterone and megestrol, 
the contraceptive progestins derived from 19-nortestosterone appeared to inter­
fere with estradiol receptor binding. The inhibition of estradiol binding in the 
presence of the latter compounds was reversible and increased in the presence 
of increasing excess of the inhibitor as could be demonstrated by sucrose gradient 
centrifugation. The ratios of the equilibrium constants of association (RAC) of 
the competing steroids compared to estradiol were calculated from the molar 
excess of the competitor, which reduced specific estradiol-3!! binding to 50%. 
The following RAC values were obtained (estradiol = 100): ethynodiol 8.7, 
norethynodrel 0.45, lynestrenol 0.25, norethindrone 0.01 and d-norgestrel 
< 0.01. The corresponding association constants Кд are (Kv e s t r a d ' 0 1 = 
2.6xl09 M'1): ethynodiol 2.2xl08 M 1 , norethynodrel 1.2xl07 M 1 , lynestrenol 
6.5x10° M 1 and norethindrone 3.8xl05 M 1 . The results demonstrate a close 
agreement between the binding characteristics of the calf and rat uterine recep­
tor. In vitro binding of the contraceptive steroids and their estrogenic activity 
in vivo have been compared. The possibilities and limitations of both kinds of 
study for the design, screening and evaluation of compounds with sex hormone 
activity are discussed. 
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SECTION Г 
P H A R M A C O K I N E T I C S O F L Y N E S T R E N O L 
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CHAPTER 12 
ABSORPTION AND DISPOSITION OF LYNESTRENOL IN THE INTACT 
AND BILE DUCT CANNULATED RAT 
INTRODUCTION 
In spite of its wide-spread use as an oral contraceptive drug and progestin, 
little information is available about the absorption and elimination of lynestrenol 
in laboratory animals and man. 
After the administration to humans (Kamyab et al., 1968; Murata, 1967) and 
rabbits (Yamamoto, 1968) lynestrenol appeared to be metabolised extensively 
to a variety of mostly unidentified compounds and was not excreted unchanged 
with the urine. Although renal excretion in man (Kamyab et al., 1968; Van 
der Molen et al., 1969) and rabbits (Yamamoto, 1968) accounted for only 
30-60% and 35%, respectively, of the dose administered, no attention has been 
paid to the significance of the bile as a route of excretion for this compound. 
Other synthetic sex hormones or their biotransformation products have been 
shown to undergo biliary excretion to a varying degree in animals (Arai et al., 
1962; Bolt & Remmer, 1972; Hanasono & Fischer, 1974; Honjo et al., 1976; 
Ishihara et al., 1975; Ishihara et al., 1976; Kamyab et al., 1967; Reed & 
Fotherby, 1975; Steinetz et al., 1967) and humans (Cargill et al., 1969; Layne 
et al., 1963). Recently, Coert et al. (1975) mentioned a high biliary excretion 
of radioactivity in the rat after the intravenous injection of lynestrenol-14C. 
In the light of the still scarce knowledge about its absorption and elimination, 
a more extensive study with regard to the fate of lynestrenol in the rat seemed 
worthwhile. In this chapter the results are described of investigations con-
cerning the extent and rate of absorption of lynestrenol from the gut, its 
disposition and routes of excretion in the intact and bile duct cannulated rat. 
The nature of the conversion products has been studied in sofar this could be 
of help in the interpretation of the experimental results obtained in the present 
and in the next chapter of this thesis (Chapter 13). 
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MATERIALS AND METHODS 
Animals and animal preparation 
In all experiments female Wistar rats were used, weighing 180-220 gram 
(Centraal Proefdierenbedrijf TNO, Zeist, The Netherlands). Some weeks before 
the start of an experiment the animals were placed periodically in the cages 
to be employed for the experiment in question to get acclimatized to the food 
and water supplies and to reduce stress in the experimental situation. Intact 
rats were housed in metabolism cages, which permitted a separate recovery of 
urine and faeces, whereas animals with urinary bladder and bile duct cannulas 
were maintained in a restraining cage after Bollman (1948) with slight modi­
fications (Kilian, 1973). The rats were starved overnight before the adminis­
tration of the test compound, afterwards they had free access to food and water 
or, in the case of bile duct cannulation, to saline instead of water to replace 
the salts lost with the bile. 
In a number of experiments bile and urine were collected continuously from 
polyethylene (Intramedic PE 10, Clay-Adams Co., Parsipanny, USA) and 
polyvinyl chloride (C 2E tubing, Talas Сотр., Ommen, The Netherlands) 
cannulas respectively. Surgery was performed under ether anaesthesia about 20 
hours before lynestrenol administration. For the biliary fistula the upper part of 
the common bile duct was used so that the outflow of the pancreatic juice via 
the lower parts of this duct was not obstructed. The surgical procedure has been 
described in detail by Lambert (1965). The urinary bladder cannula was inserted 
via a small incision through the bladder wall. The urethra was tied off externally 
to exclude loss of fluid via this pathway. Because often a sort of sediment was 
formed in this cannula, tubing was used with an inner diameter of 1 mm to 
prevent obstruction of the urine flow. The volume of urine present in the bladder 
cannula during the experiment was 0.12 ml, the urine content of the bladder 
itself was approximately 0.05-0.10 ml. The urine and bile were collected in 
vessels positioned under the animal cage. At the conclusion of each experiment 
the rats were killed and the surgical procedure was verified. 
Dosage 
Specifications of lynestrenol-4-14C, used in the present experiments, are given 
in Chapter 3. For intravenous and oral administration of lynestrenol, ethanol 
containing polysorbate 80 (OPG, Utrecht, The Netherlands) was added to the 
lynestrenol-14C solution. The solvent was evaporated and the residue solubilized 
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in saline. The final polysorbate concentration was 2%. Of this mixture a volume 
of 0.2-0.5 ml was either injected in the tail vein or administered intragastri-
cally via a stomach cannula. 
The dosage form for intraduodenal administration in case of bile duct can-
nulated animals was prepared similarly, but here saline as the solvent was 
replaced by bile collected from the same rats after surgery had been performed. 
Unless otherwise indicated, the rats received a dose of 50 μg lynestrenol 
corresponding to 1-2 μΟί " С , depending on the kind of experiment to be per­
formed. 
Fractionation of radioactivity in urine, bile and faeces 
1. Extraction 
Urine and bile to be extracted were collected on ice and weighed, pooled, in 
sofar required, after removing an aliquot (not more than 10% of the sample) 
for total radioactivity assay, and stored at 3 0 C. The pH of these samples was 
controlled and held between pH 6.0 and 7.5. Within 2 days after collection 
extraction was performed after diluting 0.5 ml urine or 0.2 ml bile with water 
to a volume of 2.5 ml. When subsequently thin-layer chromatography (TLC) 
was to be carried out five-fold volumes were used and 25 μg lynestrenol and 
norethindrone, solved in 0.1 ml ethanol, were added for reference purposes. 
The samples were consecutively extracted three times with an equal volume 
n-hexane and likewise with ethylacetate. The joint hexane fractions and ethyl-
acetate fractions were evaporated in a counting vial under a stream of air and 
assayed for radioactivity by liquid scintillation counting (LSC). When also TLC 
was to be performed, only an aliquot of the extracts was evaporated and used 
for LSC. 
Faeces were suspended in water and after dispersion a volume of 1.0 ml was 
extracted and processed as described for urine and bile. 
2. Enzymatic hydrolysis 
An aliquot of urine and bile was diluted to 2.0 ml with water and acidified 
with acetic acid to pH 5.2. Then the solution was buffered by the addition of 0.5 
ml 0.5 M sodium acetate buffer pH 5.2. Hydrolysis with 50 μΐ digestive juice of 
Helix pomatia (Boehringer, Mannheim, GFR), containing 5.2 U/ml ß-glucuro-
nidase and 2.6 U/ml arylsulphatase, was carried out by incubation overnight 
at 37 0C. Under these conditions hydrolysis was proved to be complete as longer 
References p . 142 123 
incubation periods or the addition of more enzyme led to similar results. Sub­
sequently, the solution was neutralized to pH 7.0 with sodium hydroxide and 
extracted three times with equal volumes of n-hexane and ethylacetate respec­
tively. The whole extract or an aliquot was used for LSC. In the latter case 
the other part was used for TLC. The whole procedure was then modified with 
respect to the amounts used as described above (1. Extraction). 
3. Chromatography and mass spectrometry 
Thin-layer chromatography of extracts of urine and bile was carried out over 
silicagel-precoated glass plates (Kieselgel F254, Merck) in the solvent system 
toluene/ethylacetate 80/20. The developed area (15 cm) was divided into 30 
bands, and the silicagel of each band was scraped off with a razor blade and 
put into a vial for LSC. The co-chromatographed reference compounds 
lynestrenol and norethindrone were localized by exposing the plates to iodine 
vapour. The Rf value of lynestrenol in this system was 0.7. The relative Rr 
values (Rf/Rf lynestrenol) for ethynodiol and norethindrone were 0.35 and 0.38. 
Additionally, for the study of the metabolite with Rf 0.26 in the former TLC 
system use has been made of the solvent system toluene/ethanol 90/10 (Rf value 
for lynestrenol 0.7, relative Rf values for ethynodiol and norethindrone 0.47 
and 0.71). 
Gas chromatography was performed with a Hewlett-Packard 402 gas Chroma­
tograph fitted with a flame ionization detector. The 6 feet glass column, internal 
diameter 3 mm, was packed with 1% XE-60 on Gas-Chrom Q, 100-120 mesh 
(Applied Science Labs., USA). Nitrogen was used as carrier gas. Under the 
experimental conditions and a column temperature of 210oC the retention time 
of lynestrenol and norethindrone was 1.2 and 11.4 minutes respectively. 
A VG Micromass 7070F double-focusing mass spectrometer combined with 
a Pye-Unicam 104 gas Chromatograph was used for mass spectrometry and 
mass fragmentography. The apparatus was interfaced with a VG 2040 data 
system. Experimental conditions: column 1% SE-30 on Gas-Chrom Q, 80-100 
mesh (Applied Science Labs., USA), length 6 feet; carrier gas helium, flow 
20 ml/min; temperature column 1850C, separator 200 0 C , ion source 200 oC; 
electron impact 70 eV, ionisation current 100 μΑ, accelerating voltage 4 kV. 
4. Assay of radioactivity 
Radioactivity was measured by liquid scintillation counting as described in 
Chapter 5. 
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Aliquots of aqueous solutions and dried aliquote of organic solvent extracts 
were counted after the addition of 10 ml Instagel. In case of volumes larger 
than 0.2 ml the volume was made up to 5 ml with water prior to the addition 
of Instagel. The standard error of counting was 2.5% or less and the coun­
ting efficiency varied between 80 and 92%. 
The radioactivity of faecal samples was determined after the preparation of 
a suspension in water. An aliquot of the suspension (0.05 - 0.15 g) was digested 
with 1.0 ml Soluene in a water bath at 50 o C for 2 hours. The subsequent 
procedure is also outlined in Chapter 5. The standard error of counting was 
2.5% or less, and the counting efficiency was more than 80%. 
The silicagel samples obtained from thin-layer chromatograms were prepared 
for LSC by the addition of 5 ml water and 10 ml Instagel. The standard error 
of counting was 4.5% or less and the counting efficiency was about 85%. 
RESULTS 
Excretion pattern after intravenous and oral administration to the intact rat 
In Table 12.1 the cumulative values of total radioactivity in urine and faeces 
are presented after intravenous and oral administration of lynestrenol-14C. 
Table 12.1 — Cumulative excretion of radioactivity after the administration of 
lynestrenol-4-14C*) 
Urine 
Faeces 
Total 
Urine 
Faeces 
Total 
INTRAVENOUS ADMINISTRATION 
18.9 18.6 14.2 19.4 
71.4 71.1 68.2 67.0 
90.3 89.7 82.4 86.4 
ORAL ADMINISTRATION 
33.8 19.3 22.4 19.9 
54.7 66.7 69.9 65.6 
88.5 86.0 92.3 85.5 
12.0 
76.5 
88.5 
31.0 
66.1 
97.1 
15.7 
67.8 
83.5 
Mean ± S.D. 
16.6 ± 3.3 
70.8 ± 3.7 
87.5 ± 3.2 
Mean ± S.D. 
23.7 ± 7.1 
65.1 ± 5.3 
88.8 ± 5.1 
*) The individual values of 5 and 6 rats respectively at the end of a period of 5 days are 
presented, expressed in per cent of the dose administered (50 μg lynestrenol/rat). 
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Fig. 12.1 — Cumulative excretion of radioactivity as a function of time after the adminis­
tration of lynestrenol-I4C. The data points represent the mean ± S.D. in per cent of the 
total amount excreted with the urine (O O) and faeces ( · · ) over a five days 
period. 
The total fraction of the dose recovered over a period of 5 days is about 90% 
and in this respect no difference seems to exist between the both routes of 
administration. In both experiments excretion with the faeces appeared to 
prevail widely over the renal pathway, the excretion ratio faeces/urine being 
somewhat higher in the injection experiment than in the case of oral admini­
stration. This difference, however, may be only accidentally, because it is 
principally created by the two high renal excretion values found in the oral 
experiment. As will be demonstrated in Chapter 13, the degree of renal ex­
cretion is also determined by factors not related with the route of administration 
and which might be involved in this experiment too. 
The excretion of radioactivity with the urine and faeces during 5 successive 
24-hour periods is shown in Fig. 12.1 and follows a similar pattern in both 
experiments. After 19 hours about 80% of the radioactivity to be excreted 
via the kidneys is present in the urine and this amounts to 95% 24 hours later. 
For the faeces these figures are about 50 and 90% respectively. After the third 
day the renal and faecal excretion curves coincide. Only minute amounts of 
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14C were collected over the final sampling period in spite of the fact, that 10% 
and more of the dose in most cases still was to be excreted. The parallelism in 
the respective excretion patterns after oral and intravenous administration 
suggests analogous processes to be involved in both groups of animals and thus 
may be indicative for a high degree of absorption of the drug. 
Excretion rate and absorption in the bile duct cannulated rat 
1. Excretion 
A representative example of the excretion rate and cumulative excretion of 
radioactivity in urine and bile after intravenous injection of lynestrenol-4-14C is 
shown in Fig. 12.2. The values for bile and urine production demonstrate the 
steady condition of the rat during the measurements. The biliary excretion rate 
has reached its maximal value 15 minutes after injection, being followed by a 
strong decrease to about 1% of the maximal rate 8 hours later. The renal 
excrftion râ te (10 3 dpm/mm) - flow(inç/min) 
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Fig. 12.2 — Cumulative excretion and excretion rate of radioactivity in urine and bile after 
intravenous injection of lynestrenol-14C. Urine and bile flow are shown in the upper part 
of the figure. 
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Fig. 12.3 — Computer-generated plot of the experimental data points and the corresponding 
best-fit curve of the renal (X X) and hepatic (ijc if) excretion deficit of radioactivity 
for the same experiment as shown in Fig. 12.2. The excretion deficit has been calculated 
from the values of cumulative excretion in bile and urine 48 hours after the injection of 
lynestrenol^C (see Table 12.3) and is expressed in per cent of the corresponding 48-hour 
value. 
excretion rate initially displays a more gradual pattern, rising to its maximum 
over about 1.5 hour and also rapidly declining afterwards. The slow and 
late start of the renal excretion, however, can presumably be accounted for to 
a high extent by the void volume of the bladder cannula (0.12 ml), which 
corresponds to the urine production of a 60 minutes period in this experiment. 
It is clear from the curves of cumulative excretion, that more than 90% of the 
dose is excreted from the body within 14 hours after injection, the 50% level 
of excretion being already reached within only 2 hours. 
From the cumulative excretion data in bile and urine the corresponding 
excretion-deficit was calculated and plotted as a function of time on a semi-
logarithmic scale. The curves thus obtained are biphasic and can be described 
by a bi-exponential equation. The time constants of the respective curves and a 
computer-generated plot of the best fit were obtained with the help of the non­
linear least squares curve fitting program FARMFIT (see Chapter 7). An 
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example is shown in Fig. 12.3 (same animal as in Fig. 12.2). The intercept of 
the renal excretion-deficit at zero time is exceeding the 100% level as is to be 
expected on account of the apparent delay in renal excretion occuring for 
reasons mentioned above. The times of half-life for the excretion of radio­
activity in bile and urine are presented in Table 12.2. 
The cumulative excretion in the bile, urine and faeces over the first and 
second 24 hour period after the injection of lynestrenol is shown in the upper 
half of Table 12.3. During the second day of the experiment the excretion of 
radioactivity is diminished to minute amounts. The fraction of the dose present 
in the bile after 48 hours is about 80%, 10% higher than was excreted with 
the faeces by the intact rat over a longer period of time (Table 12.1). Also the 
total excretion of radioactivity was smaller for the latter experiment. 
2. Absorption 
The absorption of lynestrenol has been studied by the determination of the 
excretion of radioactivity in bile, faeces and urine and by comparison of the 
biliary and renal excretion rate after the intravenous and intraduodenal ad­
ministration of the compound. The latter route was preferred instead of oral 
administration to avoid the passage through the stomach as a possible source 
of variation in the absorption rate. 
Table 12.2 — Half-life times for the time course of the hepatic and renal 
excretion deficit of 1 4 C in the rat after intravenous injection of lynestrenol-14C*) 
Experiment 
762a 
762b 
762c 
768a 
*) The results are expressed in minutes. tVi.a refers to the first and tVt.b to the second 
phase of the respective curves. The excretion deficit has been calculated from the values 
of cumulative excretion in bile and urine 48 hours after the injection of lynestrenoM'C 
(see Table 12.3). 
Renal excretion 
tVf,a 
99 
69 
58 
64 
tVi,b 
426 
297 
445 
474 
Hepatic 
і ьа 
45 
61 
49 
52 
excretion 
tVf,b 
449 
284 
415 
430 
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Table 12.3 — Excretion of radioactivity in the bile duct cannulated rat after the administration of lynestrenol-4-14C*) 
INTRAVENOUS ADMINISTRATION 
Bile 
Urine 
Faeces 
Total 
77.7/2.8 
11.0/0.8 
< 0 . 1 
88.7/3.6 
76.8/0.7 
16.3/0.2 
< 0 . 1 
93.1/0.9 
77.3/2.5 
16.4/0.7 
< 0 . 1 
93.7/3.2 
81.6/3.3 
13.8/1.0 
0 /0.3 
95.4/4.6 
Mean ± S.D. 
78.4 ± 2.2 2.3 ± 1.1 
14.4 ± 2.6 0.68 ± 0.34 
92.7 ± 2.9 3.1 ± 1.6 
INTRADUODENAL ADMINISTRATION 
Bile 
Urine 
Faeces 
Total 
63.4/0.9 
11.4/0.3 
13.9/1.5 
88.7/2.7 
71.7/1.4 
11.3/0.3 
5.9/0.4 
88.9/2.1 
71.4/1.4 
10.4/0.4 
2.1/0.9 
83.9/3.4 
65.7/1.3 
15.3/0.3 
9.6/1.6 
90.6/3.2 
60.9/5.2 
5.8/1.4 
10.1/2.4 
76.8/9.0 
Mean + S.D. 
66.6 ± 4.8 2.0 ± 1.8 
10.8 ± 3.4 0.54 ± 0.48 
8.3 ± 4.5 1.4 ± 0.8 
85.8 ± 5.6 4.1 ± 2.8 
*) The figures represent individual excretion values over two successive 24-hour periods after lynestrenol dosage and express per 
cent of the dose administered (50 μg lynestrenol/rat). 
cumulative ежсгеЬюп C i n b i l e ( % J 
Fig 12.4 — Cumulative excretion of radioactivity in the bile as a function of time after the 
intravenous ( ) and intraduodenal ( ) administration of lynestrenol-14C. The data 
points express per cent of the total biliary excretion over 48 hours (see also Table 12 3) 
Following intraduodenal administration of lynestrenol about 3-15% of the 
dose was excreted with the faeces (Table 12.3), so the absorption of lynestrenol 
may be supposed to be in the order of 90%. About 90% of the amount ab­
sorbed was excreted with the bile and urine after 48 hours, which is in close 
agreement with the results after intravenous injection (Table 12.3). Also in 
this experiment the total excretion with faeces and bile is higher than the faecal 
excretion observed in the intact rat after oral administration. If the fraction of 
the dose being absorbed may be assumed to be comparable in both experiments, 
in the intact rat the excretion with the faeces is smaller than is to be expected 
on account of the biliary excretion values. As will be shown in Chapter 13 this 
difference may be explained by the occurrence of an enterohepatic circulation 
of the lynestrenol metabolites. 
If the absorption of lynestrenol is the rate-limiting step in the disposition of 
the compound, then the progress of the absorption process will be reflected in 
the respective curves of cumulative excretion. The results presented in Fig. 12.4 
are consistent with this assumption. In contrast with the excretion pattern after 
References p. 142 131 
to 
Table 12.4 — Results oi 
Urine 
Bile 
Faeces 
Route of 
administration 
oral 
intraduodenal 
intravenous 
oral 
intravenous 
i fractionation of radioactivity present in 
Number of 
samples 
6 
6 
5 
4 
6 
6 
5 
5 
Sampling 
period 
0-19 h 
19-44 h 
0- 8 h 
0- 8 h 
0-19 h 
19-44 h 
0-19 h 
19-44 h 
excreta after lynestrenol-14C administration1) 
Extraction before hydrolysis 
hexane 
0.3 ± 0.2 
0.4 ± 0.4 
0.8 ± 0.2 
0.8 ± 0.1 
8.4 + 1.5 
4.5 ± 0.8 
7.5 ± 2.1 
4.0 ± 0.6 
ethylacetate 
25.1 ± 7.7 
24.9 ± 2.8 
3.3 ± 1.3 
2.2 ± 1.0 
41.4 ± 15.1 
44.4 ± 20.7 
54.9 ± 11.7 
51.8 ± 12.1 
Extraction after hydrolysis2) 
hexane 
1.7 ± 0.4 
1.4 ± 0.6 
18.0 ± 4.2 
21.3 ± 3.5 
n.d.3) 
n.d. 
n.d. 
n.d. 
ethylacetate 
47.0 ± 3.4 
42.6 ± 3.5 
55.0 ± 3.4 
51.5 ± 4.1 
n.d. 
n.d. 
n.d. 
n.d. 
') The material analysed was part of the excreta collected during the experiments with the intact rats (urine and faeces) and bile duct 
cannulated animals as presented in foregoing Tables 12.1, 12.2 and 12.3. All results are expressed in per cent of the total radio-
activity of the concerning sample ± S.D. 
2) These results were obtained after the hydrolysis of unextracted urine. 
3) n.d.: not determined. 
injection, which has been described above, the biliary excretion after intra-
duodenal administration starts at a much slower rate, but continues to increase 
for a longer period of time, attaining its maximum only after 1 to 3 hours. The 
initially wide gap between the cumulative excretion of the respective routes of 
administration is then rapidly becoming smaller until about 10 hours after 
dosage there is no essential difference left with the intravenous excretion curves. 
It will be shown in Chapter 16 (Fig. 16.3) that the period of maximal biliary 
excretion coincides with the occurrence of the maximal blood concentrations 
of lynestrenol after the intraduodenal administration of the compound. 
Fractionation of the radioactivity excreted 
1. Urine and bile 
To investigate the contribution of metabolism in the elimination of lynestrenol 
the radioactivity excreted in the urine and bile has been analysed by extraction 
before and after enzymatic hydrolysis. The results obtained are shown in Table 
12.4. It is obvious that excretion of unchanged lynestrenol, that will be ex-
tracted with hexane for more than 90% from urine and bile under the con-
ditions applied, cannot be considered of any significance in the total process of 
elimination of the compound. Furthermore it can be observed, that hexane-
extractable steroids in conjugated form are present in the bile, but neither in 
free nor conjugated form in the urine. On the other hand a significant fraction 
of the steroids in the urine is freely extractable with ethylacetate. An explanation 
for these findings may be, that the more lipophilic and unconjugated steroids 
are likely to become reabsorbed from the ultrafiltrate in the kidneys in contrast 
to what can be expected for the more polar ethylacetate-extractable compounds. 
Another factor, however, which should be taken into account is a possible 
difference between the degree and character of plasma protein binding of the 
lipophilic and the more polar metabolites, which is especially of interest in the 
glomerular filtration process. 
Thin-layer chromatography of the hexane extracts of the pooled urine and 
bile hydrolysates (Fig. 12.5) demonstrated only 1.7 and 2.4% of the respective 
radioactivity to migrate with the lynestrenol reference, so excretion of unchanged 
lynestrenol could be at best 0.5% of the dose. The chromatogram of the urine 
extract showed 70% of the radioactivity not to move at all, whereas for the bile 
20% remained at the start. The other 80% of the radioactivity in the bile extract 
was found to be principally concentrated in one major peak at Rf 0.26. This 
chromatographic behaviour is compatible with the introduction of a second 
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F/g. 12.5 — Thin-layer chromatograms of the hexane extracts of ß-glucuronidase-hydrolysed 
urine and bile after oral, respectively intraduodenal administration of lynestrenol-^C. 
Solvent system toluene/ethylacetate 80/20. The distribution of radioactivity over the 
chromatogram is shown as the percentage of the total amount 14C recovered from the plate. 
Positions of co-chromatographed standards lynestrenol (L) and norethindrone (N) are 
indicated. 
oxygen function in the lynestrenol molecule in view of Rf values of 0.23 and 
0.26 for ethynodiol and norethindrone in this solvent system. After extraction 
of the radioactivity from the silicagel in this area and TLC of the extract in the 
solvent system toluene/ethanol 90/10 more than 95% of the radioactivity was 
recovered from a spot with Rf 0.40 compared with Rf 0.48 for norethindrone 
and 0.34 for ethynodiol. To gain an insight in the identity of this metabolite a 
bile duct cannulated rat was injected with 2 mg non-radioactive lynestrenol and 
4 hours later, after changing the bile collecting vessel, again with the same 
amount of lynestrenol containing now 0.2 μΟί lynestrenol-14C. Bile collected 
from the same animal before the injection served for reference purposes. After 
hydrolysis and hexane extraction of both samples, as described before, 24% 
of the biliary radioactivity was present in the extract and 72% of this fraction 
could be recovered after chromatography in the system toluene/ethanol 90/10 
at Rf 0.40. Gas chromatography of the corresponding non-radioactive extract 
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(Fig. 12.6) demonstrated the presence of a metabolite with a retention time of 
4.2 min compared with 1.2 and 11.4 min for the lynestrenol and norethindrone 
standards. Mass fragmentography of the same extract was performed by 
repetitive scanning over the range m/e 20-400 with a speed of 1 decade/sec 
during the chromatographic run. The most abundant fragments with m/e 
> 200 present in the region of the fragmentogram and coinciding exactly with 
the elution profile of the metabolite peak were 201, 203, 215, 216, 284 and 302. 
detector response (%) 
100 
l-ZoXE - 6 0 
210°C 
range 10 
a t t e n u a t i o n as indicated 
Fig. 12.6 — Gas chromatograms of the hexane extract of hydrolysed rat bile obtained from 
the same animal before and after lynestrenol injection. The attenuation factor of the detector 
signal was readjusted some times during chromatography as indicated in the figure in 
order to obtain maximal information. Notice the large metabolite peak с present in the 
bile after lynestrenol dosage and the absence of the parent compound a and norethindrone b. 
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Fig. 12 7 — Gas chromatogram (a) and the corresponding multiple ion scan (b) of an 
hexane extract of hydrolysed bile Notice the homogeneity of the metabolite peak in the 
gas chromatogram as appearing from the multiple ion scan of the fragments m/e 201, 216, 
284 and 302 The fragments m/e 201, 216 and 284 are abundantly present in the mass 
spectrum of lynestrenol (see Fig 12 8) The ion tracing is consistent with saturation of the 
4,5 double bond and Сэ-hydroxylation of lynestrenol. Another gas chromatogram of an 
aliquot of the same sample is shown in Fig 12 6. 
No fragment could be detected with m/e > 302. The gas chromatogram and the 
corresponding multiple-ion trace of the fragments with m/e 201, 216, 284 and 
302 are shown in Fig. 12.7. The former three fragments are also present in 
the mass fragmentogram at the retention time of lynestrenol, which is consistent 
with their high intensity in the mass spectrum of this compound (Fig. 12.8). 
Mass fragmentography also revealed the presence of fragments with m/e 282 
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and 290 at slightly increased retention times as compared with the fragments 
mentioned above. Because there was some overlap between the peaks of m/e 
302, 290 and 282 in the mass fragmentogram and, therefore, the homogeneity 
of the metabolite peak in the gas chromatogram was questionable, a correct mass 
spectrum of the presumed metabolite could not be obtained from the bile extract 
studied. 
Chromatography of the ethylacetate extracts revealed this material to consist 
largely of highly polar compounds, as more than 90% of the radioactivity was 
retained at the start following TLC. 
2. Faeces 
The faeces collected over the first two sample periods of the experiments 
described in the first section of this chapter have also been extracted with hexane 
and ethylacetate. In contrast with similar extractions of the bile, between 40 and 
80% of the radioactivity appeared to be freely extractable without foregoing 
hydrolysis (Table 12.4). Apparently, a considerable fraction of the conjugated 
metabolites of lynestrenol is hydrolysed during the intestinal transport. This 
aspect will be further discussed in Chapter 13. 
DISCUSSION 
Absorption and bioavailability 
Measurements of steroid absorption in humans (Schedi et al., 1965) and rats 
(Schedi & Clifton, 1961) as their disappearance rate from the intestine during 
live abundance (m/e 284=100) 
2 
1 
1 1 
DI 
216 
OH 2S4(M*> 
O^'™ 
kДJ lynestrenol 
269 
^ r-1 1 —ι H" 1 — ι 1 1 1 
150 200 250 
Fig. 12.8 — Mass spectrum of lynestrenol between m/e 150 and 284 (molecular ion). Most 
abundant fragments are m/e 201, 216 and 284. Conditions: electron impact 70 eV, 
accelerating voltage 4 kV, ionisation current 100 μΑ. 
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steady state perfusion through a transintestinal tube, revealed that absorption 
of these compounds correlated inversely with the extent of hydroxylation. 
Furthermore, evidence was provided that the absorption rate was directly 
proportional to the perfusate concentration. It is likely, therefore, that these 
compounds are absorbed predominantly by passive diffusion. 
Little unequivocal information is available with respect to the degree of 
absorption of the contraceptive steroids. Schedi et al. (1965) observed with the 
help of their intestinal perfusion technique more than 95% absorption of 
norethindrone acetate in human subjects. Faecal excretion data after oral ad-
ministration to bile duct cannulated animals or human subjects indicate an 
absorption of 70-80% of the dose for norethynodrel in rabbits (Arai et al., 1962) 
and humans (Layne et al., 1963) and of more than 95% of ethinylestradiol and 
its 3-cyclopentyl ether in humans (Cargill et al., 1969). Most other studies 
provide information of cumulative excretion in the urine or in urine and faeces 
of intact subjects, and do not allow conclusions about the extent of absorption 
of the respective compounds administered (for review: Fotherby, 1974; Thijssen, 
1972). Comparison of the blood level profile and cumulative excretion of total 
radioactivity after the oral and intravenous administration of ethinylestradiol 
(Reed et al., 1972) and lynestrenol (Van der Molen et al., 1969) suggests a 
high degree of absorption for both compounds in humans. In view of the results 
presented here the conclusion seems justified, that in the rat lynestrenol ab-
sorption from the gastro-intestinal tract is almost complete within 14 hours, more 
than 80% of the dose being excreted after that time period in urine and bile. 
These findings are consistent with the good and rapid absorption, that is to be 
expected for a highly lipophilic compound like lynestrenol (this thesis, Chapters 
8, 10). 
Following intravenous injection of lynestrenol about 50% of the dose is 
metabolised and excreted in the urine and bile within 2 hours (Fig. 12.2). 
Coert et al. (1975) reported a biliary excretion in the rat of 40% over a period 
of 90 minutes after injection. In humans 15 minutes after the intravenous in-
jection of lynestrenol-14C less than half of the radioactivity present in the plasma 
appeared to be extractable with chloroform (Kamyab et al., 1968). Studying the 
hepatic clearance of lynestrenol in the isolated perfused rat liver we observed 
a complete extraction of the compound from the perfusion medium during its 
passage through the liver and the occurrence of an extensive biotransformation 
(Van Kordelaar et al., 1978; this thesis, Chapter 15). So the metabolic clearance 
rate of the compound in the rat in vivo is presumably rather high. After oral 
administration such a high clearance rate could result in the biotransformation 
of a considerable fraction of the dose in the liver before the lynestrenol could 
reach the systemic circulation. The lymphatic absorption of lynestrenol has 
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been demonstrated to be of little significance in comparison with absorption 
via the portal system (Kilian, 1973). So in spite of a complete absorption the 
bioavailability of lynestrenol itself, an important parameter in the dose-effect 
relationship (Ariens, 1974), may be quite low. Experimental evidence for the 
validity of this assumption is provided in Chapter 16. 
Elimination 
About 70% of the conversion products of lynestrenol present in the bile 
appeared to be conjugated and could be hydrolysed with ß-glucuronidase/aryl-
sulphatase to aglycones much more polar than the parent compound. So like for 
the rabbit (Yamamoto, 1968) and man (Kamyab et al., 1968; Murata, 1967) 
hydroxylation of lynestrenol may be assumed to be a major metabolic pathway 
in the rat. The subsequent conjugation of the greater part of the conversion 
products will result in the formation of polar compounds of anionic nature with 
a molecular weight in the order of 400 to 500. According to the concept 
described by Smith (1971) with regard to the requirements to be fulfilled for a 
high biliary excretion, in rats such compounds are, for still unclarified reasons, 
likely to become eliminated with the bile to a high extent. This is in agreement 
with the present findings and previous investigations with norethindrone, 
norethynodrel, mestranol and Chlormadinone acetate in the rat (Hanasono & 
Fischer, 1974). 
Because with respect to the biliary excretion the threshold value for the 
molecular weight in rabbits and humans is estimated to be about 475 and 500 
respectively versus 325 for the rat (Hirom et al., 1972; Millburn et al., 1967; 
Smith, 1974), in the former species the renal excretion may be of greater im-
portance. As a matter of fact Kamyab et al. (1968) and Van der Molen et al. 
(1969) observed respectively 31-59% and 46-63% of the lynestrenol dose to be 
excreted in humans with the urine and in rabbit urine about 35% of the dose 
was recovered (Yamamoto, 1968). These authors, however, did not study the 
excretion with the faeces or bile, so it remains to be cleared, whether this higher 
renal excretion is resulting from a difference in biliary excretory mechanisms, 
a difference in the metabolic pathway of lynestrenol, leading to conversion 
products more readily disposed via the kidneys, enterohepatic circulation of 
the metabolites or a combination of these factors. That enterohepatic circulation 
can be the determining factor is demonstrated for lynestrenol in the next 
chapter. Also for norethynodrel elimination in intact rabbits appeared to occur 
for more than 50% via the kidneys, whereas in animals with bile fistulae this 
was reduced to about 20% of the dose (Arai et al., 1962). In patients with bile 
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fistulae renal excretion of radioactivity after intravenous administration of 
estradiol, estrone and estriol was largely reduced compared with the excretion 
in intact subjects (Sandberg & Slaunwhite, 1957, 1965). 
Reconsidering the excretion process as characterized by the respective half-
lives mentioned before (Table 12.2), it has to be realized, that the total excretion 
was measured of a variety of metabolites of lynestrenol. So the "excretion rate" 
in this connection is influenced by various parameters, including not only the 
generation rate of the metabolites and their physicochemical properties, but 
also the blood concentration-time course of lynestrenol and its apparent volume 
of distribution. In view of the half-life observed for the hepatic and renal ex-
cretion during the first hours after lynestrenol injection together with the fact, 
that the elimination of lynestrenol itself appeared to occur solely by metabolism, 
it can be concluded that the metabolic clearance capacity of the liver for this 
compound is high in the dose range studied. Indeed, in the isolated perfused rat 
liver the hepatic clearance of lynestrenol appeared to be independent of the per-
fusate concentration over a wide concentration range (Van Kordelaar et al., 1978; 
this thesis Chapter 15). For structurally close-related and extensively meta-
bolised compounds like norethynodrel and norethindrone in the rat (Hanasono 
& Fischer, 1974) and ethynodiol diacetate in the baboon (Ishihara et al., 1975) 
comparable excretion rates in the bile and urine have been reported as for 
lynestrenol in the present study. A high metabolic clearance rate of lynestrenol 
in man, as already indicated by the findings of Kamyab et al. (1968), may 
therefore be expected. The final disposition, however, of this compound and its 
metabolites from the intact organism may be prolonged as a consequence of 
enterohepatic recycling, and will be discussed in the next chapter. 
Metabolism 
The fractionation of urine and bile revealed an extensive metabolisation of 
lynestrenol to occur. The results of chromatography indicate, that 7-10% of 
the parent compound is converted into a product less polar than ethynodiol 
and more polar than norethindrone. The results of mass fragmentography 
provide evidence for the formation of a metabolite with a molecular weight of 
302, which is consistent with the saturation of the A-ring in lynestrenol and the 
introduction of a hydroxyl group. Recently, Coert et al. (1975) isolated a 
lynestrenol metabolite from rat bile with gas chromatographic properties similar 
to 17a-ethynyl-5a-estrane-3a,17ß-diol. The structure of this compound is com-
patible with the present findings. The abundant fragments with m/e 284, 216 
and 201 observed in the fragmentogram of the metabolite (Fig. 12.7) could 
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result from a fragmentation process involving the elimination of a molecule 
H2O and a subsequent fragmentation as observed for lynestrenol (Fig. 12.8). 
Because the biotransformation involved may give rise to four isomers, viz. 3α,5α, 
3α,5β, 3β,5β and 3β,5α, further investigations are necessary to establish the 
correct stereochemistry of this metabolite. On account of the present results it is 
not clear, whether the other fragments observed with m/e 282 and 290 originate 
from another conversion product of lynestrenol or from an endogenous com­
pound. 
In an in vitro study with rabbit liver homogenate Mazaheri et al. (1970) 
reported additionally the biotransformation of lynestrenol to norethindrone. 
This compound was also reported to be present in the blood and urine of rabbits 
(Yamamoto, 1968) and in human urine (Murata, 1967) after lynestrenol ad­
ministration. The present study provided no indication for this conversion in 
the rat, although it could be present in the non-extractable fraction of the urine 
and bile. This fraction may contain non-phenolic steroid sulphates, which are 
not hydrolysed in our experimental procedure. The significance, however, of 
sulphate conjugation of these compounds in the rat may be limited, as Hanasono 
and Fischer (1974) could not demonstrate the presence of sulphates in the 
biliary and urinary excretion products of norethindrone and norethynodrel. 
Also conjugation products of glutathione and mercapturic acid may be present. 
It has been demonstrated by Elee (1972) and Elee and Harris (1971) that 
2-hydroxy-17ß-estradiol undergoes the complete mercapturic acid biosynthesis 
in the rat in vivo. Recently, Cook et al. (1974) isolated norethindrone-4,5-epoxide 
after the incubation of norethindrone with the 10,000xg supernatant of dog liver. 
Analogously, the formation of lynestrenol-4,5-epoxide as a precursor for mer-
capturic acid derivatives seems not unlikely, and norethindrone, if present as a 
metabolite of lynestrenol, may be involved, too. 
Thin-layer chromatography of the ethylacetate extracts of urine and bile 
showed exclusively very polar compounds to be present in these fractions. Their 
chromatographic behaviour indicates the introduction of at least another two 
oxygen functions in the steroid moiety. The results obtained by Kamyab et al. 
(1968) with human urine point into the same direction. Conversion of norethin-
drone (Cook et al., 1974) and norethynodrel (Cook et al., 1972; Freudenthal 
et al., 1971) to poly-oxy-steroids has been demonstrated. 
Taking into consideration on the one hand the extensive biotransformation 
of lynestrenol and the other progestins derived from 19-nortestosterone and on 
the other hand that the biotransformation routes for these compounds lead in 
part to identical intermediates and end-products (Fotherby, 1974; Thijssen, 
1972), the elucidation of the structure and the biological activity of these con-
version products should deserve further attention. 
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SUMMARY 
After oral and intravenous administration of lynestrenol-4-14C to intact 
female rats the excretion of radioactivity followed similar patterns. Within 
24 hours 50% of the dose was recovered from faeces and urine, increasing to 
80% 24 hours later. The final distribution ratio of radioactivity over urine and 
faeces was approximately 0.25. Elimination from animals prepared with bile 
fistulae did proceed more rapidly, about 90% of the dose being excreted after 
a 24-hours period. In these animals the contribution of renal excretion to the 
over-all elimination of radioactivity was decreased in favour of biliary excretion, 
indicating the possibility of enterohepatic circulation. After intravenous injection 
of lynestrenol-14C the deficit for renal and hepatic excretion as a function of 
time could be described by a bi-exponential equation with similar time constants 
of approximately 1 hour for the first and rapid phase and 7 hours for the second 
phase. About 90% of the dose was absorbed from the intestines, most of it 
within 10 hours. The progress of the absorption process could be derived by 
comparison of the cumulative biliary and renal excretion of radioactivity after 
respectively intravenous and intraduodenal administration of lynestrenol. 
Fractionation of the excretion products present in the bile and urine revealed, 
that lynestrenol is eliminated by biotransformation to more polar compounds. 
The high excretion rate of these conversion products implies a high metabolic 
clearance rate for the parent compound and could result in a low bioavailability 
after oral administration in spite of the almost complete absorption. Without 
hydrolysis about 25% of the urinary radioactivity could be freely extracted 
with ethylacetate in contrast with only 3.5% for the bile. After treatment with 
Helix pomatia ß-glucuronidase/arylsulphatase another 20% of urinary radio-
activity could be extracted, whereas this amounted to 70% for the biliary 
excretion products. Thirty percent of the latter fraction was extractable with 
n-hexane and contained a metabolite tentatively identified as 17a-ethynyl-
5i-estrane-3i,17ß-diol. About 90% of the free and enzymatically liberated 
metabolites were much more polar than norethindrone and ethynodiol. Con-
siderable hydrolysis of the biliary conjugates appeared to occur during intestinal 
transport, because half of the radioactivity present in the faeces could be ex-
tracted without foregoing hydrolysis. 
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CHAPTER 13 
ENTEROHEPATIC CIRCULATION OF THE LYNESTRENOL 
METABOLITES AND THE INTERRELATIONSHIP OF HEPATIC AND 
RENAL EXCRETION 
INTRODUCTION 
In Chapter 12 it has been shown that biliary excretion is the major pathway 
of elimination for the metabolites of lynestrenol. The metabolites appeared in 
the bile predominantly in the form of glucuronides. During intestinal transport 
an extensive hydrolysis of these conjugates to the corresponding and less polar 
aglycones was observed. According to generally accepted theories of gastro-
intestinal absorption (Kurz, 1975; Parsons, 1975) the concomitant increase of 
lipophilicity may be assumed to favour absorption considerably as far as the 
process is determined by passive diffusion. So a large fraction of the metabolites 
is likely to become involved in an enterohepatic circulation. This possibility 
may have interesting consequences for the pharmacokinetics and time course 
of action of the recycling compounds, including the nature and incidence of 
side effects. 
Enterohepatic circulation is known to play an important role in the disposi-
tion of endogenous steroidal sex hormones (Adlercreutz & Luukkainen, 1967; 
Long & Soyka, 1975; Sandberg & Slaunwhite, 1957, 1965) as well as of many 
drugs (Smith, 1971). Evidence for the absorption of the biliary excretion prod-
ucts of some contraceptive steroids in the rat has been presented by Steinetz 
et al. (1967) and recently by Hanasono & Fischer (1974). The decrease of the 
contribution of the renal elimination of the lynestrenol metabolites in the bile 
duct cannulated rat as compared with the elimination pattern shown by intact 
animals (see Chapter 12) seemed to justify further investigations into this 
direction. Therefore, a study has been made of the degree of absorption and 
the absorption rate of the lynestrenol metabolites present in the bile. Because, 
however, the demonstration of the possibility alone of reabsorption does not 
provide information about the significance of the enterohepatic circulation in 
a quantitative sense, it has been subsequently investigated to what extent 
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enterohepatic circulation could change the excretion pattern of the metabolites 
and whether such a change could serve as an indicator for the overall exten-
siveness of the recirculation. Furthermore, it was hoped, that the information 
thus obtained could throw some light upon the interrelationship of the renal 
and hepatic excretory pathways for the compounds in study. 
MATERIALS AND METHODS 
Most methods and materials used in the present investigations have already 
been described in detail in the preceding chapter. In this section, therefore, in-
formation about these aspects is only provided in sofar other procedures and 
techniques have been applied. 
Ligation of the bile duct 
Surgery of the animals was performed under ether anaesthesia. After exposure 
of the bile duct two ligatures were placed just below the junction of the hepatic 
duct. Subsequently, the bile duct was sectioned between the ligatures. In this 
way the outflow of the pancreatic juice via the distal segment of the bile duct 
remained undisturbed. An extensive description of the whole procedure, that 
was followed, is given by Lambert (1965). 
About three hours after this operation and the insertion of the urinary 
bladder cannula lynestrenol-14C was injected. This relatively short period of 
recovery of the rats was chosen on the one hand, because at that time the 
animals showed already their normal reactions and produced a steady flow of 
urine, and on the other hand in order to prevent as much as possible any 
interference of the developing jaundice with the metabolism and excretion 
processes in study. 
At the end of the experiment, 48 hours after lynestrenol injection, the animals 
were sacrificed and opened for inspection of the position of the urinary bladder 
cannula and the bile duct. The proximal segment of the bile duct was always 
slightly distended. Not more than 0.05 ml volume of a clear and yellow fluid 
could be obtained with a syringe. Its content of radioactivity appeared to be 
negligible. 
Dosage 
For intravenous administration of lynestrenol, ethanol containing polysorbate 
80 was added to the lynestrenol-14C solution. The solvent was evaporated and 
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the residue solubilized in saline. The final polysorbate concentration was 2%. 
Of this mixture a volume of 0.2-0.5 ml was injected in the tail vein. 
The enterohepatic circulation of the lynestrenol metabolites was studied with 
bile duct cannulated rats after the intraduodenal administration of radioactive 
bile, collected from donor rats during a period of 8 hours after the intravenous 
administration of lynestrenol-14C, or of a combined hexane/ethylacetate extract 
of this bile obtained after enzymatic hydrolysis. The donor bile was collected 
on ice, pooled and an aliquot was analysed to establish the content of free 
and conjugated conversion products of lynestrenol. The results obtained were 
in accordance with the previous findings (Chapter 12, Table 12.4). 
In case of administration of an extract of the donor bile, an aliquot of the 
same bile pool was buffered at pH 5.2 and hydrolysed with Helix pomatia 
ß-glucuronidase/arylsulphatase as described in the preceding chapter. The 
hexane and ethylacetate extracts of the hydrolysed bile were combined and after 
evaporation of the solvents with a weak stream of air dissolved in bile. The 
donor bile and the extracts to be administered were made up to a volume of 
1.0 ml/rat with non-radioactive bile. 
The lynestrenol dose administered was 50 μg/rat, corresponding to 0.5 цСі 1 4 C 
for the animals with ligated bile duct and 1.0 μ€ί 1 4 C for the intacts rats. The 
radioactivity content of the donor bile and the donor bile extract administered 
was 0.5 μ Ο 14C/rat. 
RESULTS 
Enterohepatic circulation 
After the intraduodenal administration of radioactive bile obtained from rats 
injected with lynestrenol-14C 10-35% of the dose was excreted with the faeces 
and 60-80% could be recovered from the urine and bile during the experiment 
(Table 13.1). So with respect to the elimination of the metabolites of lynestrenol 
a considerable degree of enterohepatic recycling has to be taken into account. 
The pattern of the cumulative excretion of radioactivity in the bile is presented 
in Fig. 13.1 and demonstrates a considerable delay in the absorption and 
excretion of radioactivity compared with the intraduodenal administration of 
lynestrenol (cf. Chapter 12, Fig. 12.4). In view of the shape of the excretion 
curves it seems probable, that in addition to a slower absorption rate of the 
biliary metabolites of lynestrenol in comparison with the absorption rate of 
lynestrenol itself, another important process is involved, namely the hydrolysis 
of the glucuronides to the free steroids by ß-glucuronidase of bacterial origin, 
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Table 13.1 — Excretion of radioactivity in the bile duct cannulated rat after the intraduodenal administration of 
radioactive bile or an extract of hydrolysed bile obtained from lynestrenol-14C injected rats1) 
BILE 
Bile 
Urine 
Faeces 
Total 
61.2/ 5.9 
9.2/ 1.6 
0.8/ 8.7 
71.2/16.2 
67.1/0.4 
9.0/0.2 
19.5/1.9 
95.6/2.5 
66.2/ 1.7 
10.5/ 0.7 
0.7/ 8.1 
77.4/10.5 
55.8/0.4 
7.0/0.1 
34.4/2.0 
97.2/2.5 
57.0/0.1 
5.8/0.2 
19.3/1.1 
82.1/1.4 
day I day II 
Mean ± S.D. 
61.5 ± 5.2 1.7 ± 2.4 
8.3 ± 1.9 0.6 ± 0.6 
14.9 ± 14.3 4.4 ± 3.7 
84.7 ± 11.4 6.6 + 6.5 
EXTRACT OF HYDROLYSED BILE 
Bile 
Urine 
Faeces 
Total 
65.4/ 2.0 
8.2/ 1.1 
no sample/ 4.4 
73.6/ 7.5 
81.2/0.1 
11.1/0.1 
0.7/0 /0* 
93.0/0.2 
82.6/ 0.1 
10.3/ 0.1 
0.4/ 0 /0* 
93.3/ 0.2 
67.2/3.9 
9.1/1.6 
0 /0.5/0* 
76.3/6.0 
Mean ± S.D. 
74.1 ± 9.1 1.5 ± 1.8 
9.7 ± 1.3 0.7 + 0.8 
84.1 ± 10.6 3.5 ± 3.8 
') The figures represent individual and mean excretion values over two and in some cases three (marked with *) successive 24-hour 
periods and are expressed in % of the dose. The bile extract was a combined hexane/ethylacetate extract of ß-glucuronidase hydroly-
sed bile. 
-a 
cumuldhve excretion in bile ( % ) 
Fig. 13.1 — Cumulative excretion of radioactivity in the bile as a function of time after 
the intraduodenal administration of radioactive bile ( ) and an extract of the same bile 
obtained after enzymatical hydrolysis ( ) The data points are expressed in per cent 
of the total excretion in the bile over a period of 48 hours (see also Table 13.1). 
which is present predominantly in lower parts of the intestine (Conchie & 
MacDonald, 1959; Kent et al., 1972; Marsh et al., 1952; Williams et al., 1970). 
Evidence for the hydrolysis of a large fraction of the biliary excretion products 
of lynestrenol in the intestine has already been provided in Chapter 12. The 
significance of this hydrolysis for the rate and degree of the absorption process 
can be derived from the cumulative excretion and excretion rate of radioactivity 
after the intraduodenal administration of a combined hexane/ethylacetate extract 
of ß-glucuronidase treated bile, also shown in Table 13.1 and Fig. 13.1 respect-
ively. The absorption of the free steroid fraction appeared to proceed with 
considerably less delay of time and to a high, almost complete, degree. The 
time lag observed for the absorption in case of administration of untreated 
bile is for this reason probably due to the additional time required for the 
transit of the substrate from the duodenum to the enzyme-rich caecum and 
colon (Conchie & MacDonald, 1959; Marsh et al., 1952). Because, however, 
in most rats the cumulative excretion with the faeces after the administration 
of radioactive bile appeared to be smaller than the non-hydrolysable fraction 
148 
of the biliary metabolites (cf. Chapter 12, Table 12.4), it is likely that part of 
this fraction may be absorbed, too. 
After the administration of the bile extract in two animals biliary excretion 
did temporarily proceed even faster than after lynestrenol injection (Chapter 12). 
Such a phenomenon is conceivable under conditions of a high absorption rate 
and a volume of distribution smaller for the metabolites than for the parent 
compound. A smaller volume of distribution for the metabolites of lynestrenol 
is a reasonable assumption, since they are more polar and in part of ionic 
nature. 
Influence of bile duct ligation and fasting on the excretion pattern 
As is shown above the elimination of metabolites reabsorbed from the ex-
creted bile takes place via the liver as well as via the kidneys. If the excretion 
ratio bile/urine after the reabsorption of the lynestrenol metabolites remains 
unchanged, then increasing frequency of enterohepatic recycling should ulti-
mately result in an increase of the total renal excretion and thus in a decrease 
of the faeces/urine excretion ratio in the intact rat. In this connection the 
difference observed between the cumulative renal excretion in the intact rat 
and the rat with bile fistula on the one hand (Chapter 12) and the high degree 
of reabsorption of the biliary metabolites on the other hand seems to indicate 
an extensive but not frequent enterohepatic recycling. In order to get proof for 
the validity of this assumption more information was collected about the potential 
capacity of the rat kidney to excrete the lynestrenol metabolites. This capacity 
was assumed to become manifest in conditions of bile duct obstruction. Sec-
ondly it was tried by creating optimal conditions for reabsorption in the intact 
rat and thus for a possible increase in the frequency of recycling, whether this 
was reflected in a decrease of the faeces/urine excretion ratio. 
/ . Renal excretion in rats with bile duct ligation 
That in certain conditions the kidneys may function as an equivalent alterna-
tive for the bile as the main route for excretion of the lynestrenol metabolites 
is obvious from the cumulative excretion data obtained after the intravenous 
administration of lynestrenol-14C to bile duct ligated rats (Table 13.2). The 
time course for renal excretion followed a biphasic pattern and could be de-
scribed by a bi-exponential equation. A survey of the time constants of the 
respective curves, calculated from the best fit of the experimental data with the 
help of the non-linear least squares curve fitting program FARMFIT (see 
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Table 13.2 — Renal excretion of radioactivity in the bile duct ligated rat after 
the intravenous administration of lynestrenol-14C*) 
Day I 
Day II 
Total 
92.0 
5.3 
97.3 
94.8 
5.2 
100.0 
86.7 
6.7 
93.4 
93.2 
5.0 
98.2 
91.5 
1.9 
93.4 
Mean ± S.D. 
91.6 + 3.0 
4.8 ± 1.8 
96.5 ± 3.0 
*) The figures represent individual and mean excretion values over two successive 24-hour 
periods and are expressed in % of the dose. 
Chapter 7) is given in Table 13.3. A representative example of the good fit of 
the experimental data to the calculated curves is shown in Fig. 13.2. Like in 
the preceding chapter, the intercept of the renal excretion-deficit at zero time is 
exceeding the 100% level as a consequence of the void volume of the bladder 
cannula used in these experiments. 
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Fig. 13.2 — Computer-generated plot of the experimental data points and the corresponding 
best-fit curve of the renal excretion deficit of radioactivity (expressed in per cent of the 
total excretion values given in Table 13.2) after the intravenous administration of 
lynestrenol-"C to a bile duct ligated rat. 
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Table 13.3 — Half-life times for the time course of the renal excretion deficit 
of radioactivity in the bile duct ligated rat after the intravenous injection of 
lynestrenol-14C*) 
tVi,a 
tVLb 
68.4 
485 
89.0 
508 
93.8 
570 
44.9 
406 
n.d. 
n.d. 
*) The results are expressed in minutes for the half-life of the first (і г.а) and second 
(\.1Іг,Ь) phase of the respective curves. Same experiment as shown in Table 13.2. From 
one animal only the 24 and 48-hour samples were collected (n.d.). The excretion deficit 
has been calculated from the values of cumulative excretion 48 h after the injection of 
lynestrenol-"C (see Table 13.2). 
That under the conditions applied the biotransformation of lynestrenol is 
unaffected and that obstruction of the bile duct results in the renal excretion 
of compounds otherwise excreted largely with the bile, can be derived from the 
composition of the urinary radioactivity as shown in Table 13.4 and Fig. 13.3. 
Summation of the relative contribution of each metabolite fraction in the bile 
Table 13.4 — Results of fractionation of radioactivity present in the urine of 
bile duct ligated rats after the intravenous administration of lynestrenol-14C*) 
Hexane extract 
Ethylacetate extract 
BEFORE HYDROLYSIS 
Mean ± S.D. 
0.48 0.51 0.68 0.65 0.76 0.61 ± 0.12 
7.9 10.1 10.2 9.8 7.0 9.0 ± 1.5 
Hexane extract 
Ethylacetate extract 
AFTER HYDROLYSIS 
Mean ± S.D. 
10.8 11.6 14.0 13.9 s a 1
m p l e
 12.6 ± 1.6 
lost 
55.4 57.9 57.7 54.7 s a 1
m p l e
 56.4 ± 1.6 
lost 
*) The urine samples of the first 24-hour period after injection were analysed (same ex­
periment as shown in Tables 13.2 and 13.3). The results after hydrolysis were obtained 
with complete unextracted urine. The data represent % of the total radioactivity of the 
concerning sample. 
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Fig. 13.3 — Thin-layer chromatogram of the combined hexane extracts of ß-glucuronidase 
hydrolysed urine of bile duct ligated rats after the intravenous injection of lynestrenol-14C. 
Solvent system toluene/ethylacetate 80/20. The distribution of radioactivity over the 
chromatogram is shown as the percentage of the total amount 14C recovered from the plate. 
Positions of co-chromatographed standards lynestrenol (L) and norethindrone (N) are in-
dicated. 
and urine as mentioned in the preceding chapter (cf. Chapter 12, Table 12.4) 
demonstrates a close agreement with the corresponding fractions in Table 13.4. 
Also the relative increase of the non-polar fraction in the hexane extract of the 
hydrolysed urine (Fig. 13.3) indicates the presence of products normally excreted 
with the bile (cf. Chapter 12, Fig. 12.5). About 2% of the radioactivity in this 
extract migrated with the lynestrenol standard, providing evidence for the com-
plete biotransformation of lynestrenol. 
2. Excretion pattern in fasting rats 
Assuming that the rate of elimination of radioactivity from the gut with the 
faeces is dependent upon the presence of food in the gut lumen and the food 
supply, and assuming furthermore, that the rate of fluid transport, i.e. bile, to 
the bacteria-rich parts of the gut is much less dependent upon these factors, 
empty bowels could result in an increase of the rate and frequency of entero-
hepatic recycling. 
In Table 13.5 the excretion pattern of radioactivity is presented after the 
intravenous injection of lynestrenol to rats fasting from 24 hours before until 
24 hours after lynestrenol dosage. From the results it is clearly visible that under 
these conditions the contribution of renal excretion in the over-all elimination 
process does indeed increase considerably. The cumulative excretion in urine 
and faeces during the 7 successive 24 hour periods is shown in Fig. 13.4 together 
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Table 13.5 — Cumulative excretion of radioactivity after the intravenous 
administration of lynestrenol-14C to fasting rats*) 
Mean ± S.D. 
Urine 27.3 40.6 43.3 25.5 39.7 35.3 ± 8.2 
Faeces 55.7 47.8 48.7 73.6 57.0 56.6 ± 10.4 
Total 83.0 88.4 92.0 99.1 96.7 91.8 ± 6.5 
*) The individual and mean values of 5 rats at the end of 7 days are presented, expressed 
in % of the dose. The animals were deprived from food from 24 hours before until 
24 hours after dosage. 
with similar results obtained with non-starved intact rats, which have already 
been presented in Chapter 12. The change in the excretion pattern is obvious. 
The faecal excretion is delayed and reduced considerably over the first 48 hours 
after lynestrenol injection, whereas the renal excretion over the same period 
is greatly enhanced, indicating a considerably increased frequency of the entero-
hepatic circulation of the lynestrenol metabolites. 
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Fig. 13.4 — Cumulative excretion of radioactivity as a function of time after the intravenous 
administration of lynestrenol-"C to fasting (n = 5) and non-fasting rats (n = 5). Fasting 
animals received no food from 24 hours before until 24 hours after lynestrenol dosage. The 
data points represent the mean ± S.D. of the excreted radioactivity in per cent of the dose. 
fecal excr non fâ&ting reite 
fecal euer fasting" rata 
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DISCUSSION 
Interrelationship of renal and hepatic excretion 
The time course of the renal excretion as observed in the present study for 
the bile duct ligated rat is in very close agreement with the results obtained in 
animals with intact bile flow (see Chapter 12). So in spite of the fact, that in 
the intact rat biliary excretion appeared to be the major pathway for the 
elimination of the lynestrenol metabolites, in certain conditions the kidneys 
may take over their excretion with equal efficiency in time as well as in amount 
eliminated. On account of these observations the conclusion seems justified, that 
the contribution of plasma protein binding to the unequal distribution of the 
excretion products over the urine and bile is negligible and that the causal factor 
is localized within the liver. In the case of lynestrenol the liver, as the metabolic 
site, is the source of the products to be excreted. These conversion products 
will be in part secreted with the bile and will be in part released into the 
blood. If the structural requirements for an extensive excretion with the bile 
are fulfilled (Smith, 1971), it is conceivable that a large fraction of the meta-
bolites does not reach the systemic circulation and as a consequence the kidneys. 
In the case of bile duct ligation, however, the total amount of metabolites is 
disposed with the blood and subsequently eliminated in the kidneys following 
a similar time course. 
Enterohepatic circulation 
The enterohepatic circulation of endogenous compounds as well as drugs or 
their metabolites is a not uncommon phenomenon in conditions, where these 
compounds appear in the bile in the form of polar conjugates such as glucu-
ronides. Intestinal absorption of the glucuronides themselves is generally limited 
due to their strongly acidic character (Schanker, 1971). The lower parts of the 
intestines, however, have been demonstrated to contain large amounts of 
ß-glucuronidase (Conchie & MacDonald, 1959; Marsh et al., 1952), mainly 
of bacterial origin (Kent et al., 1972; Williams et al., 1970). Liberation of the 
more lipophilic aglycones by this enzyme will result in their reabsorption and 
subsequent enterohepatic circulation (Smith, 1971). 
The results reported here demonstrate, that considerable reabsorption of the 
biliary excretion products of lynestrenol occurs and that the effectuation of 
their enterohepatic recycling depends largely upon the rapid breakdown of their 
glucuronides in the gut. In this respect it is important to note, that after the 
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administration of the extract of hydrolysed bile the metabolites excreted after-
wards with the bile proved to be hydrolysable with ß-glucuronidase to the same 
extent as observed after lynestrenol administration. So on these grounds 
repetition of the process seems to be very likely. 
Because with each succeeding enterohepatic circulation the absorbed com-
pounds are lost in part by renal excretion, a progressively smaller fraction of the 
dose will be excreted with the bile and will be available for the next cycle. In 
spite of the demonstration of the possibility, that ultimately the excretion could 
proceed exclusively via the kidneys, faecal elimination did prevail even in the 
fasting animals. Assuming on account of the experimental results (Table 13.1; 
Chapter 12, Table 12.3), that in the course of each enterohepatic cycle about 
80% of the biliary metabolites will become reabsorbed and subsequently ex-
creted with the urine and bile in a ratio between 1 : 8 and 1 : 6, then a final 
distribution ratio over urine and faeces of 0.7 to 1.0 is to be expected after 
repetitive enterohepatic circulations. In the present study an urine/faeces ex-
cretion ratio of respectively 0.49, 0.85, 0.89, 0.35 and 0.70 was observed in the 
fasting rats (Table 13.5). Although these ratio's are considerably increased 
compared with urine/bile excretion ratio's of 0.12 to 0.18 in the bile duct 
cannulated animals and point to an extensive and repetitive recycling, a sub-
stantial interindividual variation can be observed. This variation is probably 
the reflection of the influence of intestinal factors, which affect the absorption 
rate, like the transit time through the small intestine, the interaction with faecal 
material, that may interfere with hydrolysis and absorption, and the ß-glucuroni-
dase activity of the gut contents. 
For the intact non-fasting animals the excretion ratio urine/faeces varied 
between 0.2 and 0.3 with two exceptions of 0.47 and 0.62 after oral administra-
tion of lynestrenol (Chapter 12). On account of these findings and those 
mentioned above the conclusion seems permitted, that enterohepatic circulation 
of the lynestrenol metabolites occurs, but that in general the extensiveness of 
this process is limited, mainly as a result of the early loss of absorbable material 
with the faeces. 
Implications 
From a pharmacokinetic point of view the most important consequence of 
the enterohepatic circulation of the lynestrenol metabolites is the delaying effect 
this has upon their overall elimination from the body. If some of the recycling 
compounds, however, possess biological activity, this recycling phenomenon 
may also have an important bearing on their time course of action and the 
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nature and incidence of undesired effects. In this connection it should be 
realized, that in case of daily and long term administration of lynestrenol 
particularly the liver and bile ducts will be continuously exposed to relatively 
high concentrations of the metabolites. Little is known with regard to the 
biological activity of the lynestrenol metabolites identified thus far (Coert et 
al., 1975; Mazaheri et al., 1970; Murata, 1967; Yamamoto, 1968; this thesis, 
Chapter 12), with the exception of norethindrone. Apart from the proges-
tational activity of the latter compound its reported conversion to the cor-
responding 4,5-epoxide (Cook et al., 1974) may be of interest. This epoxide 
has been demonstrated to bind irreversibly to microsomal free sulfhydryl groups 
containing proteins of rat liver and is converted by hepatic microsomal enzymes 
to another still unidentified compound, which can also react with proteins 
(Kappus & Bolt, 1976). Re-exposure of the excreted metabolites to the meta-
bolic system of the liver as a consequence of enterohepatic circulation may give 
rise to further biotransformation via this kind of reactive intermediates. 
Although enterohepatic circulation of other contraceptive steroids has been 
demonstrated previously in the rabbit (Arai et al., 1962) and rat (Hanasono 
& Fischer, 1974; Steinetz et al., 1967), investigations in man have not yet 
been reported. In the light of the present and previous findings and in view of 
the well-known enterohepatic circulation of endogenous sex hormones in 
humans (Long & Soyka, 1975; Sandberg & Slaunwhite, 1957, 1965) this process 
deserves further study also in the field of their synthetic counterparts. 
SUMMARY 
The excretion of radioactivity was studied in rats prepared with bile fistula 
after the intraduodenal administration of bile obtained from donor rats injected 
with lynestrenol-4-14C. After 48 hours 9-36% of the dose was excreted with 
the faeces, 6-11% with the urine and 56-68% with the bile, demonstrating a 
high degree of absorption of the biliary excretion products of lynestrenol. In a 
similar experiment the cumulative excretion with urine and bile increased respect-
ively to 9-11% and 67-83% of the dose, when an extract of enzymatically 
hydrolysed bile was administered. From the time course of cumulative biliary 
excretion in these experiments it could be derived, that the rate of absorption 
is largely dependent upon the hydrolysis of the conjugates in the lower parts of 
the alimentary tract. Renal excretion of the metabolites of lynestrenol appeared 
to be an alternative possibility equivalent to the biliary pathway, as in rats with 
ligated bile duct 93-100% of the dose was excreted via this route following a 
time course similar to that observed in animals with bile fistula. The delay of 
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faecal excretion in intact rats fasting from 24 hours before until 24 hours after 
the injection of lynestrenol-14C resulted in a strong increase of the fraction 
excreted with the urine in comparison with intact non-fasting rats and rats with 
bile fistula. From the present and previous findings it may be concluded, that in 
the non-fasting intact rat extensive reabsorption of the biliary excretion products 
of lynestrenol will occur, but, subsequently, repetition of this process will 
generally be limited, mainly as a consequence of the early loss of absorbable 
material with the faeces. 
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CHAPTER 14 
DISTRIBUTION OF LYNESTRENOL IN PREGNANT 
AND NON-PREGNANT MICE 
INTRODUCTION 
Since the development of contact autoradiography for drug distribution 
studies, at first at the organ and tissue level (Ullberg, 1954; Ullberg, 1958), 
afterwards also at the cellular and subcellular level (Stumpf et al., 1971), the 
technique has proven to be a very useful tool in pharmacological and toxico-
logical research (Conference on Autoradiography in Pharmacology and Toxi-
cology, 1977). When care is taken to prevent translocation or removal of the 
drug or its metabolites, autoradiography of drugs in whole animals and tissues 
offers by far the best information on the localization of drugs in biological 
material, particularly in case of inhomogeneity of distribution within organs and 
tissues. On the other hand, quantitative analysis of the picture by densitometric 
methods suffers from inaccuracy, although recently in this respect progress has 
been made (Cross, 1977). If the drug under investigation is metabolised, com-
bination of autoradiography with tissue extraction-separation procedures may 
give essential additional information. 
In the present investigation the distribution of lynestrenol-14C in mice has 
been studied by means of whole-body autoradiography after intravenous and 
oral administration. Pregnant mice were used for the study of the rate and 
extent of placental transfer of lynestrenol and its metabolites. Because of the 
extensive and rapid biotransformation of the drug observed in the rat (Chapters 
12, 15, 16), separate experiments were undertaken to get information about the 
nature of the radioactive label as well as about the quantitative aspects of 
lynestrenol distribution with time in some selected organs and tissues. 
MATERIALS AND METHODS 
Animals 
Adult female Swiss mice (Centraal Proefdierenbedrijf TNO, Zeist, The Neth-
erlands), body weight 18-20 g, and pregnant mice, two days before delivery, 
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body weight 42-45 g, were used. The animals were starved overnight before the 
experiment. Water was supplied ad libitum. 
Radioactive lynestrenol 
Autoradiography was performed after the administration of lynestrenoI-4-14C, 
impulse counting experiments were carried out separately after the administra­
tion of lynestrenol-3H. Specifications of both compounds are given in Chapter 3. 
The synthesis of lynestrenoMH has been reported previously (Van Kordelaar 
et al., 1973) and is described in Chapter 4. 
Dosage 
For intravenous and oral administration of lynestrenol, ethanol containing 
polysorbate 80 (OPG, Utrecht, The Netherlands) was added to the radioactive 
lynestrenol solution. The solvent was evaporated with a weak stream of air 
and the residue was solubilized in saline. The final polysorbate concentration was 
2%. A volume of about 0.1 ml was injected in the tail vein. For oral ad­
ministration a volume of circa 0.25 ml was given through a stomach cannula. 
The dose injected was 17.5 μg lynestrenol/20 g body weight, corresponding to 
2 цСі lynestrenol-14C or 5 μ ο lynestrenol-3H. The tritiated material was diluted 
ten-fold with non-radioactive lynestrenol. In case of oral administration a dose 
of 3 цСі lynestrenol-,4C was given. 
Autoradiography 
Seven non-pregnant mice were sacrificed 2, 5, 10, 20, 60, 120, 180 min after 
lynestrenol-uC injection. The three pregnant animals survived for 2, 10, 20 min. 
Oral dosage was supplied to seven animals with a survival period of respectively 
5, 10, 20, 40, 60, 120, 240 min. At the appropriate time after lynestrenol 
administration the mice were anaesthetized with diethyl ether, stretched in a 
forceps and killed immediately by immersion in an isopentane bath cooled to 
about -80 o C with solid carbon dioxide. After storage for one day at 
-20 o C the fur was smoothened by moistening with water and the extremities 
were cut off. The frozen bodies were then placed on their side in a 
mould containing a 5% solution of carboxymethylcellulose (CMC) of medium 
viscosity (OPG, Utrecht, The Netherlands), precooled to 0 o C. Subsequently, 
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the mould was cooled with solid carbon dioxide for about 10 minutes and stored 
at -20 o C. For processing the sides of the mould were removed and the CMC 
block was mounted on the microtome (R. Jung A. G., Heidelberg, GFR) located 
in a chest-type freezer. Sagittal sections, 30 μτη thick, of the whole body were cut 
at -15 0 C according to the autoradiographic technique of Ullberg (1954), by 
which each section is attached onto Scotch tape (no. 810, 3M, Leiden, The 
Netherlands). The tape mounted sections were transferred to card-boards as 
described by Van der Kleijn (1969a), then dried for at least 48 hours at -20 o C, 
pressed against X-ray film (Structurix D7, Gevaert) and stored in a press at 
the same temperature. After an exposure time varying from 5 weeks to 20 weeks 
for the longest surviving animals the films were removed at room temperature 
and developed according to the manufacturer's advice. 
impulse counting 
Groups of 4 female mice were injected with lynestrenol-3H and sacrificed 2, 
5, 10, 20, 40, 60, 120 and 180 min later by decapitation under light ether 
anaesthesia. Apart from blood, bile and urine, the following samples were taken 
for impulse counting: pituitary, cerebrum, liver, kidney, adrenal, heart, uterus, 
vagina, spleen, abdominal white fat, brown fat, lung, ovary, skeletal muscle. 
After removal the tissues were immediately cooled on ice. For each group of 
animals comparable parts of the respective tissues and fluids (about 50 mg/ 
animal or the whole organ, i.e. pituitary, ovary, adrenal) were pooled in a pre-
weighed counting vial, weighed and prepared for radioactivity assay. 
Tissue extraction and chromatography 
Simultaneously with the samples taken for the measurement of total radio­
activity as described above aliquots of the same organs and tissues with the 
exception of the pituitary were collected and pooled for fractionation of the 
radioactivity by means of extraction and thin-layer chromatography. The samples 
were frozen immediately on dry ice and stored in a freezer at - 2 5 0 C until 
processing. After thawing in the cold room at 3 0 C the tissues were homogenized 
in 1.0 ml cold water using a Teflon-glass Potter-Elvehjem type homogenizer. 
The homogenate was transferred to Teflon-stoppered conical glass tubes to­
gether with the 80% ethanol rinsing fluid of the homogenizer. After the 
addition of 4 ml ethanol containing 100 μg lynestrenol and standing of the 
suspension for half an hour under occasional swirling, the precipitate was spun 
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off and washed two times with 0.5 ml ethanol 80%. In general more than 95% 
of the radioactivity present in the tissue appeared to go into solution. The 
supernatant together with the washings was extracted three times with 5 ml 
n-hexane. The volume of the alcoholic phase was then made up to 10.0 ml with 
80% ethanol and an aliquot of 1.0 ml was transferred into a counting vial for 
the assay of radioactivity. The joint hexane fractions were evaporated in a 
counting vial under a weak stream of air and radioactivity was measured 
similarly by liquid scintillation counting (LSC). 
Blood samples were diluted with an equal volume of water and after the 
addition of 4 volumes of ethanol processed as described for the tissues. Urine 
and bile were diluted with water, neutralized to pH 6.5-7.5 and extracted like-
wise with hexane. 
Part of the hexane extract of the blood and some tissues was also subjected 
to thin-layer chromatography over silicagel in order to determine the fraction 
of radioactivity representing lynestrenol. The procedure, which was followed, 
is described in Chapter 7. 
The efficiency of the extraction was studied with blank tissue (heart, liver, 
cerebrum) and blood samples to which lynestrenol-3H had been added. The 
mean recovery for each set of samples (n = 4) varied between 89 and 95%. 
The experimental values were corrected for incomplete recovery by multi-
plication by 1.09 (100/92). After thin-layer chromatography of these blank 
extracts as described in Chapter 7 more than 96% of the radioactivity could 
be recovered from the lynestrenol spot. 
Assay of radioactivity 
Radioactivity was measured by LSC as described in Chapter 5. 
RESULTS 
A utoradiography 
1. Intravenous administration to non-pregnant mice (Fig. 14.1a,b) 
After intravenous injection of lynestrenol a rapid but not uniform distribution 
of radioactivity could be observed over the whole body within some minutes. 
Already 2 min after injection blood radioactivity appeared to be less than that 
of the soft tissues with the exception of the thymus and white fat. In general, 
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Fig. 14.1a — Autoradiograms of mice 2 and 5 min after the intravenous injection of lynestren-
ol-1 4C. Note the rapid disappearance of radioactivity from the blood and the low uptake in 
the uterus, vagina and thymus in comparison with the other tissues. Excretion of radio­
activity with the bile and urine is already proceeding. The key to the abbreviations is given 
in the Appendix (p. 182). 
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Fig. 14.1b — Autoradiograms of mice 10, 60 and 180 min after the intravenous injection of 
lynestrenol-14C. The excretion of radioactivity in the urine and bile results in a considerable 
decrease of tissue radioactivity after 60 and 180 min. The 3rd and 4th picture (180 min) 
originate from the same animal, but the exposure time was increased from 5 to 20 weeks. 
Note the persistence of radioactivity in the liver and kidney, the adrenal cortex, the brown 
and white fat, Harder's gland, the corpus callosum and thalamic region in the brain, the 
trigeminal nerve, the nasal mucosa and the hair follicles. Labelling of the stomach contents 
is also apparent after 60 min. The key to the abbreviations is given in the Appendix (p. 182). 
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maximal levels of tissue radioactivity were reached within 5 min, uptake in the 
brown fat, however, continued for some time longer. High and very high levels 
of radioactivity were observed in the liver, kidneys, pituitary, adrenals, ovaries, 
lungs, central nervous system, myocard, thyroid, salivary glands, Harder's 
gland, brown fat and skeletal muscles. The rapid distribution was followed by 
rapid elimination as could be derived from increasing radioactivity levels in the 
urinary and gall bladder and the presence of radioactivity in the intestinal lumen 
from 5 minutes onwards. This coincided with a decrease of label in most organs 
and tissues. Retention of radioactivity over periods up to 3 hours after lyn-
estrenol administration and longer was most pronounced in the liver, the 
adipose tissue and the white matter, furthermore relatively high levels of radio-
activity persisted in the adrenal cortex, the kidney and Harder's gland. After 
the 3 hour interval the distribution pattern was almost uniform with regard to 
the other tissues. A more detailed description of the results is given below. 
Cardiovascular system 
As early as 2 min after injection the blood concentration was low compared 
with the radioactivity in the organs and remained so throughout the experiment. 
The myocard showed an extremely high uptake, which gradually decreased to 
the same level as the blood after about 60 min. No specific uptake could be 
observed in the blood vessel walls. 
Digestive system 
The uptake profile of the tongue was similar to that of the skeletal muscles 
reported below. Also the salivary glands showed initially a high labelling. 
The glandular part of the stomach wall built up higher levels of radioactivity 
than the other part (Fig. 14.2), but this difference had been disappeared after 
1 hour. Twenty minutes and later after drug administration the stomach lumen 
became progressively labelled. 
Liver accumulation of radioactivity was very intense and persisted during the 
whole course of the experiment. Within 5 min following lynestrenol injection 
excretion with the bile had started, radioactivity being present in the gall blad-
der and the duodenal contents. In the later stages this spread to the lower parts 
of the intestines. The initially moderate uptake of radioactivity in the intestinal 
walls decreased fairly rapid to levels slightly above the blood concentration. 
Moderate but persisting levels of radioactivity were also present in the 
pancreas. 
Urogenital system 
The kidneys showed very high labelling after 2 min, particularly in the 
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Fig. 14.2 — Detail of an autoradiogram 2 min after the intravenous injection of lynestren-
ol-14C. Note the high uptake of radioactivity in the ovary and oviduct, in the secretory part 
of the stomach wall, and the accumulation of label at the interface between the red and 
white pulp of the spleen. 
cortex, gradually decreasing during the next hour, but still distinct at the end 
of the experiment 3 hours later. At that time radioactivity was mainly con-
centrated in the pelvic region. The urinary bladder contained increasing amounts 
of radioactivity from 5 min onwards. 
Intense labelling occurred also in the ovaries, particularly in the corpora 
lutea, follicle walls and oviduct (Figs. 14.2, 14.3). Blackening of the interstitial 
tissue was only moderate. A very slight accumulation was visible in the uterus 
and vagina. 
Central nervous system 
Drug penetration into the central nervous system did proceed easily and to 
a considerable extent, maximal levels being attained after 5 min. Initially the 
concentration of the gray matter exceeded the concentration of the white matter, 
but after about 60 min the picture was reversed with the highest labelling 
occurring in the white matter. The labelling of the spinal cord parallelled that 
of the brain. Three hours after lynestrenol administration the brain and blood 
levels were about equal. In the white matter, however, still distinct labelling 
could be noticed. 
The respiratory system 
A high amount of radioactivity was present in the parenchyma of the lungs 
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Fig. 14.3 — Autoradiogram of the ovary of a pregnant mouse 20 min after the intravenous 
injection of lynestrenol-14C. Note the high uptake of radioactivity in the follicle walls and 
the corpora lutea. 
during the first 5 min, this was followed by a gradual decrease to the blood 
level 3 hours later. 
The nasal mucosa displayed increasing labelling after the 20 min interval. 
Accumulation and perhaps secretion of radioactivity were most pronounced 
after the 3 hour survival period. 
Endocrine glands 
A large difference was observed in distribution between the medulla and the 
cortex of the adrenal glands. The uptake in the latter tissue was very rapid and 
extremely high compared with the medulla of the organ as well as with the 
other organs including the liver. A slow decrease occurred with time, and after 
3 hours the cortex radioactivity still exceeded the blood concentration. 
Strong labelling of the pituitary was apparent during the first 20 min, after-
wards no difference could be observed with the brain. 
High uptake of radioactivity in the thyroid was observed 2 and 5 min after 
drug administration. 
Lymphatic organs 
In contrast with the other soft tissues radioactivity levels of the thymus, 
lymph nodes and the white pulp of the spleen did not exceed the blood levels 
even at the early stages of distribution. The red pulp of the spleen, however, 
showed slightly higher concentration than the blood during the first hour. Two 
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minutes after injection, pronounced accumulation of radioactivity was apparent 
at the interface between the red and white pulp in this organ (Fig. 14.2). 
Skeletal muscles 
A very high but heterogenous uptake of radioactivity took place in the 
skeletal muscles within some minutes, labelling, however, decreased rapidly to 
slight and low levels within 60 min. Particularly at the early survival periods the 
cervical muscle was stronger and more uniformly labelled than the other 
muscles. 
Adipose tissue 
For the adipose tissue the difference between the white and the brown fat 
appeared to be pronounced. Accumulation into the white fat did proceed slowly 
and only to a slight extent compared with the brown fat. In the latter tissue a 
high and increasing uptake could be observed during 10 min after injection. 
The decrease of the 14C-levels occurred slowly and 3 hours after lynestrenol 
administration a distinct retention of label was apparent in the brown as well 
as in the white fat. 
Skeleton, bone marrow, teeth, skin 
No labelling of the hard tissues like bone and teeth could be detected during 
the experiment. A slight to moderate labelling of the bone marrow occurred. 
Small amounts of radioactivity were taken up by the skin. The hair follicles 
of the nose showed greater affinity, resulting in a long lasting and moderate 
accumulation of label. 
2. Oral administration to non-pregnant mice (Fig. 14.4a,b) 
Although during the entire observation period of 4 hours a considerable 
amount of labelling of the stomach contents could be seen, a large fraction of 
the small intestine was filled with radioactive material already within 5 min 
after lynestrenol administration. At that time the high concentration of label 
in the liver but not yet in the other tissues was indicative for the initiation of 
the absorption process. Ten minutes after drug administration the urinary and 
gall bladder were clearly labelled. Because the accumulation of label in the 
respective organs and tissues after oral administration is largely determined 
by the relationship between the rates of absorption and elimination, respect-
ively excretion, for most tissues the maximal levels were reached only 20 to 
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Fig. I4.4a — Autoradiograms of mice 5 to 60 min after oral administration of lynestren-
ol-,4C. Note the rapid absorption of the drug and the strong and persistent labelling of 
the liver, adrenal cortex, brown fat, kidney, Harder's gland and nasal mucosa. The key to 
the abbreviations is given in the Appendix (p. 182). 
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Fig. 14.4b — Autoradiograms of mice 2 and 4 hours after the oral administration of 
lynestrenol-1',C. Tissue radioactivity undergoes only small changes between 1 and 2 hours. 
A considerable loss of label occurs during the next 2 hours. Labelling of the ovary and 
Harder's gland is still clearly visible 4 hours after drug administration. The key to the 
abbreviations is given in the Appendix (p. 182). 
40 min after drug ingestion. During the period of 20 to 120 min the distribution 
pattern was rather stabile in a qualitative and quantitative sense, probably 
reflecting a steady state of comparable absorption and excretion rates. In 
comparison with the intravenous route of administration no significant quali­
tative changes in the distribution pattern occurred: the tissues with a high 
uptake and/or retention of label were the same in both experiments. In general, 
however, the contrasts in the pictures were less sharp, probably because the 
maximal concentrations attained were lower after the oral route in spite of 
the higher dose. Four hours after lynestrenol administration the absorption rate 
of the compound was obviously declining. Still a distinct labelling of the various 
organs was visible, but the differences were negligible with an exception for 
the higher concentration of radioactivity in the liver and kidney, the adrenal 
cortex, the ovary and Harder's gland. In this stage no retention of label in the 
brown fat could be observed. 
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3. Distribution in pregnant mice after intravenous injection (Fig. 14.5) 
The distribution over the maternal tissues was similar to that described above 
for the non-pregnant animals. The uptake in the brown fat, however, seemed 
to be somewhat retarded, and was initially uneven. Ten to twenty minutes after 
injection this difference has disappeared. In one of the animals the liver dis-
played a mottled pattern of labelling, possibly representing a centrilobular 
distribution of radioactivity. The passage through the placenta into the fetus 
was rather slow as compared with the transfer into the maternal organs. Two 
minutes after injection the presence of radioactivity was limited to the fetal 
membranes. Ten minutes after drug administration the placenta showed radio-
activity levels above the maternal blood concentration. Also a slight but distinct 
uptake in some fetal tissues was apparent, particularly in the blood, liver, 
kidneys, adrenals, lungs and brown fat. The uptake process appeared to con-
tinue according to this same pattern for the next 10 min. After the 20 min 
interval a still faint distribution picture was obtained. At that time the intra-
fetal localization of radioactivity was most pronounced in the adrenal cortex, 
the liver and the lumen of the small intestine (Fig. 14.6a). Compared with the 
degree of labelling of the maternal organs the overall accumulation of radio-
activity in the fetus remained fairly low. 
Impulse counting and extraction/'chromatography 
The total and hexane-extractable radioactivity present in a number of tissues 
after various post-injection times is shown in Table 14.1. The total radioactivity 
levels are generally in good agreement with the autoradiographic pictures de-
scribed above. Apparent exceptions are the comparatively moderate maximal 
levels observed in the cerebrum, ovary and skeletal muscles. In these tissues, 
however, the distribution of label appeared to be rather inhomogeneous, too. 
The fraction of the total radioactivity, that could be extracted with hexane, 
is also shown in Table 14.1. An extremely rapid decrease of this fraction in the 
Fig. 14.5 — Autoradiograms of pregnant mice 2, 10 and 20 min after the intravenous in-
jection of lynestrenol-^C. Note the slow and limited uptake of label in the fetuses in 
comparison with the maternal levels of radioactivity. After 20 min labelling of the fetal 
liver, the intestinal contents and the adrenal cortex (not visible) is most pronounced. See 
also Fig. 14.6. The key to the abbreviations is given in the Appendix (p. 182). 
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Fig. 14.6 — a. Detail from whole-body autoradiogram showing the distribution of radio-
activity in a fetus 20 min after the intravenous administration of lynestrenol-14C to the 
parent. Note the rather uniform distribution pattern. Apart from the very strong ac-
cumulation of radioactivity in the fetal adrenal cortex, the uptake even in those fetal 
tissues showing the highest concentrations of label (liver, kidney, blood, brown fat, in-
testinal contents) does not exceed the maternal blood level. 
b. Photograph of the corresponding part of the section. Note the position of maternal and 
fetal blood vessels. 
blood and liver can be observed, followed by a more gradual decrease in the 
other tissues. In the white and brown adipose tissue, showing moreover pro-
longed accumulation of radioactivity, as well as in the central nervous system, 
the non-polar fraction remained high during the entire experimental period. 
Furthermore it can be observed, that from the early start of the experiment 
only a very small fraction of the excretion products in the urine and bile could 
be extracted with hexane in contrast with the corresponding tissue and blood 
samples. Obviously, lynestrenol is not excreted unchanged. From the present 
experiment no information was obtained about the relative significance of the 
bile and urine as routes of excretion for lynestrenol and its metabolites. 
The time course of the total radioactivity levels and the lynestrenol levels 
as derived from thin-layer chromatography of the hexane extracts of the blood 
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Table 14.1 — Total and hexane-extractable radioactivity in the blood and tissues of mice at different time intervals 
after the intravenous injection of lynestrenol-3H*) 
TIME (min) 2 5 10 20 40 60 120 180 
Blood 
Liver 
Kidney 
Cerebrum 
Pituitary 
Adrenal 
Ovary 
Uterus 
Vagina 
Lung 
Myocard 
Muscle 
Brown fat 
White fat 
Spleen 
Urine 
Bile 
397/ 194 
1643/1104 
1593/n.d. 
411/n.d. 
1494/n.d. 
3036/n.d. 
339/n.d. 
254/n.d. 
147/n.d. 
n.d./n.d. 
1863/n.d. 
667/n.d. 
407/n.d. 
82/n.d. 
328/n.d. 
- /n.d. 
- /n.d. 
346/ 160 
1656/ 614 
1246/1134 
386/ 338 
1060/n.d. 
2938/2409 
391/ 352 
211/ 127 
103/ 83.5 
1245/1134 
1159/1109 
332/ 268 
657/ 569 
102/ 90.7 
315/ 242 
- / 2.6 
- /n.d. 
282/ 69.1 
1627/ 397 
1072/ 844 
438/ 355 
913/n.d. 
2428/1651 
360/ 294 
275/ 97.6 
143/ 58.6 
875/ 760 
778/ 712 
289/ 198 
1037/ 925 
127/ 107 
361/ 275 
- /n.d. 
- / 2.8 
193/ 28.2 
1480/ 243 
708/ 460 
390/ 351 
750/n.d. 
1403/1010 
369/ 292 
208/ 134 
109/ 54.6 
655/ 540 
443/ 350 
284/ 225 
1162/1070 
265/ 223 
240/ 178 
- / 1.7 
- / 2.5 
181/ 21.4 
1304/287 
435/238 
365/317 
451/n.d. 
1017/693 
314/230 
207/123 
150/ 70.7 
530/402 
269/199 
196/158 
1022/876 
310/292 
197/105 
- / 2.2 
- /n.d. 
135/ 11.1 
898/154 
278/124 
262/236 
278/n.d. 
826/659 
195/148 
119/ 64.4 
100/ 41.1 
309/200 
153/ 96.7 
137/100 
899/810 
370/347 
112/ 59.4 
- / 0.3 
- / 0.5 
112/ 5.0 
1127/147 
260/ 82.9 
231/188 
227/n.d. 
392/260 
215/157 
133/ 91.5 
97/ 24.0 
280/192 
171/ 99.0 
104/ 92.7 
438/388 
224/202 
135/ 59.0 
- / 0.2 
- / 0.5 
86/ 3.2 
1160/ 47.6 
212/ 82.3 
169/140 
164/n.d. 
230/178 
171/103 
129/ 47.5 
93/ 36.5 
216/143 
138/ 56.6 
99/ 74.0 
202/166 
261/220 
97/ 34.3 
- / 3.3 
- / 3.8 
*) For each survival time the first figure represents the total radioactivity and the second one the hexane-extractable radioactivity, both 
expressed as désintégrations per minute (dpm) per mg wet tissue or blood. The results for the pituitary are expressed as dpm/pituitary 
(wet weight about 1 mg). The results for urine and bile are given in per cent of the total radioactivity, "n.d.": abbreviation for "not 
determined". 
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Fig. 14.7 — Concentrations of total radioactivity (closed line) and of lynestrenol (broken 
line) in the blood and liver (a), the adrenal and the uterus (b), and the cerebrum and 
brown fat (c) of mice at various times after the intravenous injection of lynestrenol-3H. 
The concentrations are given as désintégrations per minute (dpm) per mg blood and tissue 
(log scale). 
and liver, the uterus and adrenal, and the cerebrum and brown fat, are shown 
in Fig. 14.7a-c. The blood and liver curve for lynestrenol and, to a smaller 
extent, also the adrenal curve exhibit a biphasic decline, whereas the decline of 
lynestrenol in the brown fat, cerebrum and uterus proceeds monophasic. The 
time of half-life of lynestrenol as derived from these curves can be estimated to be 
in the order of 60 to 120 min. In the blood and in the liver a wide difference 
can be observed between the data of the total radioactivity and the lynestrenol 
concentrations, indicating a rapid biotransformation of the compound. 
DISCUSSION 
General considerations 
Apart from the influence of the route of administration drug distribution and 
the time course of drug distribution are governed on the one hand by the 
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physicochemical properties of the drug molecule and on the other hand by the 
anatomical and physicochemical characteristics of the organism composed as 
it is from organs, tissues, cells and subcellular structures (Goldstein et al., 
1974). Moreover, under conditions of non-equilibrium like e.g. immediately 
after intravenous injection the rate of drug delivery to the various organs and 
tissues is dependent on the blood flow and also this parameter should be con-
sidered as a determinant factor in the distribution process. Drug accumulation, 
therefore, in a certain organ or tissue is not necessarily a reflection of its locus 
of action, even under steady state conditions, but primarily an indication for a 
high affinity of that particular tissue for that particular drug. The mechanism 
responsible for the accumulation may be directly, somehow or not at all related 
to the biological activity of the drug or the biological function of the tissue 
(e.g. liver, kidney). For this reason, it is generally difficult to estimate the 
significance of drug accumulation in a certain organ or tissue without complete 
knowledge about its scala of biological activities and mechanism of action. On 
the other hand, it should be kept in mind that the time course of drug action 
may also be influenced by drug accumulation in and slow release from non-
target tissues, especially in case of rapid biotransformation of the drug into 
inactive metabolites or in case of rapid excretion. 
Pharmacokinetic aspects 
On account of the generally accepted theories about the permeability of 
biological membranes the physicochemical characteristics of lynestrenol, namely 
its molecular weight of 284, its neutral character and high lipophilicity as 
illustrated by its partition coefficient heptane/water of about 5000 (Chapter 8), 
favour a rapid passage across these membranes as far as dependent on diffusion 
processes (Goldstein et al., 1974; Raaflaub, 1970). A rapid absorption and 
subsequent distribution over highly vascularized tissues and a rapid penetration 
into the central nervous system can therefore be expected and was actually ob-
served. The significance of the blood supply in this respect is illustrated by the 
delayed uptake of label in the brown and white adipose tissue in spite of their 
obvious affinity for the drug. Drug accumulation in the latter tissue with its 
very poor blood supply remained less pronounced than the uptake in the better 
perfused brown fat, presumably as a consequence of the rapid biotransformation 
of the parent compound. On the other hand the uptake in these tissues of more 
polar conversion products of lynestrenol cannot be excluded, since 10-20% of 
their content of radioactivity could not be extracted with hexane. A strong accu-
mulation and long retention in the body fat and brain of rats has been reported 
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previously for the cyclopentylether derivative of ethinylestradiol, quinestrol, by 
Meli et al. (1963, 1965, 1968). The concentration of this very lipophilic drug 
in the brown fat appeared to be about 3 times the concentration measured in 
the white fat 24 hours after its oral administration (Steinetz et al., 1967). 
Other steroids like pregnenolone (Appelgren, 1967), progesterone (Appelgren, 
1967), mestranol (Appelgren, 1971) have also been shown to concentrate in 
the brown fat, but this accumulation was followed by a more rapid release of 
label than was observed in the present study. 
The time course of total radioactivity and of lynestrenol in the blood and 
liver (Fig. 14.7a) point to a rapid biotransformation of the drug in the latter 
organ. Although the short duration of the experiment does not allow to draw 
final conclusions from the blood and tissue curves with respect to the time 
of half-life of lynestrenol (Fig. 14.7), in any case two phases can be discerned 
in the elimination of lynestrenol from the blood. The initial and steep decline 
occurring in the blood probably represents a decline caused primarily by 
distribution and metabolism, whereas the second slower phase may be governed 
by the transfer rate of lynestrenol from a second compartment to the central 
compartment consisting among others of blood and liver. This assumption is 
supported by the similar patterns of the blood and liver curve on the one hand 
and the monophasic decay observed for the other tissues with a slope com-
parable with the second phase of the blood curve on the other hand. 
The rapid biotransformation of lynestrenol was followed by a rapid excretion 
of the metabolites with the urine and bile. An interesting observation in this 
connection was the appearance of increasing amounts of radioactive material 
in the stomach lumen 20 min after injection. Excretion of drugs by the stomach 
wall has previously been described for steroids like progesterone and preg-
nenolone (Appelgren, 1967), but also for synthetic compounds like rifampicin 
(Boman, 1975), diazepam and chlordiazepoxide in mice (Van der Kleijn, 1969) 
and zolimidine in rats (Ostrowski et al., 1976). In view of the neutral character 
of lynestrenol gastric excretion of the unchanged drug to the extent observed 
is difficult to explain on account of simple diffusion, because the blood radio-
activity was already very low at that time. Neither is an explanation offered 
by the present knowledge about the conversion products of the drug (see 
Chapter 12) for the same reason. An active excretion process could be invol-
ved. Apart from gastric excretion, however, radioactive material originating from 
the lachrymal glands and the nasal mucosa may contribute to the labelling of 
the stomach. Finally, reflux of a very slight amount of the strongly labelled 
duodenal contents to the stomach would probably be sufficient to get a similar 
phenomenon. 
In contrast with the easy and rapid passage of the blood-brain barrier the 
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diaplacental transfer of lynestrenol appeared to occur to a comparatively slight 
extent. To explain this apparent discrepancy it is necessary to discriminate 
between the permeability of these membranes for a compound on the one hand 
and the actually in vivo observed rate of permeation on the other hand (Villee, 
1965). When the placental transfer of lynestrenol like for most drugs occurs 
by means of simple diffusion, then its placental permeation rate is a function 
of the concentration gradient between the maternal and fetal blood, of the 
surface area of the membrane, and inversely proportional to the thickness of 
the membrane. Particularly for readily penetrating drugs, including probably 
lynestrenol on account of its physicochemical properties (Goldstein et al., 1974), 
the blood flow to the placenta may be a rate limiting factor in the delivery of 
the drug to the fetal circulation. In addition to the blood supply also the short 
time of half-life of lynestrenol in the maternal blood will reduce the lynestrenol 
fraction available for transplacental diffusion very rapidly and, consequently, 
will decrease the maximal and equilibrium drug levels attained otherwise in 
the fetal blood (Goldstein et al., 1974). 
Previous autoradiographic studies in mice with progesterone and the synthetic 
progestins norethindrone and ethynodiol diacetate have also revealed a pla-
cental transfer to the same degree as observed for lynestrenol (Appelgren, 
1967; Freudenthal et al., 1972). On the contrary, after the administration of 
norethynodrel, differing from norethindrone only by the position of the double 
bond at C5 1 0 instead of Ci,, the fetal tissues were strongly labelled (Freuden-
thal et al., 1973). Because this compound, which is known to be metabolised 
rapidly and extensively at least in the rat and human (Cook et al., 1972; 
Hanasono & Fisher, 1974), was given orally and in the fetal tissues almost no 
unchanged drug could be detected, it remains to be studied, whether nor-
ethynodrel itself did actually pass the placenta. 
Pharmacodynamic aspects 
With respect to the biological activity of lynestrenol its concentration-time 
course at the sites of steroid hormone synthesis and action deserves special 
attention. 
The synthesis of steroid hormones in the female is localized in the ovaries 
and the adrenal cortex. A pronounced uptake and retention of lynestrenol in 
these tissues could be observed in accordance with the behaviour of other 
contraceptive steroids like mestranol (Appelgren & Karlsson, 1971), norethin-
drone and ethynodiol diacetate (Freudenthal et al., 1972) and norethynodrel 
(Freudenthal et al., 1973) as well as the endogenous steroid hormone testo-
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sterone (Appelgren, 1969). For progesterone, however, an initially high uptake 
in the adrenal cortex was followed by a rapid decrease within 10 min after 
injection (Appelgren, 1967). Accumulation in the adrenal cortex has also been 
demonstrated for corticosteroids (Hanngren et al., 1964) and estrogens (Ullberg 
& Bengtsson, 1963), whereas the uptake of these compounds in the corpora 
lutea occurred only to a slight extent. It is tempting to assume a relationship 
between the observed accumulation of lynestrenol and the other contraceptive 
steroids in the adrenal cortex and the corpora lutea on the one hand and the 
endocrine activity of these tissues and the steroids on the other hand. It has to 
be realized, however, that for still unclarified reasons a surprisingly large 
number of other substances has also been demonstrated to accumulate at these 
same sites, e.g. diazepam and chlordia7epoxide (Van der Kleijn, 1969b), delta-9-
tetrahydrocannabinol (Kennedy & Waddell, 1972), diphenylhydantoin (Waddell 
& Mirkin, 1972), rifampicin (Boman, 1975), tofenacine (Hespe & Prins, 
1969), zolimidine (Ostrowski et al., 1976), DDT and PCB (Brandt, 1977), 
dieldrin (Bäckström et al., 1965), thiourea (Slanina et al., 1973) etc. 
In agreement with the distribution pattern of progesterone in mice (Appelgren, 
1967) the total radioactivity levels in the uterus and vagina remained low 
during the entire experiment in comparison with the concentrations in the non-
target tissues. Nevertheless, the uterine fraction representing lynestrenol ex-
ceeded the corresponding blood concentrations of lynestrenol by a factor of 
about 10 (Fig. 14.7). Binding of lynestrenol to the progesterone (Kontula et al., 
1975) and to the estradiol receptors (Van Kordelaar et al., 1975a,b; this thesis, 
Section HI) in the uterus has been demonstrated. It seems probable that at least 
part of the lynestrenol present in the uterus is bound to these receptors. 
The easy penetration of lynestrenol into the central nervous system and the 
strong labelling of the pituitary are consistent with the current concepts about 
the mechanism of ovulation inhibition of the contraceptive steroids (Labhset-
war, 1973). Also the very high uptake of lynestrenol in the pituitary and the 
relatively low uptake in the uterus compare favourably with the stronger 
reduction of estradiol uptake in the former than in the latter organ of the rat 
after intravenous injection of lynestrenol (Chapter 9, Fig. 9.2). An explanation 
of the different dose-effect curves in the rat on account of distribution factors 
seems therefore most likely. 
Comparing the potency of the contraceptive progestins to interfere with 
estradiol binding to the estrogen receptor in vivo and in vitro, a comparatively 
low activity has been observed by us for lynestrenol in vivo (Van Kordelaar 
et al., 1975a,b; this thesis, Section III). Apart from a rapid biotransform-
ation of lynestrenol to less potent derivatives a greater volume of distribution 
through accumulation and storage in the adipose tissue as a consequence of 
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its greater lipophilicity could contribute to the difference observed. The present 
results show, that in any case the accumulation and retention of unchanged 
lynestrenol in the brown fat is pronounced and may prolong its physiological 
availability by protecting it from exposure to biotransformation and excretion. 
In spite of the relatively slow uptake in the adipose tissue compared with the 
rapid distribution over the organs the levels in the brown fat are already 
remarkably high within 10 min after lynestrenol injection. Taking into con-
sideration, that maximal levels of estradiol in the rat uterus were only reached 
60 min after intravenous injection (Chapter 9, Table 9.2), a change in the 
concentration-time course of lynestrenol during this period as a result of storage 
in the body fat may, at least for this organ, substantially contribute to the 
difference between the in vivo and in vitro activity of lynestrenol. 
SUMMARY 
The distribution of labelled lynestrenol in female mice has been studied by 
means of whole-body autoradiography and impulse counting methods combined 
with tissue extraction-separation procedures. Within 2 min after intravenous 
injection the compound was distributed over the whole body including the 
central nervous system. High and very high levels of radioactivity were observed 
in the liver and kidneys, the pituitary, thyroid, adrenals, ovaries, central nervous 
system, lungs, myocard, salivary glands, Harder's gland, brown fat and skeletal 
muscles. A prolonged accumulation could be observed in the adipose tissue with 
a much steeper increase for the uptake into the brown fat than into the white 
fat. After the post-injection redistribution phase and the early absorption phase 
the patterns of distribution following oral and intravenous administration were 
essentially the same. Comparatively high levels of radioactivity were maintained 
throughout the experiment in the liver and kidneys, in the adrenal cortex, the 
adipose tissue, the follicle walls and corpora lutea of the ovary, the white 
matter of the brain and Harder's gland. Uterine and vaginal levels of radio-
activity remained relatively low. Tissue extraction with hexane and thin-
layer chromatography of some of these extracts showed, that lynestrenol was 
metabolised rapidly in the liver and disappeared from the blood and tissues 
with a time of half-life of about 1-2 hours. The fraction of total radioactivity 
representing lynestrenol remained high in the lipid-rich tissues cerebrum and 
adipose tissue, probably as a consequence of the lipophilic character of the 
drug. The rapid biotransformation was followed by a rapid excretion of the 
conversion products with the bile and the urine. After the intravenous ad-
ministration to pregnant animals the uptake of radioactivity in the fetuses 
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occurred only to a slight extent in comparison with the maternal tissue con-
centrations. Also in the fetus the accumulation of radioactivity in the adrenal 
cortex was very pronounced, a slight but distinct labelling being furthermore 
apparent in the blood, liver, kidneys, lungs, brown fat and the lumen of the 
small intestines. 
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APPENDIX 
KEY TO ABBREVIATIONS USED IN THE AUTORADIOGRAPHIC 
PICTURES SHOWN IN FIG. 14.1, 14.4 AND 14.5 
a 
b 
bf 
bo 
с 
cm 
CO 
f 
f(prefix) 
fm 
gb 
hf 
hg 
i 
к 
1 
lu 
m 
nm 
adrenal 
blood 
brown fat 
bone 
cerebrum 
cervical muscle 
colon 
foetus 
foetal 
foetal membrane 
gall bladder 
hair follicle 
Harder's gland 
intestine 
kidney 
liver 
lung 
myocard 
nasal mucosa 
о 
Ρ 
pa 
Pi 
г 
s 
sc 
sg 
sm 
sp 
t 
th 
to 
ton 
u 
ub 
ur 
V 
vc 
wf 
ovary 
pituitary 
pancreas 
placenta 
rectum 
stomach 
spinal cord 
salivary gland 
skeletal muscle 
spleen 
thymus 
thyroid 
tooth 
tongue 
uterus 
urinary bladder 
urethra 
vagina 
vena cava 
white fat 
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CHAPTER 15 
METABOLIC CLEARANCE OF LYNESTRENOL 
IN THE ISOLATED PERFUSED RAT LIVER 
INTRODUCTION 
In previous investigations (this thesis, Chapters 12, 13) we studied the 
absorption and disposition of lynestrenol and its metabolites in the rat by 
sampling of urine, faeces and bile after various routes of administration. The 
distribution of lynestrenol was studied in mice with the technique of whole-body 
autoradiography combined with impulse counting of selected tissue samples 
(this thesis, Chapter 14). From the results it could be concluded among others, 
that lynestrenol is metabolised rapidly in the liver to a variety of more polar 
metabolites, which become predominantly excreted with the bile. Excretion of 
the parent compound itself, if any, appeared to be negligible in a quantitative 
sense. In view of the experiments of Kamyab et al. (1968) rapid biotransform-
ation of lynestrenol is also likely to occur in humans: within 15 minutes after 
the intravenous injection of lynestrenol-^C less than 50% of the blood radio-
activity appeared to become extracted with chloroform. 
Taking into consideration on the one hand, that distribution and biotransform-
ation of lynestrenol will govern its time course at the receptor sites in the target 
tissues to a high extent and considering on the other hand, that plasma protein 
binding of a drug may have an important bearing on its distribution into the 
tissues as well as on its metabolism (Dayton et al., 1973; Jusko & Gretch, 
1976; Wilkinson & Shand, 1975), the present investigation was undertaken to 
gain an insight into these specific aspects of lynestrenol kinetics. This chapter 
deals with the hepatic clearance of lynestrenol studied in vitro using the isolated 
perfused rat liver preparation. In recent years this technique has been shown to 
be a very useful tool in pharmacokinetic research (e.g. Alvarez, 1971; Branch 
et al., 1973; Breimer, 1974; Nagashima et al., 1968; Rowland, 1972a; Shand et 
al., 1973, 1975, 1976; Von Bahr et al., 1970; Yih, 1976). Good correspondence 
has been demonstrated between drug clearance values in vitro and in vivo for 
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compounds eliminated mainly by metabolism (Alvarez, 1971; Breimer, 1974; 
Rowland, 1972a; Von Bahr et al., 1970; Yih, 1976). 
Using the isolated perfused rat liver it could be established, that the hepatic 
clearance of lynestrenol is dependent on the perfusate flow rate through the 
liver. Extraction of the compound from the perfusate during liver passage 
appeared to be complete in spite of its high degree of binding to serum albumin. 
Under physiological flow rate conditions there was no apparent concentration 
dependence of the hepatic clearance of the drug over a wide concentration 
range. 
MATERIALS AND METHODS 
Lynestrenol-3H 
The synthesis and the specifications of the tritiated lynestrenol used in the 
perfusion experiments are described in Chapters 3 and 4. Each time before an 
experiment the radioactive material was diluted with non-radioactive lynestrenol 
to the specific activity required. The radioactive dose injected was about 
50 μΟι. The injection solution was prepared by adding 1.0 ml ethanol con­
taining polysorbate 80 (OPG, Utrecht, The Netherlands) to an aliquot of the 
lynestrenol-3H solution. The solvent was then evaporated with a weak stream 
of air and the residue was solubilized in 0.5 ml saline. The final polysorbate 
concentration was 2%. 
Perfusion apparatus 
The apparatus (Fig. 15.1) used for the isolated perfused liver experiments was 
based on the design of Miller et al. (1951) and Fisher & Kerly (1964). With 
the exception of the pump the whole system is housed in a Plexiglass cabinet 
(50 χ 50 χ 100 cm) with a sash window at the front. The semi-synthetic per­
fusion medium (Schimassek, 1962) is brought up from the collecting vessel via 
a filter, obtained from a disposable blood transfusion set, to the top of the 
oxygenator by means of a roller pump and flows down as a film along the 
oxygenator wall. Circumferential troughs in the wall of the oxygenator ensure 
good filming of the perfusate without rivulet formation. The hydrostatic reservoir 
at the bottom of the oxygenator is provided with a bypass outlet and supplies 
via a bubble trap the liver with oxygenated medium. The flow rate of the per­
fusate through the liver could be varied by using a screw clamp between the 
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Fig. 15.1 — Schematic drawing of the apparatus used for the perfusion of the isolated rat 
liver. 
portal cannula and the hydrostatic reservoir. When the clamp was removed a 
perfusion flow rate of about 60 ml/min was obtained with livers weighing about 
8 gram and a perfusion pressure of 30 cm H20. In the organ chamber the liver 
is supported on a glass dish with perforations and the chamber is closed with 
a glass lid to protect the organ against drying. The liver flow rate was measured 
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at regular time intervals during each experiment by determining the time re-
quired for the filling of a calibrated tube into which the cavai outlet flows. 
Cavai and bypass perfusate return to the collecting vessel by gravity and are 
mixed with the contents of this vessel by a magnetic stirrer. Use of plastic 
tubing in the circuit was minimized and limited to the necessarily flexible 
connections between the oxygenator and the portal vein cannula, the liver 
chamber and the collecting vessel, and the tubing for the roller pump. The kind 
of tubing used had to be selected from a wide range of available materials 
because of the occurrence of a considerable loss of lynestrenol by adsorption 
to all but one (Flurane F 5000®, duMee, Sci. Instr., Soest, The Netherlands) 
of the materials tested. In control experiments without liver in the circulation 
system no loss of lynestrenol could be observed after the incorporation of this 
tubing. Several ball-and-socket joints were applied for glass-glass connections 
to facilitate cleaning and mounting of the components and to preserve some 
flexibility in the glass construction. 
The perfusate was oxygenated with a counter-current stream of carbogen 
(95% oxygen/5% carbon dioxide). The gas is warmed and humidified by slow 
passage through two water traps, enters the collecting vessel, reaches the oxy-
genator via the bypass and escapes from a vent at the top. The oxygen 
pressure of the perfusate without liver in the system was 350-400 mm Hg. The 
pH of the circulating medium was monitored continuously by a glass electrode 
(Radiometer 22 pH meter, Copenhagen) and held at a value of 7.35-7.45 by 
the addition of 10% sodium bicarbonate solution. The temperature of the per-
fusate and cabinet was maintained at 380C with the help of a thermostatically 
controlled fan heater. Cooling of the perfusate on its way through the pump 
outside the cabinet was reduced by heating this part of the circuit with a 100 W 
operation lamp. Samples of the perfusate were taken with a syringe from the 
medium leaving the collecting vessel. 
The apparatus was prepared for use after cleaning and mounting by bringing 
into circulation 250 ml of a solution of 5% formaldehyde in 10% sodium 
bicarbonate. After 15 minutes this desinfection was succeeded by three 5 min-
utes washes with freshly distilled water and three washes with sterile saline, 
also during 5 minutes. The last portion saline was replaced by the perfusion 
medium. 
Perfusion medium 
In 60 ml Hank's Eagle solution, prepared by dissolving 1.51 g Hank's Bss 
dried (Difco Lab., Detroit, USA) in 150 ml distilled water and neutralized to 
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pH 7.40 by the addition of 10% sodium bicarbonate in distilled water (solution 
A), 400 mg glucose (Dextropur®, Com Products Сотр., Utrecht, The Nether­
lands) and 6.0 g bovine serum albumin (BSA, Povite, Amsterdam, The Nether­
lands) were dissolved (solution B). Packed red cells were obtained from freshly 
collected heparinized dog blood. After storage of the cells, under saline, and 
both solutions A and В overnight in a refrigerator, the next morning the medium 
was prepared about 1.5 hours before starting the perfusion. In a beaker 6.0 ml 
10% sodium bicarbonate solution was mixed with 60 ml A and an equal 
volume B. If necessary, the pH was adjusted to pH 7.40 with sodium bi­
carbonate solution. Then 80 ml packed cells were added and 20 drops of Terra-
mycin® (Pfizer Ltd., Sandwick, U.K.). The final volume of the perfusion 
medium was 220 ml because of the presence of some saline in the perfusion 
apparatus as a residue of the last saline wash. The haematocrite was measured 
with a micro-haematocrite centrifuge (Hawksley, Lancing, U.K.) and varied 
between 27.0-28.5%. 
Surgical procedure 
Female Wistar rats (Centraal Proefdierenbedrijf TNO, Zeist, The Nether­
lands), 220-240 g body weight, served as liver donors. The animals were 
maintained on a standard laboratory diet (Hope Farms, Woerden, The Nether­
lands) and had free access to food and water. The animals were starved over­
night before the experiment. The surgical procedure, that was followed, has been 
described in detail by Fisher & Kerly (1964). The animal was anaesthetized with 
diethylether, the common bile duct was cannulated with polyethylene tubing 
(Intramedic PE 10, Clay-Adams Co., Parsipanny, USA) and a Braunula® 2 R 
cannula (Braun AG, Melsungen, GFR) was used for the portal vein. After 
the insertion the portal cannula usually fills with blood, but when this did not 
happen, sufficient saline was added to prevent the admission and inclusion of 
air bubbles in the portal circulation. Similar precautions were taken in con­
necting the cannula to the perfusion circuit. Immediately after the transfer of the 
liver to the organ chamber the perfusion was started with the previously 
warmed and oxygenated perfusate. Subsequently the position of the liver and 
the portal cannula were adjusted, if necessary, to increase the perfusate flow 
to its maximal value of about 60 ml/min. The bile duct cannula was led into 
the down-side closed cylinder of a 1 ml syringe and the organ chamber closed. 
The entire operation was finished in 15-20 minutes and not more than 2 min­
utes elapsed between the cannulation of the portal vein and the start of the 
perfusion. 
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Performance of the liver 
Assessment of the liver function was based on the macroscopic appearance 
of the liver, the perfusate flow rate through the organ, the oxygen consumption 
and the bile production. The liver should have a uniform red-brown colour 
without ischaemic spots during the entire experiment. About 2 min after starting 
the perfusion the unrestricted flow rate, with a value of at least 50 ml/min 
at a perfusion pressure of 30 cm water, was adjusted to the value desired (40-
20-10 ml/min) and should require only minor readjustment during the experi­
ment. The pOa deficit of the cavai perfusate was measured (Radiometer 27/ 
Gasmonitor PHA 927, Radiometer, Copenhagen, Denmark) 20 min after the 
adjustment of the flow and at the end of the experiment 0.5 to 2 h later. Both 
values were almost equal and appeared to be at least 250 mm Hg at a liver flow 
rate of 10 ml/min. The bile flow started immediately at a rate of about 0.4 
ml/hour resulting in a total production of 0.6 to 0.9 ml after 2 hours. 
Injection and sampling procedure 
The very rapid clearance of lynestrenol from the perfusion medium observed 
in preliminary experiments would result in a disproportionate loss of drug 
during its first-pass through the liver especially at the higher flow rates, if the 
distribution of the drug over the medium was not complete before the first 
liver passage. For this reason the perfusate flow to the oxygenator was tempor­
arily reversed into the opposite direction just before the drug was injected 
into the collecting vessel, thus allowing a rapid distribution of the drug over 
the entire medium with the exception of the volume present in the hydrostatic 
reservoir and in the liver (5-10% of the total volume). After a decrease of the 
volume in the hydrostatic reservoir to about 5 ml, the perfusate flow to the 
oxygenator was restored. Time was started at the moment the lynestrenol 
containing medium reached the hydrostatic reservoir. 
Samples of the perfusion medium were withdrawn from the medium just 
leaving the collecting vessel by use of a disposable syringe. Sampling was 
continued over a period of 4-5 times the expected time of half-life, according to 
the schedule г г, 5, 71/2, 10, 1242, 15, П г, 20, 221/2 min post-injection in case 
of a liver perfusate flow rate of more than 30 ml/min; 5, 10, 15, 20, 25, 30, 
40, 50 min post-injection (flow rate 20 ml/min) and 5, 10, 20, 30, 40, 50, 
60, 80, 100 min post-injection (flow rate 10 ml/min). Total radioactivity and 
the lynestrenol concentration of the perfusion medium as well as of the perfu-
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sate plasma were determined. The total amount of perfusate withdrawn during 
an experiment, excluding the last sample, did not exceed a volume of 10 ml, less 
than 5% of the circulating volume. 
Assay of lynestrenol 
Immediately after collection the samples were cooled in ice and processed 
during the same day. A volume of 0.1 ml was diluted with an equal volume of 
water. After lysis of the erythrocytes the albumin was precipitated by the 
addition of 0.8 ml ethanol, containing 100 μ§ lynestrenol/ml as a carrier and 
marker for chromatography. The solution obtained was extracted consecutively 
with 2, 1 and 1 ml n-hexane. The combined extracts were evaporated in a 
counting vial with a weak stream of air and radioactivity was measured by 
liquid scintillation counting. 
The lynestrenol content of the hexane extracts was authenticated and cor­
rected accordingly by means of thin-layer chromatography of a duplicate series 
of extracts. The sample volumes used for the extraction were increased to 0.2 ml 
and in case of the last two samples to 0.4 and 1.0 ml respectively. The volumes 
of the other solvents were correspondingly adapted. The chromatographic 
procedure and the measurement of the distribution of radioactivity over the 
developed plate is outlined in Chapter 7. The fraction of the total plate radio­
activity measured in the lynestrenol spot varied for the first sample between 
97.9 and 99.2% for the perfusate and 96.8 and 98.9% for the perfusate plasma. 
For the last sample the corresponding values were 89.2 and 97.8% for the 
perfusate and 86.5 and 92.2% for the perfusate plasma. 
For each experiment the efficiency of the extraction was determined by 
extracting 4 blank perfusate samples to which a known amount of lynestrenol-
3 H had been added. The efficiencies thus measured appeared to vary between 
88 and 94% for the perfusate (mean relative error 2.4%) and between 92 and 
95% for the perfusate plasma (mean relative error 2.1%). 
Assay of radioactivity 
Radioactivity was measured by liquid scintillation counting as described in 
Chapter 5. Except for some silicagel samples, the standard error of counting 
of the samples did not exceed 1.0%. 
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RESULTS 
Viability of the isolated liver preparation 
The viability of the liver was assessed with the criteria mentioned in the 
experimental part. The perfusate flow rate through the liver, the bile flow and 
the oxygen uptake by the organ are listed in Table 15.1a-d. The perfusate flow 
rate required only minor readjustment during the experiments. The smallest 
flow rate used was in the physiological range of 1.2-1.5 ml/min/g liver observed 
in the intact rat (Dobson & Jones, 1952; Grayson & Mendel, 1965). In view of 
the inflow рОг of at least 300 mm Hg at this flow rate and the haematocrite 
value of about 28% the oxygen supply to the liver can be considered to meet 
the requirements for maintenance of the vital processes as well as for metab­
olism (Gumming & Mannering, 1970). The rates of bile production observed 
in this study compare well with those described by other investigators (Fisher 
& Kerly, 1964; Hems et al., 1966; Nagashima et al., 1968; Yih, 1976), the rates 
being also in the range obtained with intact rats (Byers & Friedman, 1952; 
Fisher & Kerly, 1964; this thesis, Chapter 12). The continuing viability of the 
liver preparations during the experimental period is evident also from the drug 
elimination data described in the subsequent paragraph. 
Pharmacokinetics of lynestrenol elimination 
The elimination of lynestrenol by the isolated perfused rat liver under flow 
rate conditions approaching the physiological value of about 1.2-1.5 ml blood/ 
min/g liver (Dobson & Jones, 1952; Grayson & Mendel, 1965) is shown in 
Fig. 15.2. The concentration-time curves of lynestrenol in the perfusate and in 
the perfusate plasma display the same pattern, but the concentration of lyn­
estrenol in the erythrocytes is obviously much higher than the plasma con­
centration. Both curves can be described by a mono-exponential equation: 
CP = A - e " ^
1 
where Cp is the concentration of lynestrenol in the perfusate respectively 
perfusate plasma at time t, A is this concentration at zero-time and tei is the 
elimination time constant. The elimination of lynestrenol can therefore be 
considered as a clearance from a single compartment with a volume V, where 
V=dose/A. From the experimental curve the time of half-life, і г, and A 
can be easily deduced and from these parameters the elimination time constant 
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Fig. 75.2 — Time course of the lynestrenol concentration on semi-logarithmic scale in the 
perfusate (—X—X—) and in the perfusate plasma (—^c—Цс—) showing the elimination 
of the compound by the isolated perfused rat liver. The curve is the best fit of the 
experimental data according to a one compartment open model. The figure is a reproduc­
tion of a direct computer plot. See text for explanation of symbols. 
and the clearance constant, к
Г е І
, can be calculated with the help of the following 
formulas (Van Rossum, 1971): 
tVt = 0 .69 Tel krei = V/xel 
The best fit of the experimental data and the corresponding parameters have 
been obtained with the help of the non-linear least squares curve fitting program 
FARMFIT, previously outlined by Breimer (1974). A survey of the pharmaco­
kinetic parameters of the experiment shown in Fig. 15.2 and other similar 
experiments is given in Table 15.1a and Table 15.2. The clearance of lynestrenol 
from the perfusion medium appeared to be equal to the perfusate flow rate 
through the liver, resulting in a time of half-life of about 14 minutes. In these 
experiments as well as in those described below less than 0.3% of the biliary 
excretion products, representing up to 80% of the dose administered, could 
be extracted with n-hexane, so the elimination of lynestrenol seemed to proceed 
exclusively after biotransformation. 
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Table 15.1 — Experimental conditions and pharmacokinetic parameters of 
lynestrenol in the isolated perfused rat liver1) 
a. Perfusion rate about 10 ml/min, dose 20-25 μ§ lynestrenol-aH 
Rat number 
Liver weight (g) 
Bile flow (mg/min) 
before injection2) 
after injection3) 
рОг deficit (mm Hg)4) 
before injection5) 
after sampling«) 
Haematocrite (%) 
Perfusion rate (ml/min) 
Dose ^g) 
A (ng/ml) 
Tei (min) 
V(ml) 
koi (ml/min) 
kcei/flow 
Cum. excr. (% dose)7) 
1 
6.6 
5.2 
5.0 
266 
247 
28.0 
10.1 
25.84 
123.8 (3.7%) 
21.5 (1.5%) 
209 
9.7 
0.96 
71.5/100 
2 
9.1 
8.8 
8.1 
285 
289 
30.0 
10.7 
23.04 
110.5 (3.0%) 
19.7 (1.1%) 
208 
10.6 
0.99 
79.4/100 
3 
8.6 
2.4 
n.d.s) 
305 
308 
27.5 
11.0 
22.22 
101.3 (4.9%) 
19.3 (1.8%) 
219 
11.3 
1.03 
19.2/80-85») 
1) The parameters A and t
e l as well as their standard error (in parentheses) are calculated 
from the best fit of the lynestrenol concentrations measured in the perfusate with the help 
of the curve fitting program FARMFIT (Breimer, 1974). 
г) Mean value measured over 30 to 60 minutes prior to injection of lynestrenol. 
a) Mean value measured over the entire sampling period. 
4) The difference of the oxygen pressure of the perfusate before and beyond the liver. 
δ) The value measured after the equilibration of the liver under the experimental con­
ditions, but prior to injection of lynestrenol. 
") The value measured after taking the last sample. 
7) The cumulative biliary excretion (first figure) over the indicated time interval in minutes 
(second figure). 
e) n.d.: "not determined". 
*) Bile flow stopped between 80 and 85 minutes post-injection. 
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Table 15.1b — Perfusion rate about 10 ml/min, dose about 1 mg lynestrenol-3H 
Rat number 
Liver weight (g) 
Bile flow (mg/min) 
before injection2) 
after injection3) 
рОг deficit (mm Hg)*) 
before injection5) 
after sampling*) 
Haematocrite (%) 
Perfusion rate (ml/min) 
Dose ^g) 
A (ng/ml) 
tei (min) 
V(ml) 
kcei (ml/min) 
kcei/flow 
Cum. excr. (% dose)7) 
4 
6.7 
7.8 
7.7 
287 
280 
28.5 
11.0 
983 
4713 
19.8 
209 
10.5 
0.96 
(4.0%) 
(1.5%) 
63.5/104 
5 
8.3 
8.2 
7.9 
250 
260 
27.5 
10.9 
947 
4542 (4.1%) 
19.6 (1.5%) 
209 
10.6 
0.97 
64.6/105 
6 
7.3 
7.6 
4.0 
255 
259 
30.0 
10.5 
950 
4314 (4.0%) 
22.3 (1.7%) 
219 
9.8 
0.93 
15.9/104 
'-η see Table 15.1a. 
A 40-fold increase of the lynestrenol dose to about 1 mg did not affect the 
clearance (Table 15.1b). Doubling of the perfusate flow rate through the liver 
was accompanied by a corresponding increase of the clearance (Table 15.1c). 
A still further increase, however, of the perfusate flow rate to 3 and 4 times the 
physiological value was followed by an increase of the clearance in an absolute 
sense, but a decrease of the extraction ratio kCel/flow rate (Table 15.Id). 
A representative example of the time course in the perfusate and in the 
perfusate plasma of lynestrenol, of the total radioactivity and of the metabo­
lites together with the cumulative excretion of radioactivity in the bile is shown 
in Fig. 15.3a. The distribution of lynestrenol and its metabolites between the 
perfusate, respectively the red cells, and the perfusate plasma displayed opposite 
patterns. A high uptake of lynestrenol in the red cells was accompanied by a 
very low uptake of its metabolites and correspondingly high plasma concen-
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Table 15.1c — Perfusion rate about 20 ml/min, dose 20-25 μg lynestrenoPH 
Rat number 
Liver weight (g) 
Bile flow (mg/min) 
before injection2) 
after injection3) 
рОг deficit (mm Hg)4) 
before injection5) 
after sampling«) 
Haematocrite (%) 
Perfusion rate (ml/min) 
Dose ^g) 
A (ng/ml) 
tei (min) 
V(ml) 
kcei (ml/min) 
kcei/flow 
Cum. excr. (% dose)7) 
7 
9.4 
9.4 
n.d.e) 
207 
n.d.8) 
27.0 
22.2 
23.69 
106 (7.6%) 
9.9 (2.5%) 
224 
22.5 
1.01 
57.2/56 
8 
8.9 
7.4 
n.d.s) 
205 
210 
27.5 
21.2 
21.91 
104 (5.2%) 
10.4 (1.9%) 
211 
20.3 
0.96 
45.6/54 
9 
9.4 
8.1 
n.d.8) 
215 
225 
27.5 
22.1 
22.66 
99.7 (4.9%) 
10.4 (1.8%) 
228 
21.9 
0.99 
48.1/55 
'-β) see Table 15.1a. 
trations. In Fig. 15.3b similar curves are shown for experiment 3, where a low 
and untimely stop of the bile production during the experiment resulted in a 
poor excretion of the metabolites. As a consequence the accumulation of the 
conversion products in the plasma is still proceeding at the end of the experi­
ment. The slope, however, of the lynestrenol decay curves was apparently not 
affected. 
For a number of experiments, where in addition to the lynestrenol levels in 
the perfusate the plasma concentrations were measured, the pharmacokinetic 
parameters of the plasma curves were also calculated (Table 15.2). In spite of 
the high uptake of lynestrenol in the erythrocytes (Table 15.2, last column) 
resulting in only about 45% of the lynestrenol being present in the plasma 
fraction of the perfusate, the clearance of the compound from the perfusate 
appeared to be limited by the flow rate of the perfusate through the liver 
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Table IS.ld — Perfusion rate > 30 ml/min, dose about 25 μg lynestrenol-3H 
Rat number 
Liver weight (g) 
Bile flow (mg/min) 
before injection2) 
after injection3) 
рОг deficit (mm Hg)4) 
before injection5) 
after sampling8) 
Haematocrite (%) 
Perfusion rate (ml/min) 
Dose fag) 
A (ng/ml) 
tei (min) 
V(ml) 
kfei (ml/min) 
kcvi/flow 
Cum. excr. (% dose)7) 
10 
8.2 
7.2 
6.8 
145 
160 
27.5 
33.2 
24.19 
118 (3.8%) 
8.7 (2.4%) 
205 
23.6 
0.71 
53.9/40 
11 
8.1 
6.3 
5.9 
n.d.s) 
n.d.8) 
n.d.8) 
31.3 
27.41 
123 (4. 
- — 
1%) 
10.3 (3.0%) 
223 
21.7 
0.69 
17.5/41 
12 
8.0 
7.7 
7.2 
110 
113 
28.5 
44.3 
18.33 
84.7 (5.0%) 
7.9 (4.0%) 
216 
27.3 
0.62 
n.d.8) 
2
-
e) see Table 15.1a. 
(Table 15.1). This implies a very rapid exchange of lynestrenol between the 
red cells and the plasma. In this light it is not surprising, that the elimination 
time constants derived from the plasma concentration measurements are equal 
to the elimination time constants derived from the lynestrenol time course in 
the perfusate. Another consequence of the high partition-coefficient and rapid 
movement of lynestrenol from the cells to the plasma is, that a plasma 
clearance constant is calculated from the plasma concentrations, which exceeds 
by far the flow rate of the perfusate plasma through the liver (Rowland, 1972b). 
DISCUSSION 
From the present investigations lynestrenol appears as a most interesting and 
rather unique drug. In spite of an albumin bound fraction of more than 97% 
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time (mm ) 
Fig. 15.3 — Time course of the concentrations of lynestrenol, total radioactivity and 
metabolites on a semi-logarithmic scale in the perfusate (closed lines) and the perfusate 
plasma (broken lines) during perfusion of the isolated rat liver. All concentrations, measured 
as dpm/ml, were converted into ng/ml using the molecular weight and specific activity of 
lynestrenol-'H. The concentrations of the metabolites were derived from the experimental 
data of total radioactivity and lynestrenol. On a linear scale the cumulative excretion of 
radioactivity in the bile is also shown. 
(see Chapter 8), the total plasma concentration of the drug is less than one 
third of the concentration in the erythrocytes, resulting in only 45% of the 
total amount of lynestrenol being present in the plasma. At the same time the 
transfer rate of the compound from the red cells to the plasma is so rapid, 
that the decay curves of lynestrenol in the perfusate and in the perfusate plasma 
remain parallel under conditions of the highest clearance being theoretically 
possible. Conversely, the observation of the highest possible clearance under 
physiological flow conditions as observed in the present study implies a com-
plete extraction of lynestrenol from the plasma as well as from the red cells 
during liver passage and consequently an elimination process, limited only by 
the perfusate flow rate through the liver and independent of the extent of protein 
binding. Because of the latter property the elimination of lynestrenol is of the 
non-restrictive type (Shand et al., 1976; Wilkinson & Shand, 1975). 
198 
Table 15.2 — Pharmacokinetic parameters of lynestrenol in the isolated perfused rat liver as derived from 
concentrations in the perfusate plasma1) 
Rat no.2) 
1 
3 
4 
7 
8 
10 
Perfusion rate 
(ml/min) 
10.1 
11.0 
11.0 
22.2 
21.2 
33.2 
Haematocrite 
w 
28.0 
27.5 
28.5 
27.0 
27.5 
27.5 
A 
(ng/ml) 
73.0 (1.8%) 
64.4 (1.4%) 
2830 (2.3%) 
69.0 (6.5%) 
63.9 (2.2%) 
68.7 (2.4%) 
Tel 
(min) 
21.9 (0.7%) 
19.6 (0.5%) 
20.1 (0.9%) 
10.2 (2.2%) 
10.5 (0.8%) 
8.8 (1.6%) 
V 
(ml) 
353 
345 
347 
343 
343 
352 
keel 
(ml/min) 
16.1 
17.6 
17.3 
33.5 
32.7 
40.1 
Ratio 
ery/plasma3) 
3.50 
3.07 
3.33 
2.99 
3.29 
3.61 
') The parameters A en xel and their standard errors (in parentheses) are calculated from the best fit of the lynestrenol concentrations 
measured in the perfusate plasma with the help of the curve fitting program FARMFIT (Breimer, 1974). 
2) Corresponding numbers in this and the preceding table refer to the same experiment. 
s) The ratio cry/plasma is the ratio of the respective lynestrenol concentrations at zero time. The lynestrenol concentration in the ery-
throcytes has been calculated from the concentrations in the perfusate and the perfusate plasma with the help of the haematocrite 
value. 
Under flow rate conditions exceeding physiological values it was observed 
(Table 15.Id) that the clearance of lynestrenol is determined by some other 
factor than the perfusate flow rate through the liver. The hepatic clearance 
is a function of liver blood flow on the one hand and the ability of the organ 
to extract the drug as it perfuses through the hepatic capillaries on the other 
hand (Nagashima et al., 1968). It is conceivable that under conditions of an 
increased liver flow rate this latter parameter, which is a function of the activity 
of the drug metabolising enzyme system in the liver cells, may become rate-
limiting in the elimination of lynestrenol. Another explanation may be provided 
by the assumption, that at high perfusate flow rates the conditions for the 
exchange of drug between the perfusate and the liver become less favourable. 
Drug transfer from the perfusate to the liver may then become rate-limiting or 
by-pass of the perfusate through some larger liver vessels could occur. Then 
the perfusate flow rate measured changes into an apparent flow rate greater 
than the one, which actually determines the exchange process in the liver. 
The rapid biotransformation of lynestrenol, the rapid excretion of the 
conversion products and the absence of the parent compound in the bile are 
in every respect in good agreement with the results obtained in the rat in vivo 
(Chapter 12). As already could be derived from the renal and hepatic excretion 
patterns of radioactivity in the rat with and without bile duct ligation, the bio-
transformation rate of lynestrenol appeared not to be disturbed in case of 
insufficiency of the hepatic excretory mechanisms. Instead of elimination with 
the bile the conversion products are then released into the perfusate (Fig. 15.3b). 
The low biological availability of lynestrenol after oral administration in vivo, 
which is to be expected on account of the rapid metabolic clearance observed 
in the present experiments, has been validated in the rat in vivo (this thesis, 
Chapter 16). No correlation, however, could be demonstrated between the 
metabolic clearance rate in vitro and the clearance of the compound in vivo. 
This lack of correspondence is discussed in Chapter 16. 
SUMMARY 
The hepatic clearance of lynestrenol has been studied with the isolated 
perfused rat liver preparation. Lynestrenol disappearance followed a mono-
exponential decline. In spite of a 3-fold difference between the erythrocyte and 
plasma concentration of lynestrenol the elimination time constants for the 
perfusate and the perfusate plasma were similar. At perfusate liver flow rates 
between 1.2 and 2.4 ml/min/g liver the extraction of the drug from the perfusate 
during liver passage was complete. In view of the high plasma protein binding 
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of 97.4% the elimination of lynestrenol is of the non-restrictive type. There 
was no apparent concentration dependence of the clearance over a wide con­
centration range. At perfusate flow rates of 4-5 ml/min/g liver the extraction 
ratio in the liver decreased to about 0.7. Over a period of about 100 minutes 
after injection 65-80% of the dose was excreted in the bile. Less than 0.3% 
of the excretion products could be extracted with n-hexane. On account of the 
present findings a considerable pre-systemic elimination of lynestrenol after 
oral administration can be expected. 
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CHAPTER 16 
PHARMACOKINETICS AND BIOLOGICAL AVAILABILITY 
OF LYNESTRENOL IN THE RAT 
INTRODUCTION 
With respect to the pharmacokinetics of oral contraceptive steroids most 
attention has been given in the past to the study of their biotransformation in 
the liver and the nature of the excretion products isolated from the urine and 
sometimes from the bile. The study of blood concentrations has been hampered 
by the lack of analytical methods of sufficient sensitivity and specificity. Radio-
active methods cannot be considered for pharmacokinetic investigations in 
humans unless in a few selected cases. The progress being made in recent years 
in the development of radio-immunological methods (Abraham, 1974; James 
& Jeffcoate, 1974) and computerized gas chromatography-mass spectrometry 
(Carrington & Frigerio, 1977) has already been shown to provide the analytical 
tools allowing the measurement of blood concentrations of drugs administered in 
milligram and sub-milligram amounts per day, including the oral contraceptive 
steroids (Adlercreutz et al., 1974; Braselton et al., 1977; De la Pena et al., 
1975; Hiroi et al., 1975; Nieuweboer & Liibke, 1977; Nygren et al., 1974; 
Saxena et al., 1977; Stanczyk et al., 1975; Victor et al., 1977; Warren & Fo-
therby, 1974). 
Blood concentrations after the administration of lynestrenol have not been 
reported thus far except by Kamyab et al. (1968) and Van der Molen et al. 
(1969). In the latter report only total radioactivity levels were measured after 
the administration of lynestrenol-4-14C and no discrimination was made between 
the rapid decline of chloroform-extractable radioactivity and the much slower 
decrease of total radioactivity as apparent from the study of Kamyab et al. 
(1968). Apart from the lack of specificity of the assay employed in the latter 
investigation the very limited number of data presented by these authors does 
not allow a meaningful pharmacokinetic analysis to be made. 
The rapid hepatic clearance of lynestrenol as observed by us in the isolated 
perfused rat liver preparation (this thesis, Chapter 15; Van Kordelaar et al., 
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1978) and the extensive and rapid biotransformation of the steroid also in the 
rat in vivo (this thesis, Chapters 12, 13) made an extension of the investigations 
to its blood level profile in the rat interesting and desirable. In the present 
chapter we provide information about the pharmacokinetics and biological 
availability of lynestrenol in the rat following intra-arterial and intraduodenal 
administration. 
MATERIALS AND METHODS 
Animals 
In all experiments female Wistar rats, age 3-5 months, were used (Centraal 
Proefdierenbedrijf TNO, Zeist, The Netherlands). The animals were maintained 
on a standard laboratory diet (Hope Farms, Woerden, The Netherlands) and 
tap water. During the experiments the animals were housed in a restraining 
cage after Bollman (1948) with small modifications (Kilian, 1973). Some weeks 
before the experiment the animals were placed periodically in these cages in 
order to acclimatize and to reduce stress in the experimental situation. The rats 
were starved overnight before the administration of the test compound, after-
wards they had free access to food and water or, in the case of bile duct 
cannulation, to saline instead of water to replace the salts lost with the bile. 
For the biliary fistula a polyethylene cannula (Intramedic PE 10, Clay-Adams 
Co., Parsipanny, USA) was inserted in the upper part of the common bile duct 
the day before the experiment. Surgery was performed under ether anaesthesia 
according to the procedure described by Lambert (1965). The collection of bile 
allowed the determination of the fraction of the dose absorbed after intra-
duodenal administration of lynestrenol and the measurement of the cumulative 
excretion of radioactivity in the bile. 
Blood sampling 
In each experiment 13 blood samples were taken over a period of 23-28 h 
after drug administration. Samples of 0.15-1 ml volume were collected using a 
heparinized syringe (Sherwood Medical Industries Ltd., Crawley, U.K.) fitted 
with a hypodermic needle. Sampling was accomplished via a polyethylene 
cannula (Intramedic PE 10, Clay-Adams Co., Parsipanny, USA) introduced in 
the aorta through the carotid artery the day before the experiment. This method 
of sampling combines a number of features especially of advantage in pharmaco-
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kinetic investigations using radiolabelled compounds. The technique is simple 
and rapid, clean and does not disturb the animal. Moreover, by using a syringe 
of 1 ml the volume of the sample can be accurately restricted to the quantity 
desired so that the small blood volume available for sampling (see Chapter 7) 
can be actually used with the greatest economy. 
Dosage 
Specifications of the administered drug, lynestrenol-3H, have been given in 
Chapter 3. For intra-arterial administration of lynestrenol ethanol, containing 
polysorbate 80 (OPG, Utrecht, The Netherlands), was added to the lynestrenol-
3 H solution. The solvent was evaporated with a weak stream of air and the 
residue solubilized in saline. The final polysorbate concentration was 2%. A 
volume of about 0.3 ml was injected via the carotid artery cannula. 
The dosage form for intraduodenal administration was prepared similarly, but 
here saline as the solvent was replaced by 1.0 ml bile collected from the same 
rat after surgery had been performed. 
The rats received a dose of about 50 μg lynestrenol-3H, corresponding to 
125 μΟ. 
Sample analysis and presentation of results 
A detailed description of the analytical procedure applied has been given in 
Chapter 7. As pointed out, a complete analysis of each sample, including thin-
layer chromatography of the hexane extracts, was not feasible for several 
reasons. The results, however, obtained with chromatography of the blood 
extracts in the course of the investigations revealed that the fraction of these 
extracts representing lynestrenol varied always between 85 and 95%. We 
thought it, therefore, justified to extrapolate these results to the extracts not 
subjected to chromatography and to calculate the lynestrenol content of these 
extracts by multiplication by 0.9. Although for this reason the present results 
may differ from the pharmacokinetic data of lynestrenol, deviations of more 
than 5% in the calculated concentrations and in the fitted parameters are not 
likely. 
No corrections have been applied to the values of hexane-extractable radio­
activity measured following intraduodenal administration of lynestrenol, because 
in these experiments chromatography was performed with only one sample and 
the lynestrenol content of the blood extracts seemed to be less uniform. The 
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results of these experiments have been presented, therefore, as concentrations 
of hexane-extractable radioactivity instead of lynestrenol concentrations. 
Assay of radioactivity 
The measurement of radioactivity by means of liquid scintillation counting 
and the preparation of the samples has been described in Chapter 5. For the 
measurement of the blood levels of total radioactivity 10-20 mg blood was used. 
RESULTS 
Intra-artcrial administration 
The blood or plasma concentration of lynestrenol was measured over a 
period of about 24 hours after injection. After an initial rapid fall of the con­
centration primarily as a result of the distribution of the drug into the tissues 
a more gradual decline of the blood and plasma levels was observed. About 
4 hours after lynestrenol administration a third phase became apparent in the 
semi-logarithmic concentration-time curve (Fig. 16.1). The entire curve can be 
described mathematically as a sum of three exponentials according to the three-
compartment open model: 
α ^ Α , . β ^ + Α , . β - ^ + Α , . β " ^ » 
where C, is the lynestrenol concentration (ng/ml) at time t, τ,, t 2 and τ 3 are the 
time constants (min) and Aj, A2 and Aj are the coefficients (ng/ml). From the 
linear part of the semi-logarithmic concentration-time curve τ
Ά
 and A3 can be 
deduced, representing the slope and the intercept of the extrapolated curve at 
zero-time respectively. Similarly Aj and A2 and τ 1 and х2 may be obtained from 
the intercepts and slopes of the lines found by stripping of the original curve 
using the subtraction method or by a non-linear regression analysis of a three-
term exponential equation. 
The pharmacokinetic parameters of the parenteral experiments are summar­
ized in Table 16.1 and have been derived from the best fit of the experimental 
curves according to the equation shown above. Curve-fitting and calculations 
have been accomplished with the help of the computer program FARMFIT in 
use in our department (see Chapter 7). The volume of the central compartment 
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Fig. 16.1 — Concentration-time course of lynestrenol in rat blood after intra-arterial in­
jection of the compound. The curve is the best fit of the experimental data according to a 
three-compartment open model. The pharmacokinetic parameters are given in Table 16.1. 
The figure is a reproduction of a direct computer plot. 
(Vj), the area under the curve (AUC) and the apparent volume of distribution 
(Va) have been calculated by means of the following equations: 
V, = T 
dose 
A * ~t" A 2 "I" A<j 
AUC = Aj. xi + A 2 . τ2 + Aj . x3 
Vd = 
dose (A1. t i 2 + Az . τ2 2 + A3 . x*) 
( A j . t j + A 2 . x2 + A3 . tg) 2 
The biological half-life (t%) has been calculated from the largest time constant 
(і г = 0.69 тз) and the elimination clearance constant (kcci) by dividing the 
dose (D) by the area under the curve (koi = D/AUC). 
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Table 16.1 — \ 
EXPERIMENT 
Body weight (g) 
Dose ^g) 
Dose/100 g fag) 
Cum. excr. (%)') 
Tj (min) 
τ£ (min) 
τ, (min) 
tVi (min) 
A, (ng/ml) 
Aj (ng/ml) 
A, (ng/ml) 
V, (ml) 
V,(l) 
kC e l (ml/min) 
AUC (ng.min/ml) 
AUC/μg/100 g 
Fitted and calculated pharmacokinetic parameters for 
1 
190 
44.1 
23.2 
68.8 
6.9 
84 
1040 
723 
101 
25.8 
6.03 
333 
3.56 
4.8 
9143 
394 
(23.3%) 
(17.7%) 
(11.4%) 
(20.6%) 
(16.7%) 
(11.5%) 
2 
185 
47.4 
25.6 
67.3 
5.6 
94 
910 
631 
153 
41.5 
the compound 
(29.5%) 
(15.2%) 
(10.7%) 
(34.9%) 
(11.7%) 
7.55 (14.7%) 
234 
2.32 
4.1 
11,640 
455 
3 
241 
48.3 
20.0 
— 
7.6 
91 
1840 
1274 
212 
28.1 
lynestrenol after intra-arterial administration of 
to 6 rats1) 
(18.5%) 
(18.5%) 
(25.7%) 
(20.5%) 
(14.9%) 
7.00 (13.1%) 
196 
3.98 
2.8 
17,030 
852 
4 
239 
45.4 
19.0 
— 
2.8 
52 
1218 
844 
375 
29.3 
(35.7%) 
(19.2%) 
(16.0%) 
(74.6%) 
(18.5%) 
6.78 (10.3%) 
111 
3.92 
4.2 
10,830 
570 
5 
227 
51.1 
22.5 
71.2 
5.9 
61 
1076 
746 
230 
46.6 
7.07 
180 
3.06 
4.3 
11,820 
525 
(15.8%) 
(8.2%) 
(7.2%) 
(17.9%) 
(9.9%) 
(5.7%) 
6*) 
175 
52.0 
29.7 
78.3 
18.2 (11.2%) 
136 (7.9%) 
995 (7.3%) 
689 
126 (5.8%) 
62.9 (7.0%) 
12.8 (9.9%) 
258 
1.30 
2.2 
23,590 
794 
') The parameters were derived from the best fit of the blood (experiment 1-5) or plasma (experiment 6) concentration-time curve of 
lynestrenol according to a three-compartment open model. The figures in parentheses denote the relative errors (%) of the fitted 
parameters. For pharmacokinetic symbols and calculations see text. 
2) The parameters of experiment 6 have been derived from plasma concentrations instead of blood concentrations and cannot be con­
sidered to be equivalent to the parameters derived from experiments 1-5 (Gibaldi & Реггіег, 1974; Rowland, 1972). 
Q ') Cumulative biliary excretion of radioactivity in rats with bile fistula (experiments 1, 2, 5 and 6). 
blood c o n c e n l r a t i o n ( n g / m l ) 
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Fig. 16.2 — Time course of the blood concentration of total radioactivity, of lynestrenol 
and of the metabolites after intra-arterial injection of lynestrenol-3H. All concentrations, 
measured as dpm/ml, were converted into ng/ml using the molecular weight and specific 
activity of lynestrenoI-3H. The concentration of the metabolites was derived from the 
experimental data of total radioactivity and of lynestrenol. 
The simultaneous measurement of the blood levels of total radioactivity 
showed a large difference with the blood levels of lynestrenol (Fig. 16.2) in 
spite of the rapid excretion of the metabolites with the bile, that is to be 
expected on account of previous findings (see Chapter 12). Generally, the peak 
level of the metabolite curve was already attained before the first sample was 
taken. Its relatively late appearance in the experiment shown (Fig. 16.2) can be 
attributed to some delay in the biliary excretion of radioactivity observed during 
the first 15 minutes after injection. The final slope of the metabolite curve 
indicated in all experiments a substantial increase of the time of half-life of the 
metabolites as compared with the parent compound (30-90 h versus about 12 h). 
The longest half-life was observed in the intact rats, namely 75 h and 88 h, 
and a contribution of enterohepatic recycling of the metabolites to the slow 
elimination in these animals seems likely. It should be realized, however, that 
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this half-life as measured in the present study does not provide conclusive 
information about the real disappearance rate of the lynestrenol metabolites, 
because in the course of the biotransformation of lynestrenol-3H tritiated water 
may be formed. The slow elimination and the small volume of distribution of 
this tritiated water could influence the final slope of the blood level-time curve 
of the total radioactivity to a high extent. With respect to the time course of 
the metabolites more reliable information can be obtained when a metabolically 
indifferent radiolabel is used like is present in lynestrenol-4-14C. 
Intraduodenal administration 
After the intraduodenal administration of lynestrenol-3H dissolved in bile 
rapid absorption occurred as can be derived from the peak level times of the 
various blood concentration-time curves as well as from the rapid excretion of 
radioactivity in the bile (Fig. 16.3). Although the blood level profile of the 
hexane-extractable radioactivity during the absorption phase was rather irregu-
lar, beyond the peak level time a biphasic decline appeared to occur. The first 
phase observed after injection of the steroid is not visible after intraduodenal 
administration, probably because in these experiments the first-phase distribution 
and the absorption process coincide. In spite of the rapid absorption the maximal 
blood concentration of hexane-extractable radioactivity remained considerably 
below the lynestrenol levels observed after parenteral administration (Figs. 
16.1, 16.2). For this and other reasons mentioned in Chapter 7 only the sample 
taken at time 90 min was subjected to thin-layer chromatography. The results 
of chromatography are also shown in Fig. 16.3. With one exception the fraction 
of the hexane extract representing lynestrenol varied between 80 and 90%. 
The hexane-extractable radioactivity, on the contrary, represented only 10-20% 
of the total radioactivity levels (not shown) during the first two hours after drug 
administration and decreased afterwards progressively below 5%. 
The fraction of the dose absorbed was determined by measurement of the 
amount of radioactivity present in the faeces and gut contents after 24 h and 
appeared to be more than 90% (Table 16.2). The biological availability (F) of 
lynestrenol was determined by comparing the area under the blood concen-
tration-time curve after intraduodenal (AUClcl) and intra-arterial (AUCia) ad-
ministration with the proper dose correction for the body weight and for the 
unabsorbed fraction in the intraduodenal experiments included, using the 
formula: 
T , / / W 4 AUC l d .D l â
 л п п F (%) = χ 100 
А и С . Д а 
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• experiment A 
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Fig. 16.3 — Time course of hexane-extractable radioactivity in rat blood following the 
intraduodenal administration of about 50 μΕ lynestrenol-'H to four rats with bile fistula. 
The concentrations, measured as dpm/ml blood, were converted into ng/ml using the 
molecular weight and the specific activity of lynestrenol-'H. The cumulative excretion of 
radioactivity in the bile is also shown in the figure. For the 90 min samples the per­
centage of the hexane-extractable radioactivity representing lynestrenol is indicated. Notice 
the rapid fall of the blood concentration beyond the peak level time and the overall low 
concentrations in comparison with the parenteral route of administration (cf. Figs. 16.1 
and 16.2). 
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58.9 
94.1 
23.1 
0.49 
1728 
1801 
846 
2647 
115 
18.5 
228 
55.9 
94.6 
23.2 
0.67 
1339 
2769 
897 
3666 
158 
25.4 
229 
45.0 
89.1 
17.6 
0.12 
691 
1063 
83 
1146 
65.1 
10.5 
235 
64.5 
92.7 
25.4 
0.24 
994 
1803 
238 
2041 
80.4 
12.9 
Table 16.2 — Absorption and biological availability after the intraduodenal 
administration of lynestrenol-3H to 4 rats1) 
EXPERIMENT A B C D 
Body weight (g) 
Dose ^g) 
Absorption (%)2) 
Dose absVlOO g ^g) 
Q (ng/inl)3) 
tei (min)4) 
AUC 0-t (ng.min/ml) 
AUC t - с э (ng.min/ml) 
AUC 0- оэ (ng.min/ml) 
AUC 0-~/dose abs./100 g 
F (%)5) 
(12.1,26.2) (16.7,36.0) (6.9,14.8) (8.5,18.3) 
·) The individual blood concentration-time curves of these experiments are shown in Fig. 
16.3. For symbols and calculations see text. 
2) The fraction absorbed (% dose) was calculated as the difference between the radioactive 
dose administered and the quantity of radioactivity recovered from the faeces and gut 
contents about 24 h later at the end of the experiment. 
3) The last blood concentration measured. 
*) The elimination time constant derived from the ultimate slope of the semi-logarithmic 
blood concentration-time curve. 
s ) The biological availability of hexane-extractable radioactivity after intraduodenal ad­
ministration of lynestrenol-3H calculated by using the mean or, in parentheses, the 
maximal and minimal value respectively of the area under the blood concentration-time 
curve of hexane-extractable radioactivity following intra-arterial injection ( A U C i a as 
shown in Table 16.1 and multiplied by 1,11). 
The areas under the curve, AUC i d and AUC i a, were calculated for the hexane-
extractable radioactivity fraction of the blood level-time curve. Following intra­
arterial injection the best fit of the respective curves was used for the calcu­
lations. In case of intraduodenal administration the AUC i d for the portion 
between zero-time and the time of the last sample was determined by comparing 
its weight relative to a standard area. If at the last data point, 24 h after drug 
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administration, absorption is complete, and this condition is obviously fulfilled 
in our experimental set-up, the area beyond this point can be determined using 
Dost's law of corresponding areas. The following equation applies for the area 
from zero-time up to infinite time (Dost, 1968): 
oo * oo 
AUG = i Ci dt = J Ci dt + J Ci dt = AUG 0-t + Q . td 
о о t 
where Ct is the last blood concentration determined and Tei is the terminal 
elimination time constant. So the residual area can be calculated by multiplying 
Q by tei- The latter parameter was derived from the terminal phase of the 
semi-logarithmic blood concentration-time curves. 
Because for all experiments different rats were used no comparison was 
possible of parenteral and intraduodenal curves for one and the same animal. 
This implies, that the biological availability obtained by comparing the AUC l d 
and AUC i a after drug administration to different animals is influenced also by 
the value of the total body clearance of the respective rats. The clearance 
constants, however, observed after intra-arterial injection of lynestrenol varied 
within rather narrow limits (Table 16.1). For this reason interindividual vari­
ation of this parameter is probably not a complicating factor for the biological 
availability as measured in the present study. Moreover, it has to be realized 
that as a result of interindividual variations in the clearance constant the 
biological availability will always have only absolute significance for one 
individual and under well-defined experimental conditions. In Table 16.2 the 
extreme values of the biological availability have been presented for each rat as 
derived from the ratio of the AUC l d and the minimal as well as the maximal 
AUC1!V observed in the former experiments (Table 16.1). 
DISCUSSION 
Physiological and pharmacological meaning of the pharmacokinetic data 
The present results emphasize that measurement of the blood levels of total 
radioactivity does provide hardly any information about the time course of 
lynestrenol in the blood. The three-term exponential decline of the blood con­
centration indicates the distribution of the drug over a central compartment 
comprising the blood and those tissues and fluids, which are instantaneously 
accessible to the drug, and two more slowly accessible peripheral tissue com-
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partments. It is generally assumed that the liver, where the elimination of lyn-
estrenol takes place, belongs to the central compartment. The peripheral com-
partments will include among others the target tissues of lynestrenol and the 
adipose tissue. Accumulation of the very lipophilic lynestrenol (this thesis, 
Chapter 8) in the latter tissue may explain at least in part the remarkably large 
volume of distribution of the drug. On the other hand, the slow release of lyn-
estrenol from the poorly perfused body fat may govern the shallow slope of the 
terminal phase of the blood concentration-time curve. Retention, however, of 
the steroid in the target tissues as a result of its binding to the estradiol and 
progesterone receptor molecules will certainly not be reflected in the blood 
profile of the compound as measured in the present study. Current knowledge 
of the total binding capacity of the estrogen receptor (Eisenfeld et al., 1977; 
Ginsburg et al., 1975; Korach & Muldoon, 1974a,b; Lee & Jacobson, 1971; 
Sen & Menon, 1978) and the receptor for progesterone (Booth & Colas, 1977; 
Kato & Onouchi, 1977; Walters & Clark, 1977) in the rat indicate that the 
total binding capacity of these receptors does not exceed an amount of 50 pmol/ 
animal. Taking the double value it can be easily calculated that the instantaneous 
distribution of 100 pmol lynestrenol over the smallest volume of distribution 
of the central compartment found in the present study (111 ml) would result in 
a blood concentration of only 0.25 ng lynestrenol/ml. 
In Chapter 9 the inhibition of estradiol-3!! receptor binding by lynestrenol 
was studied in the rat in vivo using the intravenous route of administration. 
A significant decrease of estradiol-3!! binding in the pituitary and preoptic area 
could be observed following the injection of a 250-fold excess of lynestrenol 
over estradiol-3!! (see Chapter 9, Fig. 9.2). The physiological blood levels of 
estradiol in the rat vary between 20 and 90 pg/ml (Butcher et al., 1974). 
Assuming that the ratios of the blood/target tissue concentration for estradiol 
and lynestrenol are about equal, it follows that blood concentrations of 5-20 ng 
lynestrenol/ml and higher will interfere with the binding of estradiol to the 
estrogen receptor. Taking into account the results presented in Fig. 16.3 it may 
be inferred that inhibition of estradiol receptor binding will also be of signifi-
cance following oral administration of lynestrenol, the more so because the 
anti-ovulatory dose range of this compound for the oral route is in the order 
of 1-5 mg/rat (Overbeek et al., 1962). 
A bsorption and biological availability 
The high percentage of lynestrenol found to be absorbed after intraduodenal 
administration of the drug is in good agreement with the estimation on basis 
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of the cumulative excretion data in the urine, bile and faeces in the intact and 
bile duct cannulated rat (this thesis, Chapter 12). Kilian (1973) reported an 
"apparent" absorption of lynestrenol-14C in the rat after oral administration 
of only 45.9 and 73.6% of the dose. These values were calculated as in the 
present study but instead of rats with bile fistula animals with intact bile ducts 
were used. Because 24 h after lynestrenol administration about 65% of the 
lynestrenol dose is excreted with the bile (Fig. 16.3 and Chapter 12) and is 
included by Kilian in the unabsorbed fraction, the "apparent" absorption in 
his study does not reflect the actually occurring absorption, which is consider-
ably greater. On the other hand the lymphatic absorption of lynestrenol of 
3.2% and 6.2% of the dose observed by Kilian (1973), although representing 
a minor portion of the total absorbed amount, may be nevertheless of import-
ance for the biological activity of lynestrenol in view of its poor biological 
availability of about 15%. 
The measurement of the biological availability, using the concentrations of 
hexane-extractable radioactivity instead of lynestrenol concentrations, may be 
considered to provide strong evidence for a considerable first-pass elimination of 
lynestrenol in the liver and a concurrently low fraction of the oral dose reaching 
the general circulation. Although the data calculated represent an apparent 
rather than a true value for the biological availability, an overestimation of this 
parameter in the present investigation is more likely to occur than an under-
estimation. Underestimation of the biological availability in this study would 
imply, that the lynestrenol fraction in the hexane extract should be almost per-
manently smaller after parenteral than after enteral administration. Such an 
assumption is very unlikely in the light of the rapid metabolism of lynestrenol as 
observed in the isolated perfused rat liver (this thesis. Chapter 15). In fact, the 
lynestrenol fraction in the hexane extract showed a tendency to decrease rather 
than to increase in case of intraduodenal administration. 
The limited bioavailability of lynestrenol raises the question, whether and to 
what extent the biological activity of this steroid is an intrinsic property of the 
drug itself or is derived from its bioactivation in the liver. In the first case it 
seems worthwhile to study the possibility of increasing the biological availability 
by using another route of administration which avoids the first passage through 
the liver, e.g. buccal administration. Also an increase of the fraction absorbed 
via the intestinal lymphatics under the influence of biopharmaceutical modifica-
tions in the dosage form may serve this purpose as has been shown by Kilian 
(1973) for DDT, by Coert et al. (1975) for testosterone undecanoate and by 
De Visser & Van der Vies (1977) for estradiol decanoate. A concurrent reduc-
tion of the therapeutic dose would be advantageous with regard to the incidence 
of side effects, which accompany the use of oral contraceptives. In the second 
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case, however, when activity resides in a metabolite of lynestrenol, and it has 
been suggested that lynestrenol might be the pro-drug of norethindrone (Fother-
by, 1972; Kontula et al., 1975; Mazaheri et al., 1970), it seems logical to replace 
lynestrenol by this conversion product. 
In vivo and in vitro clearance of lynestrenol 
On account of the flow-limited metabolic clearance rate of lynestrenol in the 
isolated perfused rat liver as well as the low biological availability of the com-
pound observed in the present study a higher elimination clearance constant was 
expected than we actually observed after injection. When the liver is an integral 
part of the central compartment, when furthermore elimination occurs solely by 
hepatic metabolism and when the metabolic clearance rate is independent of the 
route of administration, the following relationship applies (Gibaldi et al., 1971; 
Rowland, 1972): 
F = 1 — — - -Q 
Using this equation the value of the apparent hepatic blood flow (Q) can be 
calculated to be about 5 ml/min for F = 0.15 and k<>i = 4 ml/min (see Tables 
16.1 and 16.2). According to Dobson & Jones (1952) and Grayson & Mendel 
(1965) the physiological blood flow through the rat liver is 1.2-1.5 ml/min/g 
liver, which should result in a hepatic blood flow of 9-12 ml/min in the present 
study. So, the apparent hepatic blood flow is about half of the physiological 
value. The lack of correlation between the first-pass metabolism and in vivo 
clearance on the one hand and between in vivo and in vitro clearance on the 
other hand are indications that the pharmacokinetics of lynestrenol in vivo may 
be more complex than the model experiments with the isolated rat liver sug-
gested. Although the possibility should not be neglected that the liver blood now 
in the experimental animals was actually smaller than the normal value, some 
other possible complicating factors deserve consideration. 
The metabolic clearance rate was studied in the isolated liver using instead of 
rat blood a semi-synthetic medium consisting of dog erythrocytes and an electro-
lyte solution containing bovine serum albumin (BSA) as the only protein (this 
thesis, Chapter 15). That lynestrenol behaves differently in rat blood than in the 
perfusion medium under the experimental conditions may be derived from 
experiment 6 (Table 16.1), where plasma concentrations of lynestrenol have 
been measured instead of blood concentrations. In this experiment a strong 
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reduction of the calculated apparent volume of distribution was found. So, it 
seems likely that the plasma concentration of lynestrenol is much higher than 
the blood concentration, whereas an opposite relationship appeared to exist in 
the perfusion medium (see Chapter 15, Tables 15.1 and 15.2). 
An explanation which could reconcile the in vivo and in vitro results, but 
which awaits experimental proof, may be found in binding of lynestrenol to 
some fraction of the rat plasma proteins with a higher affinity than the binding 
to BSA. Then the non-restrictive elimination of lynestrenol observed in vitro 
may be restrictive of character in vivo. Consequently, the clearance in vivo may 
become dependent upon the capacity of those hypothetical binding sites. The 
presence and significance of such high affinity binding sites in the globulin frac-
tion of the plasma proteins and their influence on the metabolic clearance rate, 
distribution and activity of endogenous steroid hormones (Anderson, 1974; 
Burke & Anderson, 1972; Vermeulen et al., 1969) as well as of synthetic 
derivatives (Chan & Slaunwhite, 1977; Raynaud, 1973), including some of the 
contraceptive progestins (Murugesan & Laumas, 1975; Uniyal & Laumas, 1976; 
Victor et al., 1977) has been demonstrated. The low biological availability of 
lynestrenol after oral administration may then be explained by saturation of the 
high affinity binding sites in the portal blood entering the liver during the ab-
sorption process and a concurrently non-restrictive elimination of the free and 
more loosely bound lynestrenol fraction. Similarly, when lynestrenol levels are 
falling after injection of the steroid, the significance of the restrictive elimination 
will gradually increase and the metabolic clearance rate will slow down. 
Apart from the involvement of the hepatic blood flow and plasma protein 
binding the metabolic clearance rate of lynestrenol in vivo could also be reduced 
as a result of competition of the compound with other substrates for the meta-
bolic sites on the liver enzymes. In this case the low biological availability may 
be caused by the occurrence of significant pre-hepatic metabolism, e.g. in the 
gut wall. Biotransformation of orally administered progesterone and testo-
sterone in the gut wall has been reported to occur in the dog (Harri, 1970a,b; 
Niensted et al., 1969). 
Further investigations are needed to gain an insight, whether one or more of 
the complicating factors touched in the present discussion are pertinent to the 
pharmacokinetics of lynestrenol. Moreover, studies in humans are to be con-
sidered an indispensable sequel to the present work and should be initiated now 
suitable analytical tools have recently become available. Extrapolation of the 
results obtained in the rat to the human is hazardous in view of the possibly 
significant species differences with regard to the metabolic clearance rate in the 
rat and in man. No information is available at present with respect to the bio-
logical availability of the contraceptive steroids in animals and humans. Com-
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parison, however, of the anti-ovulatory activity of these compounds showed a 
good correlation to exist between the effective subcutaneous dose in the rat and 
the oral dose in humans, whereas a bad correlation was found between the 
effective dose after oral administration to both species (Neumann et al., 1977). 
It seems possible that pharmacokinetic investigations could provide the key to 
this and other, still open, questions. 
SUMMARY 
The pharmacokinetics and biological availability of lynestrenol have been 
studied in the rat after the administration of 50 μg lynestrenol-3H. Blood and 
plasma concentrations were measured over a period of about 24 h. The analy­
tical procedure allowed discrimination between concentrations of total radioactiv­
ity, hexane-extractable radioactivity and lynestrenol. Within 1 h after injection 
lynestrenol represented less than 10% of the total radioactivity levels. The time 
course of the drug in the blood and plasma could be described by a three-term 
exponential equation according to the three-compartment open model. The time 
of half-life varied between 10-21 h (mean value 13.6 h, 6 animals). The large 
apparent volume of distribution V,i (12-19 1/kg, mean value 15.5 1/kg) and the 
high lipophilicity of the compound indicate the occurrence of accumulation in 
the adipose tissue. The decreased V,i of 7.4 I/kg when derived from the plasma 
curve (one animal) indicates an uneven distribution of lynestrenol between the 
plasma and the erythrocytes. The total body clearance constant varied between 
2.8-4.8 ml/min (mean value 4.0 ml/min, 5 animals). Following intraduodenal 
administration to animals prepared with bile fistula 89-95% of the dose (mean 
value 92.6%, 4 animals) was absorbed and 65-70% was excreted with the bile 
during the experiment. Maximal concentrations of hexane-extractable radioactiv­
ity were measured 1-2 h after lynestrenol ingestion. The blood concentrations 
remained considerably below the levels observed after injection. The biological 
availability varied between 11-25% (mean value 16.8%). Neither was a cor­
relation found between the in vivo clearance of lynestrenol and its clearance in 
the isolated perfused rat liver (this thesis, Chapter 15) nor between the in vivo 
clearance and the biological availability. Possible explanations for this apparent 
discrepancy are discussed. The present findings, however, provide evidence that 
interference of lynestrenol with estradiol receptor binding in the rat in vivo (this 
thesis, Chapter 9) may also be of significance after oral administration of this 
progestin. 
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SAMENVATTING 
Het doel van het farmacologisch onderzoek beschreven in dit proefschrift is 
tweeledig. Enerzijds is gepoogd meer inzicht te krijgen in de relatie tussen 
chemische structuur en werking van de meest gebruikte synthetische pro-
gestativa, terwijl anderzijds de jarmacokinetiek van een van deze stoffen, 
het lynestrenol, diepgaand is bestudeerd. Beide aspecten van het onderzoek 
vullen elkaar aan, omdat de biologische activiteit van een stof niet los gezien 
kan worden van haar structuur en daarnaast mede bepaald dan wel gemodu-
leerd wordt door haar absorptie, distributie, metabolisme en excretie. 
Voor wat betreft de relatie tussen structuur en werking is de aandacht gericht 
op de estrogene component, aanwezig in het werkingsspectrum van de progesta-
tiva afgeleid van 19-nortestosteron, te weten het lynestrenol, ethynodiol, nor-
ethynodrel en norethindron. Al sedert de introductie van deze stoffen was het 
een twistpunt, of de estrogene (bij)werking een intrinsieke eigenschap is van de 
stof dan wel het gevolg is van een omzetting in vivo in estrogene metabolieten. 
Onderzocht is door ons of, en zo ja in welke mate, progestativa met en zonder 
estrogene activiteit de binding van estradiol-3H aan de receptor moleculen in de 
estrogene target weefsels van de rat kunnen beïnvloeden. Weliswaar is binding 
aan de receptor niet synoniem met biologische activiteit, aangezien behalve de 
affiniteit ook de intrinsieke activiteit een rol speelt, maar anderzijds is het op-
treden van binding een absolute voorwaarde wil er van activiteit sprake kunnen 
zijn. Daarnaast is gepoogd door onderzoek aan het bindingsgedrag van deze 
en een aantal andere, medisch niet toegepaste, Steroiden een inzicht te krijgen 
in de relatie tussen chemische structuur en bindingsaffiniteit. Dit laatste aspect 
is bestudeerd in vitro met behulp van de lOSOOOxg supernatant van kalfs- en 
ratte-uterus homogenaten. Deze preparaten zijn relatief zeer rijk aan receptor 
moleculen en bieden het voordeel, dat invloeden van distributie, metabolisme 
en excretie worden vermeden. 
Het farmacokinetisch gedeelte van het onderzoek is toegespitst op lynestrenol. 
Vanwege het feit dat geen methode beschikbaar is, die zich leent voor de be-
paling van de uiterst lage bloedconcentraties van deze stof bij de mens, moest 
gebruik worden gemaakt van de radioactief gemerkte verbinding, waardoor het 
onderzoek beperkt bleef tot de rat en de muis. Het verdelingspatroon van 
lynestrenol en de passage door de placenta is bestudeerd bij de muis door 
middel van autoradiografie in combinatie met analytisch-chemische methoden. 
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De metabole klaring van lynestrenol is onderzocht met de techniek van de 
geïsoleerde doorstroomde rattelever. Voor de studie van absorptie, eliminatie 
en excretie van lynestrenol en zijn metabolieten is gebruik gemaakt van de 
intacte rat en de rat met gecannuleerde urineblaas en galbuis. Daarnaast werd 
gemeten de verdelingscoëfficiënt van lynestrenol en met behulp van even-
wichtsdialyse de binding aan serum albumine. 
Het proefschrift is verdeeld in 4 secties: 
In Sectie I, Hoofdstuk 1, wordt een korte schets gegeven van een aantal fun-
damentele begrippen uit de farmacologie, die de interactie tussen het farmacon 
en het biosysteem in kwalitatieve en kwantitatieve zin bepalen. Daarnaast geeft 
dit hoofdstuk ter inleiding op Sectie III een literatuuroverzicht van de grote 
vorderingen gedurende de laatste 10 jaar op het gebied van het werkings-
mechanisme van estrogene hormonen alsmede een beschouwing over de farma-
cologische implicaties daarvan. 
Hoofdstuk 2 bevat een korte beschrijving van de historie, medische toe-
passing en farmacologie van de orale anticonceptiva, waaraan in het kader van 
het onderhavige onderzoek aandacht is besteed. De doelstelling van het onder-
zoek wordt aangegeven. 
Sectie H, Hoofdstukken 3-8, omvat het algemeen experimenteel gedeelte. 
Hoofdstuk 3 behandelt de controle op zuiverheid en de zuiveringsprocedure 
van de gebruikte radioactief gemerkte Steroiden, te weten estradiol-6,7-3H, 
lynestrenol-4-14C en lynestrenoHH. Verder worden hier de bronnen van deze 
en de overige, radioinerte, Steroiden vermeld. 
Aangezien het voor de farmacokinetische onderzoekingen benodigde lyn-
estrenol-3H niet voorhanden was, moest hierin zelf worden voorzien. De syn-
these van deze stof is beschreven in Hoofdstuk 4. 
Het principe van de radioactiviteitsmeting door vloeistof-scintillatietelling, de 
monstervoorbereiding en een evaluatie van deze techniek vormen het onderwerp 
van Hoofdstuk 5. 
De interactie van de anticonceptieve Steroiden met de estradiol receptor 
in vitro is gemeten met behulp van een verdringingsmethode. Hoofdstuk 6 bevat 
een beschrijving en verantwoording van de gevolgde experimentele procedure 
alsmede de toetsing van deze techniek op haar bruikbaarheid in het kader van 
de vraagstelling van dit onderzoek. Het principe van de bepalingsmethode is, 
dat de mate, waarin een competerende niet-radioactieve verbinding in staat is 
het radioactief gemerkte estradiol uit zijn bindingsplaatsen op de receptor mole-
culen te verdrijven, een graadmeter is voor de affiniteit van deze stof voor de 
receptor. Een voorwaarde is wel, dat er sprake dient te zijn van een reversibele 
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interactie en er gemeten wordt onder evenwichtscondities. Indien men twee van 
de drie variabelen, te weten de totale estradiol concentratie in de oplossing, de 
receptor-gebonden en de vrije estradiolfractie kan bepalen, is de affiniteit van 
het competerende steroid te kwantificeren. In de door ons toegepaste procedure 
wordt het receptor-gebonden estradiol gescheiden van de vrije fractie door 
adsorptie van deze laatste fractie aan adsorberende kool. Het gebonden estra-
diol en de totale estradiol concentratie worden gemeten door vloeistof-scintil-
latie telling. 
De beperkende factoren, die een rol spelen bij bio-analyses ten behoeve van 
farmacokinetisch onderzoek, in het bijzonder van laag gedoseerde geneesmid-
delen zoals orale anticonceptiva, komen aan de orde in Hoofdstuk 7. Een ver-
antwoording wordt gegeven van de toegepaste bepalingsmethode voor lyn-
estrenol in het bloed van de rat in vivo, resp. het perfusiemedium van de ge-
isoleerde doorstroomde rattelever in vitro. De analyse berust op een extractie 
van het radioactief gemerkte lynestrenol uit het monster met hexaan en een 
dunne-laag chromatografische scheiding van de moederstof en meegeëxtra-
heerde omzettingsprodukten. 
De bepaling van de verdelingscoëfficiënt van lynestrenol over heptaan/ 
buffer en de binding van de stof aan runder serum albumine wordt beschreven 
in Hoofdstuk 8. Het lynestrenol is zeer lipofiel getuige de waarde van circa 
5000 voor de verdelingscoëfficiënt. De eitwitgebonden fractie is eveneens hoog 
(97,4%) en constant over een breed concentratiegebied van 2-1700 ng/ml, de 
associatieconstante bedraagt 8,9xl04 M '. 
In Sectie Ш (Hoofdstukken 9, 10, 11) wordt verslag gedaan van het onderzoek 
naar de binding van de anticonceptieve progestativa aan de estradiol receptor 
van de rat en het kalf. 
Het verdelingspatroon van estradiol-3H in de rat na intraveneuze injectie 
(Hoofdstuk 9) laat een groot verschil zien tussen het verloop van de concen­
tratie in enerzijds de zogenaamde target weefsels en anderzijds het bloed-
plasma en de andere organen. In de target weefsels zoals uterus, vagina, 
hypofyse-voorkwab, preoptisch gebied en hypothalamus, vindt een sterke 
accumulatie en retentie plaats van estradiol ten gevolge van de binding 
van het hormoon aan de estradiol receptoren in deze weefsels. Deze binding 
is specifiek voor estrogene stoffen en verzadigbaar: gelijktijdige toediening 
van testosteron naast het estradiol heeft geen invloed op het distributie­
patroon, bij gelijktijdige injectie van een overmaat (d.w.z. een niet-fysiologische 
dosis) van niet-radioactief estradiol of een andere estrogene stof daarentegen 
gaat het verschil in opname van estradiol-3H tussen de target organen en de 
andere weefsels verloren. Het blijkt, dat de Steroiden afgeleid van 19-nortesto-
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steron de binding van estradiol-3H in alle target weefsels, zowel perifeer als in 
het centrale zenuwstelsel, in aanzienlijke mate kunnen remmen. Enkele van deze 
target weefsels, zoals de hypothalamus, het preoptisch gebied en de hypofyse, 
spelen een sleutelrol bij de regulering van het ovulatieproces. Het meest effectief 
is ethynodiol, gevolgd door resp. norethynodrel, lynestrenol en norethindron. 
Ook 19-nortestosteron vertoont enige activiteit, terwijl het marginale effect van 
norgestrel beperkt blijft tot de hypofyse en het preoptisch gebied in de herse-
nen. Het effect van de medisch eveneens veel toegepaste acetaatesters van deze 
stoffen komt overeen met dat van de moederverbindingen. De orale anticoncep-
tiva afgeleid van hydroxyprogesteron, namelijk medroxyprogesteron, Chlorma-
dinon en megestrol en hun acetaten, hebben geen invloed op de receptorbinding 
van estradiol. Voor lynestrenol is bovendien nagegaan de relatie tussen de 
dosis, resp. het tijdstip van toediening ten opzichte van estradiol, en het effect. 
Het blijkt, dat de remming van de receptorbinding in de hypofyse sterker is 
dan in de uterus. Dit is waarschijnlijk een gevolg van het verdelingsproces van 
lynestrenol in het organisme. De betekenis van deze resultaten wordt besproken 
in het licht van andere, onderling strijdige, onderzoekingen en het werkings-
mechanisme van deze stoffen bij de ovulatieremming. 
De receptor moleculen van estradiol zijn eiwitmoleculen, die gelocaliseerd 
zijn in het cytoplasma van de target cellen. De eigenschappen van de receptor 
en de bindingsparameters van estradiol kan men bestuderen door onderzoek van 
het bindingsgedrag van getritieerd estradiol onder diverse experimentele con-
dities (Hoofdstuk 10, 11). Zo sedimenteert het estradiol-receptor complex bij 
centrifugeren door een sucrose dichtheidsgradiënt in het 8-9S gebied en wordt 
het bindingsgedrag van estradiol niet beïnvloed door de aanwezigheid van een 
2000-voudige overmaat van niet-estrogene steroide hormonen. De dissociatie-
constante van het estradiol-receptor complex is zeer laag (KD З Х І О 1 0 M). De 
bestudering van de invloed van de anticonceptiva en structuur-verwante Ste­
roiden op de receptorbinding van estradiol in vitro heeft het voordeel, dat 
behalve de mogelijke invloed van biotransformatie ook die van distributie en 
excretie processen op de resultaten wordt voorkomen, zodat kwantificering van 
de interactie in vitro direct gerelateerd kan worden aan de chemische structuur. 
De 19-nortestosteron derivaten blijken ook in vitro de binding van estradiol te 
remmen, de acetaatesters zijn in vitro echter veel minder actief dan in het 
in vivo experiment (Hoofdstuk 10). Vermoedelijk wordt de acetaatgroep in vivo 
zeer snel afgekoppeld. De hydroxyprogesteron derivaten en norgestrel vertonen 
in vitro evenmin activiteit. De remming van de receptorbinding van estradiol 
door lynestrenol is dosis-afhankelijk en competitief (K, 1,1x107 M). Blijkbaar 
binden estradiol en lynestrenol op dezelfde plaats aan het receptor molecuul. 
De relatie tussen de remming van de receptorbinding van estradiol door de orale 
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anticonceptiva en andere onderzochte Stoffen en hun chemische structuur wordt 
uitvoerig besproken en vergeleken met gegevens uit ander onderzoek. 
In Hoofdstuk 11 wordt gewezen op de voordelen van het gebruik van de kalfs-
uterus als alternatieve bron van receptor materiaal ten behoeve van bindings­
studies. De cytosol van kalfs-uterus homogenaat is gebruikt voor verdringings­
experimenten, waarmee de verhouding van de associatieconstanten van het 
competerende steroid en estradiol kon worden bepaald en daaruit, na meting 
van de associatieconstante van het estradiol-receptor complex, de associatie-
constante van de inhiberende stof. De volgende waarden zijn gevonden voor de 
anticonceptieve Steroiden met activiteit (Кд estradiol 2,6xl09 M л ) : ethynodiol 
2,2xl08, norethynodrel l,2xl07, lynestrenol 6,5x10«, norethindrone 3,8xl05. Ten­
slotte worden in dit hoofdstuk de resultaten van de bindingsstudies vergeleken 
met de activiteit van deze stoffen in de biologische test voor estrogene werking 
(Allen-Doisy test) zoals bekend uit ander onderzoek, een en ander in samen­
hang met de invloed van farmacokinetische factoren. 
De resultaten van het onderzoek beschreven in Sectie III pleiten voor de op­
vatting, dat de estrogene werking van de bovengenoemde stoffen een direct 
gevolg is van hun binding aan de estradiol receptor. Een mogelijke bijdrage 
hierin van estrogene omzettingsprodukten kan echter niet worden uitgesloten. 
De gemeten bindingsaffiniteiten zijn behalve voor het ethynodiol weliswaar 
niet hoog, maar daarbij dient bedacht te worden, dat deze progestativa in de 
medische praktijk veelal ca. 100-voudig worden gedoseerd in vergelijking met 
estrogene hormonen. Onze onderzoeksresultaten illustreren verder de mogelijk­
heden, die de bestudering van de receptorbinding biedt naast de klassieke onder­
zoekmethoden ten aanzien van de evaluering van het werkingsspectrum van 
de reeds toegepaste steroide hormonen alsmede ten aanzien van de ontwikkeling 
van nieuwe Steroiden met een smaller werkingsspectrum. Vooral dit laatste 
aspect zal voor de praktische therapie van betekenis zijn, ervan uitgaande, dat 
idealiter gestreefd dient te worden naar een therapeutisch arsenaal van farmaca 
met één bepaalde farmacologische werking en zonder bijwerkingen. 
Sectie IV, Hoofdstukken 12-16, is gewijd aan het onderzoek naar de farmaco-
kinetiek van lynestrenol in de rat en de muis. 
De excretie van lynestrenol-14C en zijn metabolieten na orale en intraveneuze 
toediening aan de intacte vrouwelijke rat vertoont hetzelfde beeld (Hoofdstuk 
12). Binnen een tijdsbestek van 24 uur wordt 50% van de dosis uitgescheiden 
met de faeces en de urine, en dit neemt toe tot 80% 24 uur later. Ongeveer 
4/5 van de totale excretie verloopt via de faeces. Bij ratten voorzien van 
een galfistel verloopt de excretie sneller, terwijl het aandeel van de galexcretie 
in de totale excretie toeneemt in vergelijking met de intacte rat. Dit laatste 
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aspect doet het bestaan van een enterohepatische kringloop vermoeden 
van de excretieprodukten aanwezig in de gal. Informatie omtrent de absorptie 
van lynestrenol is verkregen door vergelijking van de cumulatieve excretie 
van ,4C in de gal en urine na intraveneuze en intraduodenale toediening 
van lynestrenol-14C. Ongeveer 90% van de dosis blijkt te worden geabsor-
beerd (zie ook Hoofdstuk 16). Een indruk van de absorptiesnelheid is ver-
kregen door de excretie in de gal als functie van de tijd te vervolgen na intra-
veneuze en intraduodenale toediening. De absorptie verloopt snel en na ongeveer 
10 uur is er geen verschil meer in de cumulatieve excretie voor beide applicatie-
routes. Fractionering van het uitgescheiden radioactief gemerkte materiaal in 
gal, urine en faeces door extractie met hexaan en ethylacetaat voor en na enzy-
matische hydrolyse en dunne-laag chromatografie van deze extracten laat zien, 
dat lynestrenol volledig wordt gebiotransformeerd tot polaire verbindingen. Met 
behulp van gas-chromatografie en massa-spectrometrie werd de identiteit van de 
kwantitatief belangrijkste metaboliet in het hexaanextract van de gal nader 
onderzocht. De verkregen gegevens duiden op het optreden van een mono-
hydroxylering en hydrogenering van lynestrenol in de A-ring en naar analogie 
van de biotransformatie van andere 19-nortestosteron derivaten is het ge-
vormde produkt vermoedelijk 17a-ethynyl-5i-estrane-3|,17ß-diol. De hoge 
excretiesnelheid van de omzettingsprodukten impliceert een hoge metabole 
klaringssnelheid en een vermoedelijk lage biologische beschikbaarheid van het 
lynestrenol ondanks de bijna volledige absorptie. 
Hoofdstuk 13 beschrijft de excretie van 14C bij ratten met een galfistel na de 
intraduodenale toediening van gal verkregen van donor-ratten, ingespoten met 
lynestrenol-4-14C. Er treedt een aanzienlijke absorptie op van de galmetabolie-
ten. De geabsorbeerde fractie is groter, indien een extract van vooraf langs en-
zymatische weg gesplitste gal wordt toegediend. Uit het verloop van de 14C 
excretie in de gal als functie van de tijd kan worden afgeleid, dat de absorptie-
snelheid grotendeels bepaald wordt door het enzymatische splitsingsproces van 
de geconjugeerde galmetabolieten in de lagere delen van de darm. Het optreden 
van deze hydrolyse in de darm van de intacte rat blijkt uit het feit, dat de zonder 
voorafgaande hydrolytische splitsing extraheerbare fractie van de metabolieten 
veel groter is in de faeces dan in de gal. De conjugaten lijken als zodanig niet 
of slechts langzaam te worden geabsorbeerd. De betekenis van de enterohepa-
tische kringloop voor het excretieproces neemt verder toe, indien de excretie 
met de faeces wordt vertraagd of verminderd en de condities voor absorptie 
worden begunstigd. Zo gaat een tragere eliminatie van 14C via de faeces bij 
vastende ratten gepaard met een grote stijging van de renale excretie. Tenslotte 
is gezocht naar een antwoord op de vraag, of het grote overwicht van de hepa-
tische over de renale excretie bij de uitscheiding van de lynestrenol metabo-
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lieten bepaald wordt door structurele verschillen tussen het excretieproces in 
de lever en in de nier, alsmede door binding aan de plasma eiwitten, dan wel 
door andere factoren. Een volledige excretie van de lynestrenol metabolieten 
met de urine blijkt plaats te vinden in ratten met geobstrueerde galbuis. Het 
metabolisme en het excretieproces volgen in deze ratten overigens hetzelfde 
patroon als is waargenomen bij de intacte rat. De verdeling van de excretie-
produkten over urine en gal in de verhouding van circa 1 : 6 kan derhalve ver-
klaard worden door aan te nemen dat een groot deel van de biotransformatie-
produkten in de lever direct in de gal overgaat en derhalve niet meer beschik-
baar komt voor de renale excretieroute, tenzij via de genoemde enterohepatische 
kringloop. 
De verdeling van lynestrenol en zijn metabolieten over de diverse organen 
en weefsels en de passage door de placenta is bestudeerd bij de vrouwelijke 
muis door middel van autoradiografie en analytisch-chemische methoden 
(Hoofdstuk 14). De stof blijkt zich binnen enkele minuten na intraveneuze 
injectie te verdelen over alle weefsels en organen, inclusief de hersenen. Ge-
durende deze verdelingsfase lijkt de doorbloeding van de organen bepalend te 
zijn voor het verdelingspatroon. Na de redistributiefase en na orale toediening 
van lynestrenol blijven gedurende enige uren relatief hoge concentraties aan-
wezig in de organen betrokken bij de eliminatie (lever en nier), in vetrijk weefsel 
(bruin en wit vet, haarfollikels en klieren van Harder) en sommige endocrino-
logisch actieve weefsels (ovarium en bijnierschors). Opvallend is de naar ver-
houding geringe opname in de vagina en uterus. Extractie van bloed en weefsel-
homogenaten met hexaan en dunne-laag chromatografie van enige van deze 
extracten toont aan, dat lynestrenol zeer snel wordt omgezet in de lever en 
gedurende de eerste 3 uur na injectie uit bloed en weefsels wordt geëlimineerd 
met een halfwaardetijd van 1 tot 2 uur. De lynestrenolfractie blijft gedurende 
deze periode relatief hoog in de vetrijke weefsels zoals wit en bruin vet en 
cerebrum, waarschijnlijk ten gevolge van de grote vetoplosbaarheid van de stof. 
De placenta passage en de opname van de stof in het foetale compartiment is 
kwantitatief van geringe betekenis. Ophoping van radioactiviteit is het meest 
uitgesproken in de foetale bijnier, maar is ook zichtbaar in lever, nier, long, 
bruin vet en lumen van de darm. 
In Hoofdstuk 15 zijn de resultaten beschreven van het onderzoek naar de 
metabole klaringssnelheid van lynestrenol met behulp van de geïsoleerde door-
stroomde rattelever. Lynestrenol wordt tijdens de leverpassage volledig geëxtra-
heerd uit het perfusiemedium en gemetaboliseerd, ondanks de hoge binding 
aan het serum albumine aanwezig in het semi-synthetische perfusiemedium. De 
afname van de lynestrenolconcentratie in het perfusiemedium als functie van 
de tijd verloopt mono-exponentieel bij fysiologische (10 en 20 ml/min) en 
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hogere (35 tot 45 ml/min) perfusiesnelheden door het orgaan. De klaringssnel-
heid is onafhankelijk van de lynestrenolconcentratie over een groot concen-
tratiegebied. De stof hoopt zich in het perfusiemedium op in de rode bloed-
cellen, maar de uitwisseling met het "plasma" verloopt zo snel, dat voor de 
"plasma"concentratie-tijd curve dezelfde eliminatie tijdconstante wordt ge-
vonden als voor de "bloed"concentratie-tijd curve. 
De absorptie en de biologische beschikbaarheid van lynestrenol zijn bestu-
deerd in de rat na intra-arteriële en intraduodenale toediening van 50 μg lyn-
estrenol-3H (Hoofdstuk 16). Behalve de meting van de totale radioactiviteit in 
bloed en plasma als funktie van de tijd gedurende een periode van ongeveer 
24 uur is de concentratie bepaald van hexaan-extraheerbare radioactiviteit (on­
geveer voor 90% bestaande uit lynestrenol) en van lynestrenol, de laatstge­
noemde concentratie alleen na injectie van de stof. Binnen 1 uur na injectie 
blijkt nog slechts 10% van de radioactiviteit in het bloed aanwezig in de vorm 
van lynestrenol. Het verloop van de semilogarithmische bloed, respectievelijk 
plasmaconcentratie-tijd curve wordt bepaald door 3 tijdconstanten (drie-com­
partimenten model). De biologische half waarde-tijd varieert van 10 tot 21 uur 
(gemiddelde 13,6 uur, 6 dieren). Het schijnbare verdelingsvolume van lynestrenol 
is erg groot, 12 tot 19 l/kg (gemiddelde 15,5 l/kg). Mede in aanmerking ge­
nomen de grote lipofiliteit van de stof kan het grote verdelingsvolume waar­
schijnlijk worden verklaard door stapeling van het lynestrenol in het lichaams-
vet. In tegenstelling tot de accumulatie van lynestrenol in de erythrocyten van 
het perfusiemedium (zie Hoofdstuk 15) wijst het schijnbare verdelingsvolume 
van 7,4 l/kg berekend uit de plasmacurve (één experiment) op een tegenover-
gestelde verdeling van de stof over plasma en rode cellen in vivo. De totale 
lichaamsklaring bedraagt ongeveer 2,8-4,8 ml/min (gemiddelde 4,0 ml/min, 
5 dieren). Na intraduodenale toediening van lynestrenol aan 4 ratten met een 
galfistel wordt 89-95% van de dosis geabsorbeerd (gemiddelde 92,6%) en 
65-70% uitgescheiden met de gal over een periode van 24 uur. De bloedccn-
centraties zijn maximaal 1-2 uur na toediening. De concentraties blijven aan-
zienlijk lager dan de concentraties na injectie. De biologische beschikbaarheid 
varieert van 11 tot 25% (gemiddelde 16,8%). Deze waarde is kleiner dan ver-
wacht op basis van de klaring gemeten na injectie. Er wordt geen correlatie 
gevonden tussen de klaring in vivo en de klaring gemeten in de experimenten 
met de geïsoleerde lever (zie Hoofdstuk 15). Mogelijke oorzaken van deze 
schijnbare tegenstrijdigheden worden besproken. Op grond van de bloedconcen-
traties van lynestrenol kan verwacht worden, dat de remming van de receptor 
binding van estradiol na intraveneuze injectie van lynestrenol (zie Hoofdstuk 9) 
ook van betekenis zal zijn na orale toediening van de stof. 
Zoals veel onderzoekingen roept ook het onderzoek beschreven in Sectie IV 
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van dit proefschrift nieuwe vragen op. Van de aspecten, die stellig nadere be-
studering verdienen, kunnen genoemd worden in het bijzonder de binding van het 
lynestrenol aan de plasma-eiwitten, de klaring van de stof in de met ratte-bloed 
doorstroomde geïsoleerde lever, de biologische beschikbaarheid na intraperito-
neale toediening en het metabolisme. Naast dit dier-experimentele onderzoek 
dient de bestudering van de farmacokinetiek van het lynestrenol bij de mens ter 
hand te worden genomen. De hiertoe benodigde analytische technologie is de 
laatste jaren beschikbaar gekomen. Optimalisering en rationalisering van de 
therapie met orale anticonceptiva op basis van nog ontbrekende farmacokine-
tische gegevens lijkt nog zeer wel mogelijk ondanks of misschien juist dank zij de 
ruime klinische ervaring, die de afgelopen 15 jaar met deze stoffen is opgedaan. 
Zo zou een lage biologische beschikbaarheid bij de mens als in dit onderzoek 
waargenomen voor lynestrenol bij de rat, kunnen leiden tot een verdere ver-
laging van de effectieve dosis door de keuze van een andere toedieningsweg, 
bijv. de sublinguale route. Een en ander zou leiden tot een geringere belasting 
van de lever en galwegen met stoffen, waarvan identiteit en werking niet vast 
staan. Zou echter de omzetting van bijv. lynestrenol in de lever juist noodzake-
lijk blijken voor de biologische werkzaamheid (bioactivering), en er zijn ge-
gevens, die dit vermoeden wettigen, dan lijkt nadere bezinning op de plaats 
van deze stof in de therapie met de orale anticonceptiva op zijn plaats. 
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